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SUMMARY
The principal aim of this study was to compare a number of in vitro 
and in vivo systems, to establish the most suitable methods for detecting 
and quantitating anti-influenzal activity, and with these methods to 
compare the activity of different compounds. Eight strains of virus, two 
from each of the 4 sub-types, were used.
For in vitro work two primary cell lines, chick embryo and calf kidney 
cells, and the allantois-on-shell system (AOS) were compared. Antiviral 
activity was assessed by yield reduction determination under either single 
or multiple cycle conditions, and by plaque inhibition and reduction tests. 
Chick tracheal organ cultures were also used on a limited basis to detect 
activity. For in vivo work mice were used, with activity determined by 
reductions in virus content of the lungs of infected mice, the results of 
which were compared with those of mortality tests. The effect of mouse
lung passage history of virus on the results was also examined.
The three in vitro systems used all proved satisfactory, with the 
AOS system the easiest to prepare. Plaque inhibition and reduction tests 
proved useful for detecting and quantitating activity, although single cycle 
tests were more suitable for comparing the sensitivity of different strains 
and the results obtained with different cultures. Multiple cycle tests 
gave rather variable results. In vivo the titrations of the virus content 
of lungs proved satisfactory for detecting and quantitating activity, and 
good agreement was obtained with mortality tests. With mouse lung passage 
history variation in results occurred, and highly adapted strains were found 
to be most suitable for comparative work.
A total of 60 compounds were examined for activity, out of which only 
amantadine hydrochloride and Ribavirin proved sufficiently active for
further work. The activity of amantadine hydrochloride varied in 
different systems and \<rith different strains of virus. With Ribavirin 
minor variations occurred between systems, but all 8 strains examined 
were similar in sensitivity. Overall it was impossible to say which 
compound was more active, but the differences in activity between the 
two compounds iirere generally not great.
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INTRODUCTION
1.1 GENERAL ASPECTS OF INFLUENZA
1.1.1 History of isolation
Influenza, a disease of considerable antiquity, is unique today 
in its ability to cause world wide epidemics. The earliest scientific 
report on one of these pandemics was made in 1892 when Pfeiffer isolated 
the !influenza bacillus’, Haemophilus influenzae, which was thought to 
be the aetiological agent. A major pandemic occurred about twenty years 
later in 1918, leaving approximately 20 million dead throughout the 
world (Hoyle, 1968). By this time it was considered that H. influenzae 
was only a secondary invader, and that a filterable virus was involved. 
However, definite evidence that a virus was the causative agent was not 
obtained until 1933 when Smith et al. (1933) successfully transmitted 
the disease to ferrets, and demonstrated its filterable nature and 
its neutralization by human convalescent serum. In subsequent years 
several isolations were made and shown to be antigenically similar to 
this original isolate.
1.1.2 Classification
Since the initial isolation of the influenza virus, the structure 
and much of the chemical composition of the virus has been elucidated* 
Briefly, the virus contains ribonucleic acid, surrounded by protein, 
the ribonucleoprotein. This ribonucleoprotein, or soluble complement- 
fixing antigen, differs within the group and has led to the subdivision 
of the group into types A, B and C (idIO Committee, 1953). The majority
O
of virus particles are roughly spherical, measuring 800 - 1200 A in 
diameter, and are surrounded by an envelope with radial projections.
These radial projections, made up of glycoproteins, are associated with
two properties of the virus. These are; the haemagglutxnin, which 
confers on the virus the ability to agglutinate fowl and some mammalian 
red blood cells; and the enzyme neuraminidase, which breaks down the 
attachment of virus to red blood cells. These properties are common 
to a number of viruses which constitute the group Myxoviruses, originally 
described by AndrewesAct al. (1950). This group has been divided into 
two sub-groups, the Orthomyxoviruses, which include the influenza viruses 
types A, B and C only, and the Paramyxoviruses, which include 
parainfluenza viruses types 1, 2 (including simian viruses SV5 and SV4l),
3 and 4, Newcastle disease virus, mumps virus, respiratory syncytial virus, 
and the measles, distemper, rinderpest triad. Members of the latter 
group all possess a number of common properties which differ from those 
of the influenza viruses.
1.1,3 Epidemiology and nomenclature
Influenza group A viruses are associated with the major epidemics 
of today and presumably .with the epidemics reported before the isolation 
of the virus. The epidemiology of influenza A has followed a very 
distinct pattern over the last 80 years. In the previous 30 years 
influenza had become rare, but since the pandemic in 1889-90 influenza 
has been much more prevalent, possibly due to the growth of world industry 
and travel. The main characteristic of influenza A epidemiology is 
that approximately every 10 years a major pandemic occurs, associated 
with a new antigenic type which completely replaces any previous strain 
(Table l.l). Such changes are termed antigenic shift and ha\re led to 
much speculation, but little evidence as to their origin. In between 
pandemics, outbreaks in any one area tend to occur every few years, 
almost always in winter months. During these times minor antigenic 
changes, termed antigenic drift, occur.
Initiall5r every virus isolate was labelled in an arbitrary manner, 
often after the place of isolation. The variation found within the 
influenza viruses necessitated some form of classification and 
nomenclature. As stated earlier, the WIO Committee (1953) recommended 
the division of the group into types A, 3 and C. In addition, a 
major change in the A group associated with a change in the', haemagglutiniri- 
antigen ■ (detected by neutralization of haemagglutination by antisera) had 
occurred. Thus the V/HO Committee recommended sub-typing the influenza A 
group on the basis of the haemagglutinin antigen. The above two properties 
(ribonucleoprotein and haemagglutinin antigen), plus place of isolation, 
strain serial number, and year of isolation, formed a comprehensive naming 
system. However, in later years a further property of the influenza A 
virus, the neuraminidase, was found to undergo independent antigenic 
variation. Thus in 1971 the'V/HO Committee recommended the inclusion 
of the neuraminidase antigenic subtypes into the nomenclature system.
In Table 1.1 examples of both the old and new nomenclature systems are 
given, together with the years of prevalence of each major type.
Apart from human influenza, members of this group also infect a 
number of domestic animals, causing respiratory infections in swine, 
horses, ducks and turkeys, and a fatal general infection, fowl plague, 
in chickens. The method of nomenclature for these animal viruses is 
similar to that of the human isolates, but in addition the host is 
included in the name. The host is also designated for the haemagglutinin 
and neuraminidase, which refers to the source of the virus where the 
antigen was first characterized. From Table 1.1, with the new 
nomenclature system, it may be seen that antigens common to both human 
and animal strains occur, and may be important in the epidemiology of 
influenza A.
TABLE 1.1 NOMENCLATURE'OF THE INFLUENZA A GROUP
Prevalent years Reference strain Reference strain
for each subtype (1953 nomenclature) (1972 nomenclature)
1933-1946 AO/PH/8/34 A/PR/8/34(HON1)
1946 - 1957 Al/FM/l/47 A/FM/l/47 (li IN l)
1957 - 1967 A2/S ingap ore/1/57 A/Singapore/1/57(H2N2)
1957 - A3/Hong Kong/l/68 A/Hong Kong/l/68(lI3N2)
1930 A/Swine/i/iscdnsin/l5/30 A/Swine/hIisconsin/l5/30(H SwlNl)
1970 A3/Swine/Taiwan/l/70 A/Swine/Xaiwan/l/70(H3N2)
The influenza B viruses also undergo antigenic drift. However, 
both the haemagglutinin and neuraminidase antigens of recently isolated 
strains have been shown to be related to the antigens of early isolates 
of influenza B (Schild et al., 1973), and thus no subtyping is necessary. 
Small epidemics of influenza B do occur periodically, and on occasion 
i/idespread outbreaks are associated with increased mortality, as in 
1982 in the United Kingdom (Schild et al., 1975).
Influenza C is of small concern to man. Although antibody has 
been found to be widely distributed in adults (Minuse et al., 1954) 
the virus is rarely isolated from epidemic situations, and probably 
causes inapparent more often than overt infections.
1.1.4 Clinical features of influenza and problems of diagnosis
Influenza is an airborne infection/involving replication of the 
virus in the surface epithelium of the respiratory tract. After an 
incubation period of 24 ~ 48 hours, symptoms of two kinds develop.
These involve symptoms dependent on cellular infection, and those 
resulting from the toxic properties of the virus. Symptoms associated 
with cellular destruction in the respiratory tract include coryza, coughin 
and congestion of the conjunctivae, and are common to all respiratory 
infections despite the diversity in aetiology. Toxic symptoms, fever, 
headache, lassitude and muscular pains are typically much more severe 
in influenza than in any other respiratory infection. Despite the 
debilitating effect of the disease recovery normally occurs after 
approximately a week. The high mortality associated with influenza 
epidemics in the past has been attributed largely to secondary bacterial 
infection. With the advent of the antibiotics this mortality has been 
greatly reduced. However, today increased mortality is still associated
with influenza epidemics, and occurs chiefly in the elderly and 
chronically sick (Assaad and Reid, 197l). In the epidemic of 1918 
pneumonic symptoms.-were severe, and death even in.young adults frequently 
occurred within 24 hours of onset (Hoyle, 1968). Whether this mortality 
was caused directly by a strongly pneumotropic influenza strain or some 
other factor is not known. In more recent years, in terminal cases of 
influenza where no bacterial pathogens have been isolated, influenza virus 
has been considered the primary cause of death (Hers et al♦, 1958;
Lindsay et al., 1970).
To the general practitioner the diagnosis of influenza does not pose 
a very great problem, mainly because the treatment of infection does not 
require a specific diagnosis; in these cases clinical diagnosis suffices. 
However, clinical trials to determine the efficacy of a new vaccine or 
anti-influenzal compound, and epidemiological studies, pose a much greater 
problem. In Table 1.2 a list of all the viruses reported to have caused 
respiratory infections, many of which may be mistaken clinically for 
influenza, has been compiled from work by Tyrrell (1969) and Andrewes and 
Pereira (1972). It is impossible with complete certainty to diagnose 
influenza on a clinical basis alone. Even during an epidemic of influenza 
other respiratory viruses may be circulating. Thus for critical studies 
of influenza to be made in the situations mentioned, it is imperative that 
either the virus is isolated and identified, or that a rise in influenza 
antibody is detected during infection. With clinical trials it is also 
desirable that antibody levels in subjects should be matched in treated 
and untreated groups before commencing a trial. The presence of pre­
existing antibody may greatly affect the disease syndrome, and thus the 
outcome of a trial. ,
TABLE 1.2 VIRUSES CAPABLE OF CAUSING RESPIRATORY INFECTIONS
Virus group Type of nucleic acid Virus and serotypes involved
Poxvirus
Herpesvirus
Adenovirus
Myxovirus 
(Orthomyxovirus)
Myxovirus 
(Paramyxovirus)
Reovirus
Coronavirus
Picornaviridae
DMA
DNA
DMA
RNA
RNA
RNA
RNA
RNA
Variola
Herpes simplex type 1
Types 1, 2,3, 4, 5, 6, 7,
14 and 21
Influenza A, B, C
Parainfluenza types 1, 2, 3, 4 
Respiratory syncytial virus
3 mammalian serotypes
Not recorded
Coxsackie, group A, 24 types 
group B, 6 types
Echovirus, over 30 types
Rhinovirus, over 89 types
1.2 INFLUENZA CHEMOTHERAPY
1.2.1 Methods employed in influenza chemotherapy
1.2.1.1 General problems and requirements for detecting and quantitating
an t i-in1 1u enzaI ac t i v i ty
In experimental chemotherapy preferably at least two systems are 
required for detecting and quantitating antiviral activity. These are, 
firstly, a fairly simple, rapid in vitro method which may be used to detect 
antiviral activity, and secondly, an in vivo system which may be used to 
establish whether the antiviral activity is great enough to be demonstrable 
in animals. This system of screening for antiviral compounds is not 
without drawbacks. Compounds not active in vitro may possibly become 
active when metabolised within the animal body, and similarly compounds 
not active in animals may be active in man. However, in vitro methods 
are' important to antiviral chemotherapy because of the time factor involved 
in screening a large number of compounds. Likewise, in vivo methods are 
necessary because of the time and expense involved in conducting trials 
in man. Apart from establishing antiviral activity in vivo, animals are 
also very important in determining the pharmacology and toxicology of a 
compound before it is administered to man.
For any system to be suitable for use in antiviral chemotherapy, 
the virus involved must grow reasonably well and reliably in that system.
It is also desirable that the virus may be titrated in the chosen system, 
so that the input dose of virus may be calculated which will be 'dependent 
on the sensitivity of the virus to that system. "Where- some effect of the 
virus infection is measured, such as cytopathic effect in cell culture, 
or survival time in animals, it is necessary that such an effect be 
related to the input dose of virus, before an antiviral effect may be 
quantitated. Accurate titration of virus growth is of prime importance 
to chemotherapy research. Influenza virus strains may be titrated in a
number of ways. The most simple method is by haemagglutination 
(Salk, 1944). Here two-fold dilutions of virus are made, followed by 
the addition of an equal volume of a 0.25% suspension of red blood cells. 
After 1^- - 2 hours incubation the virus titre is read as the dilution of 
virus \diich gave 50% haemagglutination. However, this method does not
titrate infectivity of the virus, since incomplete virus particles may
6
still be capable of agglutination; also approximately 10 virus particles 
per millilitre are required for haemagglutination to occur (Fazekas and 
Cairns, 1952). Infectivity titrations of virus may be conducted in two 
different ways. Firstly, quanta! assay, where dilutions (10-fold or 
3.2-fold) of a virus are inoculated in replicate into a system capable 
of maintaining growth of the virus (cell cultures, eggs or animals).
Growth in each replicate is then scored as plus or minus and the 
50% infective dose (ID50) is calculated as described by Karher (l93l) or 
Reed and Muench (1937). Presence of growth may be determined in a 
number of ways, but the method most commonly used with influenza is 
haemagglutination. In animals death (LD50) is the criterion frequently 
used, and in cell cultures the cytopathic effect (CPE). However, the 
majority of influenza strains produce poor CPE in cell cultures and an 
alternative method, haemadsorption, is employed. Haemadsorption was 
first observed by Vogel and Shelokov (1957), and involves adsorption of 
red blood cells by cells infected with influenza virus. The alternative 
method of titrating infectivity is by enumeration of focal lesion 
produced by a virus. With influenza virus strains the method used is 
plaquing in cell cultures. Plaques are foci of cell destruction 
produced under a solid medium which limits the spread of the virus.
It is assumed that with this method each plaque is produced by a single 
infective particle, and allowing for dilution of the virus a direct count
of infective virus particles can be made. -.However, with influenza 
virus strains not all particles appear capable of producing plaques, and 
thus lower titres are obtained with this method than with some methods 
employing quantal assay (Beare and Keast, 1974).
Numerous methods have been employed to study the chemotherapy of 
influenza because of the lack of any single reliable system, and because 
influenza is capable of infecting'a wide range of hosts. Ferrets, mice, 
fertile, hens’ eggs and various cell cultures have been used. Apart 
from these variations, other variables within a single method make 
comparison of the activity of reported anti-influenzal compounds.a 
difficult task. . Such variations have included the input of virus used,
"which may in in vitro systems vary from 100 virus particles per cell 
(single cycle growth) down to 10 ID50 per culture system (multiple cycle 
growth), and in vivo from 600 LD50 down, to doses below 1 LD50. The other 
main variable, particularly „in animal systems, has been the administration 
of the test compound. Not only has the range of doses of compound used 
differed, but the time of administration, whether commencing before or 
after infection, has varied greatly. In vivo the compound has been 
administered by a number of different routes, which have included 
intranasal spray, intraperitoneally, orally or subcutaneously, and on 
occasion even in the drinking water.
Apart from detecting antiviral activity a quantitative estimate
of the toxicity of an active compound within the same system is also
required to indicate the selectivity of a compound. The selectivity
or therapeutic index of a compound is generally defined as the
Maximum subtoxic dose ( M S P ) _________  . Again variation arises;
Minimum inhibitory concentration (MIC)
the MIC, which may vary with the dose of virus employed, has been taken
to be the dose of compound iv'hich causes 50% inhibition (McLaren andPot*terjl973) ,
75/o inhibition (Tamm et al., 1953c) or greater than 90% inhibition 
(Tovoshima et al_., 1963) .
Another variable is the methods employed to determine the toxicity 
of a compound. In cell culture systems these have included gross 
morphology of cells (Tamm, 1956), oxygen consumption of cells (Tamm et al., 
1952), uptake of neutral red (Finter, 1969), retardation of cell growth 
(Davies £t aJ., 1964), direct count of viable cells (Neumayer et al., 1965) 
and inhibition of cell protein synthesis (Huffman et al., 1973).
In vivo a rough measure of toxicity has been made by determining the 
dose of compound which will cause 50> mortality or give visible signs 
of toxicity (e.g. weight loss). Detailed histological studies are 
generally only conducted when a compound is sufficiently active to be 
considered for trials in man.
The systems employed in anti-influenzal chemotherapy will;be 
discussed in chronological order. It is worthy of note that many of 
the methods initially employed have been used fairly extensively in 
recent years. The introduction of new methods, not always an improvement 
on the old, has made the situation more, not less, complex.
1.2.1.2 In vivo systems
As stated earlier, influenza was first isolated successfully 
in ferrets (Smith et al,, 1933). Despite the fact that the disease 
syndrome in these animals after intranasal inoculation of virus is 
comparable to influenza in man, they have only rarely, and in recent 
years, been used for studies in. chemotherapy (Pollikoff et al., 1965; 
Cochran et al., 1965; Pinto and Ilaff, 1969; Ilaff and Pinto, 1970).
In these papers methods used to detect antiviral activity included 
reduction .in mortality, lung consolidation, excretion of virus into the
nasal cavities, and rectal.temperature. The limited application of this 
system in testing for anti-influenzal activity has presumably arisen from
the availability, cost and difficulty of working with such animals,
particularly since mice have been found to be susceptible to influenza 
infection (Andrewes et al*, 1934). When virus infected lung extracts 
were passaged intrahasally in mice the virus was found to become adapted, 
causing pneumonia with massive lung consolidation and subsequent death 
(Francis and Magill, 1937a).
The earliest papers on influenza chemotherapy involve screening 
for antiviral activity in mice infected with- the mouse-adapted 
A/PR8/34(lI0Nl) strain (Coggeshall and Maier, 1942; Andrewes et al*, 1943;
Krueger, 1943). The method employed consisted of inoculating mice
intranasaily under light ether anaesthesia with a lethal dose of virus 
(2-10 LD50). Results were recorded either as death of mice up to 
10 days and comparison with mortality in controls, or surviving mice 
were killed at day 7 and the extent of lung consolidation was scored 
from 0 5. In later work the sensitivity of the method was increased
by including the mean survival time of mice (days) in the analysis of 
activity (Fleisher, 1949; Vinson and ^alslrijlOoO) . This criterion has
been employed repeatedly. However, the time allowed before termination 
of the experiment has varied greatly, from 12 days (Schild cind Sutton,
1965) to 21 days (Khare et al., 1973), and this has affected the 
calculation of mean survival time when 100% mortality was not obtained.
Further modifications of the methods employed in mice have 
involved direct titration of the virus content of the lungs, either 
by infectivity titrations conducted in ovo (Ackermann, 1951b) or 
less frequently in cell culture (Style et al., 1964), or by haemagglutination 
after first treating with cholera filtrate to remove unspecific inhibitors
of haemagglutinin (Mogabgaban^Hors?all,l952) . All the above methods have 
been employed in screening for anti-influenzal activity from the earliest 
years up to the present time. However, reduction in mortality has been, 
and is, much more widely used than any other method, despite the 
observations by Groupe <et <fL. (1952) that x.erosin, an extract from 
culture filtrates of Achromobactcr species, inhibited lung consolidation, 
and consequently mortality, without inhibiting growth of the virus within 
the lungs. Thus when compounds have been found which significantly reduce 
mortality in mice, detection of a reduction in virus growth in the lungs 
is necessary to demonstrate specific activity (Davies et al., 1966).
However, a linear dose response effect of compound against percentage 
mortality has been observed, although much variation has necessitated that 
a large number of mice be used for each reading (Link et alU , 1961a, 1961b; 
Grunert et al., 1965; Flagg et al., 1989; Peters et al., 1970),
Some workers in more recent years have attempted further modification
of the system, by detecting reduction in the frequency of rales (Kaji
et al., 1970), the weight loss of infected mice (Hoffmann, 1973), and 
reduction in the water uptake of infected mice (Hoffmann, 1973). Again 
these methods depend on indirect effects of the virus, and have not been 
widely employed.
Finally two different methods of infecting mice intranasally 
have been employed in influenza research. These are: direct inoculation
of virus (0.05 ml) under light ether anaesthesia, and natural inhalation 
of an aerosol of influenza virus within closed conditions. Although 
the initial method has been criticised for giving variable results 
(Bowers et al., 1952), both methods have been used repeatedly and appear
to give comparable results. Apart from mice and ferrets, both dogs
(Coombes et af., 1970) and horses (Bryans et al., 1986) have been employed 
in this line of research.
1.2.1.3 In ovo and related systems
Soon after the isolation of the first influenza virus strain, 
the virus was shown to be capable of growth in the amniotic sac of the 
embryonated hen’s egg (Burnet, 1940), and later in the allantoic cavity 
(Burnet, 1941). The earliest report on the use of eggs in influenza 
chemotherapy appeared in 1946 (Green et al., 1946). From this time, 
chicken eggs have been used widely in screening for anti-influenzal 
activity, with little change in the procedure adopted in this initial 
paper. Generally, a virus dose of 10 - 100 EIDSOyis used, and 
test compound is administered either into the allantoic cavity or the 
yolk sac. Antiviral activity is detected by a reduction in haemagglutinin 
titre after 24 or 48 hours incubation.
The in ovo system is not ideal for anti-influenza screening.
Apart from being rather cumbersome on a large scale, such a complex 
isolated system offers conditions totally unrelated to those fotfnd within 
the animal body. A modification of the in ovo technique was developed 
by Bernkopf (1949). Here, the eggs were de-embryonated, leaving the 
chorioallantoic membrane still attached to the shell, and after infection 
a suitable medium was used to fill the eggs, which were finally sealed. 
Although this system is less complex than the whole egg, it is again 
uneconomical for large scale work, and has only rarely been used for 
detecting anti-influenzal activity (Liu et al., 1957; Engle and. Ltu, 1962; 
Altucci et al., 1969).
Further adaptation of the in ovo system was devised by Fulton 
and Armitage (1951). The chorioallantoic membrane was removed from the 
egg and cut into squares which were placed in cups of a tray, with 
suitable medium, and shaken to obtain sufficient oxygenation. Horvath (1954) 
modified the method further by mincing the chorioallantoic membranes of
several eggs, which were placed in tubes with medium and rolled.
Both methods, with variations, have been employed in detecting and 
quantitating anti-influenzal activity, with activity determined either 
by inhibition of infectivity or haemagglutination. Apart from being 
much more economical and simpler than the in ovo system, it became 
possible to initiate single cycles of infection with high multiplicities 
of virus, thus allowing much more sensitive quantitative work (Tamm et al., 
1953a).
These methods are analogous to cell culture systems, and were 
the main methods employed in influenza chemotherapy research during 
the 1950’s. However, Fazekas and White (1958) improved the method 
further, by cutting squares of chorioallantoic membrane still attached 
to the eggshell. These ”egg pieces” were placed in cups of a sterile 
haemagglutination tray and shaken mechanically during incubation. The 
eggshell was found to act as a stronger buffer, keeping the pH at 
approximately 7.4 throughout the experiment, as opposed to pH 8.3 when 
no shell was present. This resulted in higher yields of virus and a 
much more efficient titration system. Although titres obtained with 
this system are lower than with in ovo titrations, the egg piece technique 
has largely replaced the latter. In recent years this method has also 
been adopted in detecting anti-influenzal activity (Oxfordan<lPerrin/973).
1.2.1.4 Cell culture systems
The first true cell culture method used for the cultivation of 
influenza virus strains was not surprisingly developed from the chick 
embryo. Minced chick embryo cells grown in Tyrode's solution were 
first used to isolate influenza from man by Francis and Magill (1937b). 
However, chick embryo cell culture was not used to study influenzii
chemotherapy for many years (Cushing and Morgan, 1952), and was not widely 
used within this field until the last decade. Primary monkey kidney cells 
have also been employed fairly extensively in influenza chemotherapy 
research.
Over the years attempts have been made to cultivate influenza 
in a wide range of cell cultures, in particular continuous cell cultures 
as opposed to the cumbersome and more variable primary cultures. Many 
of these attempts have been successful, with the result that many 
different cell cultures have been employed in influenza research.
A summary of the cell cultures used, together with methods of detecting 
and titrating antiviral activity, has been compiled in Table 1.3.
Where inhibition of some effect of the virus such as CPE or haemadsorption 
has been employed in detecting activity, quantitative results have been 
obtained by scoring the extent of such an effect. In this way the 
concentration of compound which causes 50% inhibition of viral growth 
can be found (Jensen et al., 1961). Similarly, where immunofluorescent 
antibody has been used to detect virus growth, a quantitative result has 
been obtained by counting the proportion of cells showing positive 
fluorescence (Tsunoda et al., 1965; Oxford and Schild, 1968). However, 
for haemadsorption a non-subjective quantitative method has been developed 
(Ginzburg and Traub, 1959) where the haemoglobin of adsorbed erythrocytes 
is assayed spectrophotometrically, after being released by treatment with 
pyridine or distilled v/ater.
The wide range of cell cultures employed in influenza chemotherapy 
indicates the lack of a "good” reliable cell culture system for influenza 
research. Similarly plaquing, which is an ideal method for detecting and 
quantitating antiviral activity, has rarely been employed in influenza 
chemotherapy, although many virus strains are reported to plaque in a
TABLE 1*3 CELL CULTURES EMPLOYED IN INFLUENZA CHEMOTHERAPY RESEARCH
Cell culture Type of culture Method of detecting and titrating virus
Chick embryo fibroblast cells Primary
Monkey kidney cells
Dog kidney cells
Calf kidney cells
Baby hamster kidney cells
Chick lung cells 
HeLa cells
Krebs2 ascites cells 
Svrine kidney cells
Chang conjunctival cells 
clone 1-5G-4
Primary and 
secondary
Primary
Continuous line, 
e.g. MDCK line
Primary
Continuous
(B H K 2 1 )
Primary
Continuous
Continuous
Primary
Continuous
Haemagglutination
Kaemadsorption
CPE
Plaquing
Haemagglutination 
Haemadsorption 
CPE
Immunofluorescence 
Infectivity (in ovo)
Plaquing
Plaquing
CPE
Haemagglutination .
Haemagglutination 
Haemadsorption 
Infectivity (egg piece) 
Immunofluorescence
Haemadsorption 
Immunofluorescence
Haemagglutination
Haemadsorption 
Immunofluorescence
Haemagglutination
CPE
Haemagglutination 
Infectivity (in cell 
culture)
Haemagglutination 
Infectivity (in ovo) 
Plaquing
wide range of cell cultures (Choppin, 1982; Gaush and Smith, 1988;
Beare and Keast, 1974). However, there are many reports of the 
difficulties of obtaining plaques with the majority of influenza strains. 
Only a few "laboratory" strains, such as A/NWS/33(HONl) and A/FPV/Batch/ 
27(Hav'lNeql) fowl plague virus, are reported to plaque reliably, and 
thus have frequently been employed in research. These strains, however, 
are unsuitable for detecting anti-influenzal activity since their 
sensitivity may differ from that of more recent strains.
1.2.1.5 Organ culture systems
Organ cultures of ciliated respiratory epithelium have been 
employed in recent years in the study of respiratory viral diseases, 
and have proved particularly useful in the isolation of previously 
unknown respiratory viruses (Hoorn and Tyrrell, 1969). In addition, 
organ cultures from a number of animal species have been examined for 
their suitability for the propagation of influenza A and B virus strains. 
The cultures employed have included human foetal tracheal and nasal 
cultures (Hoorn and Tyrrell, 1965), ferret tracheal (Gould et al., 1972), 
mouse tracheal (V/esterberg et al., 1972) and chick embryo tracheal 
cultures (Blaskovic et al., 1972). In the majority of examinations 
growth of the virus was recorded, and was frequently but not always 
associated with a loss of ciliary activity. Organ cultures have only 
been employed on a limited basis in the field of influenza chemotherapy. 
At least two studies have been conducted, one with human tracheal and 
nasal cultures (Tyrrell et al., 1965), and one with dog tracheal cultures 
(Williamson and Jackson, 1989). In both studies a reduction in virus 
yield was recorded, together with a reduction in damage to the ciliated 
epithelium. Although the effect of compounds on differentiated cells of
the ciliated epithelium is of interest to chemotherapy,. the cumbersome 
nature of such systems has meant that they have not been employed widely 
in anti-influenza! chemotherapy.
1.2.1*6 Enzyme assay systems
In addition to detecting antiviral activity by inhibition of 
growth of the virus, two enzyme assay systems have been employed to 
detect compounds capable of inhibiting enzyme activity. The first of 
these enzymes, neuraminidase, was initially employed in screening for 
potential anti-influenzal compounds by Edmond et al. (1956). Similar 
methods have since been employed in screens by Wagner et al. (1967),
Tute et al. (1970) and Haskell et al.'; (1970). Briefly, a glycoprotein- 
rich substrate (erythrocyte stroma, mucoid) with the enzyme (intact 
influenza particles) were mixed at 37°C at a pH of 5.5 - 6.5. 
N-acetylneurarainic acid or sialic acid liberated by the reaction was 
estimated colorimetrically.
RNA-dependent RNA polymerase, or RNA synthetase, has been
found to be synthesized in infected cells by a number of RNA viruses
including influenza virus (Glasky and Holper, 1965). This enzyme
was first extracted from influenza infected cells by Glasky and
Holper (1963), who later developed an assay system which was used to
detect inhibition of this enzyme (Glasky and Holper, 1965). A similar
method has also been employed by Ho et al. (1967) and Oxford (1973),
but with the latter intact purified virus particles were employed as a
source of the enzyme (i.e. particle-associated RNA polymerase). The
substrate employed in the assay consisted of a mixture of adenosine,
cytidine, uridine and guanosine triphosphate, with one of the nucleotide
14labelled with either C or tritium. The amount of radioactive 
labelled nucleotide incorporated into RNA was determined by
scintillation counting of the acid-precipitated RNA.
The above two assay systems are both of considerable interest 
in that they offer a new approach to antiviral chemotherapy. Inhibition 
of these virus-specific enzymes may not only give further understanding 
of the replication of the influenza virus, but offer areas of replication 
where selective compounds may act. Neither method is ideal as an 
initial screening method,unless employed alongside a cell culture 
system, since many compounds found active in enzyme assay may not be 
active In vitro and vice versa.
1«2.2 Compounds of minor interest to anti-influenzal chemotherapy
A great number of compounds have been reported active against 
influenza virus. The earliest reports appeared in the 1940's, when a 
large number of antibiotics and sulphonamide derivatives were screened 
for activity against influenza viruses, but with little success 
(Krueger, 1943; Coggeshall and Mciier, 1942). Despite the number of 
compounds reported active, few have undergone further study.
Several possible reasons why such compounds have not undergone 
further development may be put forward. Probably one of the most 
frequent has been their high toxicity. The replication of viruses 
is so closely linked to cell metabolism that toxicity forms a major 
drawback to developing antiviral compounds. In some cases the levels 
of toxicity reported have been so high that the validity of the 
experimental findings appears questionable (Green et al., 1946;
Machlowitz et aJ•, 1933). Another important factor has been inactivity 
in vivo. Many compounds are either insufficiently active, act on a 
stage in replication difficult to inhibit within the animal body, or 
are broken down too rapidly in vivo. A third major reason has been
the high concentration at which activity has been reported, often 
too high to be considered for use in man. Particularly in earlier 
papers, the concentrations of compounds employed for detecting activity 
were very high. However, in more recent years, particularly since a 
number of compounds have undergone trials in man, much lower levels 
have been employed. In cell culture systems concentrations of 
50 - 100 pg/ml have been employed for initial detection of activity, 
which in ovo is equivalent to 1 - 2 mg/egg, and in vivo to a dose of 
50 - 100 mg/kg, assuming that the compound is perfectly absorbed and 
distributed. However, if these levels are calculated to apply to a 
70 kg.man, an unacceptably high dose of 3.5 - 7 g would be required 
even before alloi/ing for incomplete absorption and loss by metabolism 
and excretion. These high dosage levels have been employed for 
detecting activity, to ensure that no active compound is missed.
However, any compound found active must show substantial activity at 
much lower concentrations before it can be considered for use in man. 
Other reasons why compounds have not been developed, such as problems 
in synthesis and cost of production, have probably played some part in 
eliminating certain compounds.
A knowledge of the replication of influenza viruses is of 
great importance to anti-influenzal chemotherapy for establishing the 
mode of action of active compounds. Although it is possible to divide 
the replicative process up into a number of stages, little detail of 
the factors and reactions involved in these stages is known. Anti- 
influenza.l agents have helped to elucidate much of the process involved. 
Basically there are four stages where an antiviral agent may act.
These are on
1. infectious virus particles not associated with the cell;
2. virus attachment to and penetration into the cell;
3. virus production within the cell;
4. virus release from the cell.
By finding the time at which a compound is active during the replicative
process it is possible to establish which of the above stages is affected
However, to elucidate the exact mechanism by which a compound acts is
much more difficult, and has rarely been achieved. Stage 3 encompasses
the whole reproduction of viral components, which for influenza includes
synthesis of viral RNA, proteins and glycoproteins. Although our
knowledge is incomplete, it has been established that both a cell DNA-
dependent RNA polymerase (Barry, 1964) and a viral RNA-dependent RNA 
and Holper
polymerase (Glasky^ 196o) are involved in the synthesis of influenza RNA.
The compounds considered within this section have been divided up 
into groups as far as possible, depending on the stage of replication 
affected by the compound. Stages 2 and 4 have been combined, since the 
process involved in attachment and release from the cell appears to be 
similar, in that some compounds inhibit both stages. Compounds which 
affect stage 3 have been further divided into those which affect protein 
synthesis, carbohydrate synthesis and nucleic acid synthesis. Many of 
the compounds within these sub-divisions have been included because 
they are structural analogues of virus constituents, and in many cases 
their activity has been reversed by adding the appropriate constituent.
In addition, apart from compounds where no mode of action has been 
established, a number of compounds known to inhibit energy production 
within the cell have been examined for antiviral activity. A list of 
all the compounds included vrithin these groups, together with their 
structures, are given in Tables 1.4 - 1.10.
1.2.2.1 Group 1 : Compounds causing direct inactivation of the virus 
Compounds within this group are of little importance to anti-
influenzal chemotherapy. Although inactivating agents have been 
considered for use in chemotherapy (Oxford et al., 197l), none have 
shown substantial activity in vivo« This is not surprising, since 
free virus particles are only present within the body for short periods.
Even specific antibody, a highly potent inactivating agent, is of limited 
value in treating virus infections. However, such agents may be of 
interest in other fields of study, such as the structure of the influenza 
viruses (Nerome et al., 1972).
1.2.2.2 Group 2 : Compounds affecting virus entry into and exit from the cell 
The structure of compounds included within this group is
given in Table 1.5. Only two of these compounds, caprochlorone and 
the a-arainosulphonic acid, appear to affect both entry into and exit from 
the cell. Although a-amino-p-methoxyphenylmethanesulphonic acid is an 
analogue of tyrosine, its activity is not reversed by this amino-acid.
A number of compounds such as apple pectin and the dextran sulphates 
inhibit the haemagglutination reaction, and their activity is attributed 
to their adsorption to cells. Kelp extract, the N~substituted oxamie 
acids and 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid are 
neuraminidase inhibitors, which also inhibit growth of the virus iur vitro. 
These compounds have been included within this section because 
neuraminidase is considered to be involved in release of the virus 
from the cell (Seto and Chang, 1969). Only three compounds, caprochlorone, 
the a~aminosulphonic acids and 2-diethylandnoethyl-4-methylpiperazine-l~ 
carboxylate, showed marginal activity iji vivo.
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1.2.2.3 Group 5 t Compounds affecting replication within the cell :
a) Inhibitors of protein synthesis
The majority of compounds included under the above heading are 
amino~ac.id analogues. V/here examined, the inhibitory activity of these 
analogues has been reversed by the appropriate amino-acid. This implies 
that these analogues are acting as competitive inhibitors in enzyme 
reactions, probably involving synthesis of viral proteins. The mode of 
action of p-fluorophenylalanine has been studied in greater detail 
(Scholtissek and Rott, 1961). This analogue was found to have a dual 
effect. When added at the time of infection/synthesis of viral RNA 
was completely suppressed, but when added 2 hours after infection 
RNA but no infectious virus was synthesized. The inhibition of RNA 
synthesis was considered to be caused by inhibition of some 1 early viral 
protein1, possibly the RNA-dependent RNA polymerase of the virus, and the 
latter effect caused by incorporation of the analogue into virus structura 
proteins. Most work with ainino-acid analogues has been conducted 
in vitro; where the analogues were tested for activity in vivo all were 
inactive, with one exception. Certain alanine analogues examined by 
Fujita (1973) reduced mortality in mice by reducing multiplication of 
the virus and the pulmonary consolidation induced by the virus. Finally, 
an analogue of the vitamin pyridoxine has been found to inhibit influenza 
replication (Cushing and Morgan, 1952). Although no attempts were made 
to elucidate the mode of action of this analogue, inhibition of protein 
synthesis was suggested because pyridoxine is involved in transamination 
reactions within the cell.
b) Inhibitors of carbohydrate synthesis
Only two glucose derivatives, D-glucosamine and 2~deoxy-U- 
glucose, may be included under the above heading. Both of these sugars
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are'known to interfere with carbohydrate metabolism of cells, and are 
highly toxic. However, many workers in recent years have studied the 
effect of these two inhibitors on influenza virus replication 
(Kaluza et al., 1972; Gandhi et al., 1972; Klenk et al., 1972).
These sugars at high concentration (3 mg/ml) were found to inhibit 
the production of the glycoproteins which constitute the haemagglutinin 
and neuraminidase of the envelope of the virus. Viral RNA and protein 
synthesis were unaffected, and carbohydrate-free protein precursors of 
the haemagglutinin were detected within infected cells (Klenk et al., 
1972). It was postulated that these sugars may act by creating an 
imbalance in the nucleotide pool of the cell, from which uridine 
diphosphate is intricately linked with polysaccharide synthesis 
(Gandhi et al,, 1972).
c) Inhibitors of nucleic acid synthesis
Included within this category are a number of compounds which 
have been further divided under a number of headings. The first of 
these sub-groups includes compounds which are known to or considered to 
inhibit the cell enzyme, DNA-dependent RNA polymerase, either directly 
(a-amani.tin) or by affecting cell DNA (actinomycin D, mithramycin).
The most extensively studied within this sub-group is actinomycin D.
These studies have revealed that the DNA-dependent RNA polymerase of 
the cell is required in influenza virus replication (Barry et al., 1962; 
Barry, 1964). Although the compounds within this sub-group have been 
important in studying virus replication, all are too toxic to be 
considered for use in chemotherapy. The members of the second sub-group 
are all analogues - apart from Aminopterin - of constituents of nucleic 
acids. The modes of action of many of these analogues have not been 
elucidated, but in view of their structure all are considered to affect
a; INHIBITORS OF CELLULAR DNA-DEPENDENT RNA POLYMERASE
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nucleic acid synthesis. The mode of action of Aminopterin, an analogue 
of folic acid, is less certain. Folic acid, an important compound within 
the ceil, is involved in several metabolic processes, including the 
synthesis of purine bases. Thus it has been suggested that Aminopterin 
affects nucleic acid synthesis. The members of the final sub-group 
are all inhibitors of viral RNA polymerase, and were investigated by 
the enzyme assay system described in the previous section. Both 
selenocystamine and 1-methylisatin 3-thiosemicarbazone have been shown to 
inhibit replication of the virus in vitro (Bauer et al., 1970; Oxford and 
Perrin, 1974) , and selenocystine and l-methylisatin 3-thiosemicarbazone 
have been found active in vivo (Ho et al., 1967; Smejkal et al., 1971) .
1.2.2.4 Group 4 : Compounds affecting energy production of the cell 
The majority of compounds included under this heading were 
studied by earlier workers to establish the importance of cellular energy 
production in viral replication. Both 2,4-dinitrophenol and butyl-3,5- 
diiodo-4-hydroxybenzoate (and other thyroxine analogues) uncouple 
oxidative phosphorylation, and sodium fluoroacetate poisons the Krebs 
cycle. All these compounds are highly toxic to the cell, and have 
never been seriously considered as possible chemotherapeutic agents. 
However, Ackermann (1951) suggested that less toxic compounds developed 
along these lines of research may possibly be of use in chemotherapy.
The fact that no such compounds have appeared further substantiates 
that viral synthesis is totally dependent on energy production by the 
cell, as indicated by the above workers.
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Eaton and Perry 
(1953)
Butyl~315~di iodo- 
4-hydroxybenzoate 
(analogue of 
thyroxine)
0n
c1
9
c4h9
Eaton et al. 
(1953)
3 jS-Diiodo-d- 
hydroxybenzene 
sulphonamide 
(analogue of 
thyroxine)
s-nh 2
Kundin et al 
(1964)
Tetramethyldipicryl Rosenbaum et al.
amine CH3 N 0 2 h^02 CH3 (1969)
ch3 n o 2 n o 2 ch3
1.2.2.5 Group 5 : Compounds with no established mode of action
Finally, in Table 1.10, compounds displaying a diversity of 
structure have been grouped together, simply on the basis that no 
information is available on their mode of action. This table completes 
the list of compounds included within this section.
1.2.3 Compounds of major interest to anti-influenzal chemotherapy
Apart from the numerous compounds reported to possess activity 
against influenza virus, a number have undergone more extensive study. 
Such studies have included the quantitation of activity in vitro and 
in vivo, mode of action studies, determination of the spectrum of 
activity, and examination of structurally related compounds. In a 
few cases development of resistance has been examined, and clinical 
trials have been conducted. The compounds included under the above 
heading are here considered individually and as far as possible in 
chronological order.
1.2.3.1 Benzimidazole derivatives
Structure-activity studies
Benzimidazole and its derivatives were first examined by Tamm 
and colleagues (Tamm et al., 1952) for anti-influenzal activity against 
influenza B/Lee/40 and A/PR8/34(H0Nl) by means of the egg-piece technique 
of Fulton and Armitage (1951). For all structure-activity studies an 
approximate multiplicity of 0.01 virus particle per cell was employed, 
and the virus yield was determined after 36 hours incubation by 
haemagglutinin titration. A 75% inhibition of haemagglutination was 
taken as the criterion of activity. The parent compounds of the 
derivatives to be discussed are illustrated in Fig. 1.1.
TABLE 1.10 COMPOUNDS WITH UNKNOWN MODES OF ACTION
Compound Structure References
Terramycin Vinson and Walsh 
(1950)
Nitroacridine
2,3-Dimethoxy~6* 
nitro-9(diethyl- 
aminooxypropyl) * 
arainoacridine 
dihydrochloride NHCH2CH(OH)CH2N (QH^
Green et al. 
(1946)
Rasmussen and 
Stokes (1951)
Cardiein 
(from Nocardia 
cultures)
Machlowitz et al. 
(1953)
D L -  Noforrnycin
(from Nocardia 
formica cultures)
H NHn
H N ^ N .  CO N H C H £ H 2CNH 2 Sidwell et al* 
(196S)
Urethane NH 2C O O C 2H5 Link et al* 
(1961a, b)
S-triazine
derivatives
e.g. 2-N-o- 
phenoxyphenyl- 
amino-4-amino- 
1,3,5-triazine
Angelucci et al. 
(1983)
Caffeic acid
3,4-Dihydroxy- 
cinnamic acid
1,l-Diaryl-2-
propynyl
carbamates
e.g. l-(4-Fluoro 
phenyl)-1-phenyl* 
2-propyny1-N- 
cyclohexyl 
carbamate
CH=CHCOOH
C = CH
Pollikoff
et al (1965)
Delong et al. 
(1967)
Compound Structure References
Benzthiazole
derivatives
e.g. 2-(4'- 
Pyridyl)benz­
thiazole mono­
methyl iodide
i+) l-l 
N-CH 3I
Vaczi et al* 
(1968)
Gergely et al. 
(1968)
2-Amino-4-chloro-
benzthiazole Akerfeldt (1970)
Thiazolidines
e.g. 5-Carboxy-
methyl-3-p-
tolylthiazolide-
2,4-dione 2-
acetophenone
hydrazone
c h 3c o Schauer et al. 
CH3 (1970)
Oxyamylose
(Polyacetal 
carboxylic acid)
Billau et al. 
(1971)
Sulphonaraide
derivatives
e.g. N-Carbo- 
ethoxysulpharaide
NH^qNHCOOCH.
Denys and Arnold 
(1971)
The first compound reported active was 2,5~diinethylbenzimidazole 
(Tamm et al., 1952, 1953a). After these initial papers Tamm et al.
(1953b, 1953c) studied the activity of a number of alkyl derivatives of 
benzimidazole. In summary, these workers observed that by increasing 
the number of substituents from one to three methyl groups in either the 
benzene or the imidazole ring, minor increases in activity were caused, 
and that increasing the size of the substituents from methyl up to 
propyl or butyl groups caused much greater increases in activity.
Next, Tamm et al. (1954) studied the structure-activity relationships 
of chloro and ehloroalkyl derivatives of benzimidazole and chloro and 
methyl derivatives of N-glycosylbenzimidazole. The chloro and 
ehloroalkyl derivatives of benzimidazole were found to possess increased 
activity over the corresponding alkyl derivatives. When chloro N-glycosyl 
derivatives were examined a great increase in activity was observed *vhen 
ribose was attached to the molecule (e.g. 5,6-dichloro-l-|3-B-ribofuranosyl 
benzimidazole, DRB), but this activity was again lowered if other sugars 
were substituted. The methyl derivatives of N-glycosylbenziniidazole 
were completely without activity. Further substitution with chlorine 
and other halogens increased activity, but there was no significant 
difference in activity between the various halogens employed (Tamm et al., 
1956). The (3-linked ribofuranosides were reported to be more active 
and selective than the a-isomers. All the above results have been 
summarised in Table 1.11, which was compiled from tables in the above- 
mentioned papers.
From this table it may be seen that benzimidazole and certain 
methyl derivatives are not sufficiently active to be considered for use 
in chemotherapy, but that the (3-linked ribofuranosylbenzimidazoles, in 
particular 4,5,6-trichloro-l-p-D-ribofuranosyl, TRB, possess significant
Benzimidazole derivatives
benzenoid i imidazole 
ring | ring
Benzimidazole
Sugar
N-glycosylbenzimidazole
Bicarbonyl compound*
0 0  
If II 
HC-CII
Glyoxal
H O  0 
I II I 
CH3~C-C-CH
; oc h2ch3
Kethoxal
/V /-CO-OH— N H  00^5 v_7■COOH
Xenalamine a-GxoH2-(4-biphenyl)-p*~ethoxy--P~{4--carboxyphenyi)&mine“e^hane
ABOB
/ \ lil /NH,
HO N - C - N - C
v _ /
ii
NH NH HCI
N 1,N*-anhydrobis-(p-hydroxyethyl)biguanide hydrochloride
Isoquinoline compounds
HCI
R = Cl l-(p-Chlorophenoxymethyl) -3,4~
dihydro-isoquinoline hydrochloride 
[UK 2054]
R = OCH^ l~(p-Methoxyphenoxymethyl)~3,4~
dihydro-isoquinoline hydrochloride 
[UK 2371]
TABLE 1.11 STRUCTURE-ACTIVITY RELATIONSHIPS OF BENZIMIDAZOLE DERIVATIVES
Benzimidazole derivative
75% Inhibitory 
pM
concentration
pg/ml
Inhibitory activity 
relative to 
benzimidazole
Benzimidazole 3500 410 1.0
2,5-Dimethyl- 1300 190 2.7
2,4,5-Trimethyl- 630 100 5.5
2-Butyl-5-methyl- 170 32 21.0
5-Chloro-2-methyl 470 78 7.5
5,6-Dichloro-l-p-D- 
ribofuranosyl (DRB) 38 12 92
5,6-Dichloro~l-P-B~
arabinopyranosyl 1100 343 a . 1
4,5,6-Trichloro-l-p-D- 
ribofuranosyl (TRB) 4.6 1.6 760
4,5,6-Trichloro-l-a-B-
ribofuranosyl 21 7.3 165
activity. DRB was tested for activity in mice by Tamm et al. (1954), 
and at 200 mg/kg/day was found to cause a ten-fold reduction in 
haemagglutinin production.
Mode of action studies
The mode of action of DRB was examined by Tamm et al. (1954, I960)
In the former paper it was found that DRB did not inactivate the virus
directly, and did not affect adsorption or release of virus from the 
cell. In view of the structure of DRB it was considered probable that 
the compound affected nucleic acid synthesis. This theory was 
substantiated in the second paper. The action of DRB was found to be 
blocked by adenosine but not by guanosine. The selectivity of TRB 
was determined by Tamm (1956), who compared the microscopic effects 
of the compound on chorioallantoic cells with the inhibitory activity
of the compound. He demonstrated a twenty-fold difference between the
75% inhibitory concentration and the lowest toxic dose. However, 
Bucknall (1967) reported that the inhibitory activity was nonselective, 
in that inhibition of virus parallelled the inhibition of cell RNA 
synthesis. These findings, together with problems of synthesis, appear 
to have been responsible for the lack of any further development of 
these compounds.
1.2.5.2 Dicarbonyl compounds
The dicarbonyls are compounds containing an a-ketoaldehyde 
moiety. Two compounds in this series, glyoxal and kethoxal (Fig. l.l), 
were first shown to inactivate influenza A/PR8/34 (HONl) by Underwood 
and Weed (1956). These observations stimulated the synthesis of a 
large number of aliphatic and aromatic glyoxals together with related 
a-hydroxyaldehydes and (3-aminolactaldehydes(Tiffany et al., 1957;
Moffett et alo, 1957; Wright et al*, 1957). Many of these compounds, 
although of widely differing structure, were reported to prevent the 
death of chick embryos infected ’with influenza A/PR8/34 (IIONl).
De Bock et al. (1957) demonstrated that many derivatives reduced 
multiplication of A/JFM/l/47(HlNl) in chick embryos, but attributed 
this activity to the strong virucidal activity of these compounds. 
However, in vivo, kethoxal was reported to be without activity 
(Underwood et al., 1959). Cavallini and Massarani (1959) produced 
further derivatives with a biphenyl 1 supporting' moiety, which v/as 
considered to confer activity in vivo on these compounds. Out of 
this series of derivatives one compound, named xenalamine (Fig. 1.1), 
was considered sufficiently active in vivo to undergo further studies. 
This compound was reported to reduce the mortality in mice infected 
with 5 LD50 of virus down to a dose of 15 rag/kg/day if administered 
up to 24 hours after infection (Magrassi et -al*.* 1960a).
Engle and Liu (1962) reported that xenalamine had considerable 
virucidal activity, causing a 0.5 log drop in infectivity at 0.5 pg/ral 
after 1 hour of incubation at 25°C. However, these workers postulated 
that the compound also inhibited the intracellular replication of the 
virus, on the basis that allantoic fluid rapidly inhibited the virucidal 
activity of xenalamine and related compounds, but did not inhibit the 
replication of virus. Altucci et al. (1969) suggested that the 
intracellular activity of xenalamine may be attributed to inactivation 
of newly synthesised viral nucleic acid and components.
Clinical trials
At least two clinical trials have been conducted with xenalamine 
(Magrassi et al., 1960b ^ Drake and Sawchuk, 1963). In the first of 
these trials some reduction in the febrile period and duration of illness
was reported for both influenza A (H2N2) and influenza B infections.
In the second trial a slight beneficial effect was also reported; 
however, the aetiological agent involved in the epidemic was not identified 
and it may not have been influenza. No further development of this 
compound has occurred, presumably as a result of the inconclusive nature 
of the results obtained.
1.2.5.5 Interferon and interferon inducers
Interferon was first discovered by Isaacs and Lindenmann (1957) 
when studying interference (suppression of replication of one virus by 
another) by influenza viruses in chick embryo egg pieces. Later 
interferon was found to be species specific (Tyrrell, 1959), that is, 
interferon produced in one animal species only demonstrated a maximum 
antiviral effect in that species, a lesser effect in closely related 
species and no effect in other species. However, interferon from any 
species is active against a variety of viruses, to varying degrees, 
with adenoviruses showing complete resistance. The interferons have 
thus been defined as a group of antiviral proteins produced by cells 
in response to virus infection or exposure to some nonviral substances 
(Friedman and Buckler, 1972). The interferons are therefore not 
strictly chemotherapeutic agents, in that they are complex macromolecules 
impossible to synthesize. Production of interferon is at present an 
insurmountable problem. Not only must human interferon be produced 
safely and in a highly purified form, but in sufficient quantities to 
be of practical use to man. Nevertheless some studies have been 
conducted with interferon against influenza infections in animals and 
man. Takano et al. (1963) demonstrated a prophylactic but no therapeutic 
effect of interferon administered intranasally to mice against
influenza B virus infection.
One clinical trial conducted by Solov’ev (1969) with human 
leucocyte interferon demonstrated a slight prophylactic effect against 
a natural epidemic of influenza A/Hong Kong/l/68(H3N2).
A second approach to interferon therapy has involved the 
stimulation of interferon production by chemical agents. Such agents 
include synthetic polyionic copolymers (Merigan and Finkelstein, 1967), 
and double-stranded RNA (Lampson et al., 1967). A synthetic double­
stranded complex of polyinosine and polycytidylic acid (poly I:C) 
has been shown to be active prophylactically against influenza infections 
in mice when administered intranasally (Lindl et al., 1989; Gerone 
et al., 1971; Hill jet al., 1969). In a challenge trial with 
influenza A/Hong Kong/l/68(H3N2), the intranasal .administration of 
poly I:C (0.1 mg/kg) was found to produce a marginal reduction in 
clinical symptoms, but no reduction in frequency of illness or in 
shedding of virus (Hill et al., 1972). However, poly IsC has proved 
to be too toxic for clinical use. Studies in mice with a variety of 
synthetic polynucleotides revealed a correlation between toxicity and 
ability to induce interferon (Black et al., 1973). This apparent
limitation in the development of interferon inducers with improved 
therapeutic ratios appears to exclude such agents from the treatment 
of infections in man.
1 11.2.3.4 N ,N -anhydrobis-(B-hydroxyethyl)biguanide hydrochloride 
1 1N .,N -anhydrobis-(P“hydroxyethyl)biguanide hydrochloride (ABOB, 
Fig. 1.1) was first reported to possess anti-influenzal activity by 
Melander (i960) and Sjoberg (i960) in mice and in man respectively.
In the former paper no activity was reported in mice with ABOB alone,
but in combination with methatropine nitrate (2 mg/kg/day) and 
methscopolamine nitrate (2 mg/kg/day) a marginal reduction in lung 
consolidation was reported at 25 and 100 mg/kg/day of ABOB. The 
above two compounds were included with ABOB in the treatment regime 
because they increase the permeability of the respiratory membrane, 
by reducing secretion. This combination, ABOB-X, has been marketed 
under the names of Flumidin and Virugon.
In clinical trials during an epidemic of A/Sweden(HINl)
Sjoberg (i960) initially found that ABOB significantly reduced the 
duration of symptoms and elevated rectal temperature when administered - 
therapeutically at 200 mg/day. Later, in an epidemic of Asian influenza 
(II2N2) ABOB-X in a dose of 600 mg/day was found to have a significant 
prophylactic and therapeutic effect. However, no beneficial effect was 
reported in later trials. These included a prophylactic trial during 
an influenza A(H2N2) epidemic (Meiklejohn et al., 1963), a prophylactic 
trial involving challenge with an attenuated Asian (H2N2) virus (Jackson 
et al., 1961) and one therapeutic trial involving general, unidentified 
respiratory disease (Parker et al., 1962). Although the above trials 
were not well controlled, and only in the challenge trial (Jackson et al., 
1961) were the subjects matched for antibody status before commencement 
of the trial, these results indicate that the effect of ABOB was not great. 
The compound was not developed further, and in view of the marginal results 
obtained in mice the evaluation of this compound in man does not seem to 
have been justifiable.
1.2.3.5 Amantadine hydrochloride and related compounds 
Structure and inhibitory activity
A few years before the first publication on amantadine hydrochloride, 
a tricyclic amine (Davies et al., 1964), ammonium ions had been shown to 
inhibit the reproduction of influenza virus in vitro (Jensen et al., 1961). 
Later, Jensen and Liu (1963) demonstrated that simple aliphatic amines 
also caused inhibition. Whether these findings.stimulated the research 
of Davies et al. (1964) is not stated, but the activity of amantadine 
hydrochloride shows striking similarities to the activity of ammonium ions. 
The cyclic structure of amantadine hydrochloride (Fig. 1.2) probably plays 
an important part in conferring stability, and thus greater activity, to the 
molecule, than the simple ammonium salts.
The spectrum of activity of amantadine hydrochloride is restricted 
to enveloped (ether sensitive) RNA viruses, which include influenza A and C, 
parainfluenza 1 (Davies et auL., 1964), arenaviruses (Pfau et al», 1972) , 
rubella virus (Maassab and Cochran, 1964) and the oncogenic Rous sarcoma 
virus (Oker~Blom and Andersen, 1965). However, many enveloped RNA viruses 
are insensitive, including influenza B, respiratory syncytial virus and 
parainfluenza viruses (Davies et al., 1964), and all sensitive viruses, 
apart from influenza A, are insensitive in vivo. With influenza A, 
although all strains are reported to be inhibited, their sensitivity to 
amantadine hydrochloride varies greatly. A detailed comparison of the 
activity of amantadine hydrochloride against a number of strains of 
influenza A was conducted by Schild and Sutton (1965) in chick embryo 
cells and monkey kidney cells. From this work it appears that members 
of the H0N1 and H1N1 sub-types are relatively insensitive, whilst 
members of the H2N2 sub-type are more strongly inhibited, and that these 
variations also occur in vivo. Later, members of the most recent H3N2
Amantadine hydrochloride and related compounds
NH.
VK7 HC!
Amantadine hydrochloride
(l-Adamantanamine_hydrochloride/ 
Tricyclo[3.3.1.1 * ]decan-l~amine)
NH 2
H - C - G H 3 Rimantadine hydrochloride
(a-Methyl-1-adamantoylraethylamine 
hydrochloride)
HCI
NH,
HCI
Cyclooctylamine hydrochloride
N-CH.
HCI
N-MethyladaRiantane-2-spiro-3-pyrrolidine
hydrochloride
(DU 34569)
sub-type were shown to be of similar sensitivity to those of the H2N2 
sub-type (Jo, 1970). Both Schild and Sutton (1985) and Neumayer et al.
(1965) found a variation in sensitivity within the H2N2 sub-type. 
Significant inhibition by amantadine hydrochloride in cell cultures 
has been reported at 25 jig/ml for less sensitive strains (Schild and 
Sutton, 1985) down to 0.06 pg/ml for more sensitive strains (McLaren and 
Potter, 1973) under multiple cycle conditions. Under single cycle 
conditions the maximum effect of the compound was a ten-fold reduction 
in virus titre (Davies et al., 1984). The toxicity of amantadine 
hydrochloride was examined by Neumayer et al. (1965). By direct 
examination of cells and uptake of dye a slight deleterious effect was 
observed at 25 pg/ral. However, determination of the effect of amantadine 
hydrochloride on the multiplication rate of cells revealed a retardation 
in cell growth only at a concentration of 100 pg/ml and above. In ovo 
activity ivas demonstrated at 500 pg per egg (Davies et al., 1964).
With in vivo studies the majority of work has been conducted with 
A/AA/2/60(H2N2) and other H2N2 strains and A/swine/S15(HswlNl). However, 
all strains tested in vivo have shown some sensitivity to amantadine 
hydrochloride except for A/PR8/34(HONl) (Schild and Sutton, 1965).
Davies et al. (1964) reported activity (reduction in mortality and 
increase in survival time) when the compound was administered in doses 
of 0.6 - 40 mg/kg every 4 hours commencing 30 minutes before infection 
(3.6 - 240 mg/kg/day). Comparable results were obtained with a single 
dose of the compound given 30 minutes before infection. With virus 
doses of greater than 20 LD50 no increase in rate of survival was 
recorded, only an increase in survival time, with a slight effect 
observed up to an infecting dose of 600 LD50 (Wood, 1965). When 
A/AA/2/60(H2N2) infections were treated with 40 mg/kg/4 hours a delay 
in treatment up to 72 hours after infection still produced a beneficial
effect (Grunert et al.., 1965). Similar results t/ere obtained with other 
H2N2 strains (Solovyov and Tolmacheva, 1967; McGahen and Hoffmann, 1968). 
However, Wood (1965) and Grunert et al. (1965) found that A/swine/S15 
(HswlNl) was refractory to any treatment given 1 hour after infection.
No explanation was given for these differences in susceptibility. In 
addition Grunert et al. (1965) observed a plateau effect with A/swine/S 15 
(HswlNl) at a dose range from 60 mg/kg/day up to 240 mg/kg/day.
Davies et al. (1966) when titrating virus content of the lungs of mice 
infected with 5 LD50 of A/swine/S15(HswlNl) demonstrated a 1000-fold 
reduction in virus titre at 20 hours after treatment with amantadine 
hydrochloride at 20 mg/kg/4 hours, beginning 1 hour before infection.
In ferrets amantadine hydrochloride was found to be considerably more 
toxic, and enhanced rather than reduced infection (Cochran et al., 1965). 
Mode of action studies
The mode of action of amantadine hydrochloride was soon found to 
be concerned with the entry of the virus into the cell. Under single 
cycle conditions, with influenza A/V/SN/33(HONl) and A/Japan/305/S7(H2N2) 
the compound was only active when administered within 10 minutes of 
infection (Hoffmann et al., 1965). Adsorption of the virus to the 
cells was not affected, since a considerable drop in the virus titre 
of the supernatant fluid occurred within 1 hour.of infection in the 
presence of amantadine hydrochloride. The above workers showed that 
penetration of the virus into the cell was inhibited by amantadine 
hydrochloride, by demonstrating that infectious virus remained attached 
to the surface of the cells and thus sensitive to neutralisation by 
antisera. However, Kato and Eggers (1969) in similar experiments 
found that the penetration of fowl plague virus was not inhibited by
amantadine hydrochloride. By employing virus labelled with neutral red 
these workers demonstrated that amantadine hydrochloride inhibited uncoating 
of the virus. Loss of photosensitivity of neutral red labelled virus was 
shown to be associated with virus uncoating, and in the presence of 
amantadine hydrochloride this process was inhibited. Later Goedmans (1970) 
demonstrated that adsorption of A/swine (HswlNl) but not A/Japan/305/57 (H2N 2) 
was inhibited by the compound. Thus it was postulated that amantadine 
hydrochloride may have a. multiple mode of action depending on the virus 
involved. Despite these differences, it has been established that this 
compound acts early in the replicative cycle, before any synthesis of 
viral components has occurred. These findings are comparable to results 
obtained with ammonium ions and other amines (Oxford and Schild, 1967; 
Fletcher et al., 1965), and thus indicate that the amino group is probably 
an important constituent in conferring activity.
Clinical trials
Numerous clinical trials with amantadine hydrochloride have been 
conducted over the past 10 years. These trials may be divided into 
groups, depending on whether they were conducted with a known isolated 
strain (challenge trials) or under natural epidemic conditions. A 
further division may be made depending on whether the effect of the 
compound was tested prophylactically or therapeutically. In all trials 
with amantadine hydrochloride the compound was administered orally, , 
generally in a dose of 100 mg, given twice daily (200 mg/day). Only 
trials where subjects were serologically matched for pre-existing 
influenza antibodies, and the disease was confirmed serologically, 
have been discussed in detail within this section.
The earliest trial with amantadine hydrochloride was conducted 
by Jackson et al. (1964), with an attenuated live virus vaccine strain
of Asian (H2N2) influenza. Two serologically matched groups of subjects 
were included in the trial; 'those-with a low preliminary antibody titre 
(10) showed a 60% decrease in rate of infection when treated prophylactically, 
and those with higher preliminary antibody titre (20 or greater) showed a 
75% decrease in rate of infection. However, this latter figure was not 
significant because the level of infection within this group was not high, 
but the results demonstrated that amantadine hydrochloride can supplement 
the effect of antibody.
The majority of trials have been conducted under natural epidemic 
conditions. Two trials which have kept most rigidly to normal 
environmental conditions have been conducted by Galbraith et al. (1969a, b). 
The former trial was carried out while an Asian strain A/England/10/67 
(II2N2) was prevalent, and the latter when A/Hong Kong/l/68(H3N2) first 
appeared in England. These trials were conducted in family units; 
once one person in a family had contracted influenza (index case) the 
remaining members of that family (contacts) were all treated with either 
amantadine hydrochloride or placebo. In the former trial there was a 
significant (p 0.05 - 0.01) reduction in the incidence of serologically 
confirmed influenza in the contacts. The protective effect was again 
found to be correlated with levels of pre-existing antibody. However, 
in the second trial no protective effect could be demonstrated. The 
only explanation which could be given for these results, since both of 
the above viruses were of equal sensitivity to amantadine hydrochloride 
in vitro, was the lower levels of pre-existing antibody in the latter 
trial. Oker-Blom et al. (1970) found that amantadine hydrochloride 
had a significant protective effect (52%) in an A/Hong Kong/l/68(H3N2) 
epidemic, but here the pre-existing antibody levels were higher than in 
the above trial.
At least 14 prophylactic trials have been made, and all except two 
(Tyrrell et at., 1965; Callamander and Hellgren, 1968) have shown a 
significant level of protection. In both of these trials the antibody 
status of the subjects does not appear to have been matched. In a 
review on influenza chemotherapy an overall mean protective level of 63% 
liras reported for prophylactic trials throughout the world (Oxford, 1975).
A number of trials have also been carried out to establish the 
usefulness of amantadine hydrochloride in treating influenza. The 
main effect found in these studies was a shortening of the period of 
fever and reduction of the maximum temperature observed. Knight et al. 
(1970) also reported a significant reduction in other symptoms, including 
nasal congestion, cough and sore throat. In the majority of trials 
treatment was restricted to individuals who had been ill less than 
48 hours. Only one trial did not show a significant reduction in 
any symptoms, but subjects were included with illness of greater than 
48 hours duration (Wendel et al., 1966).
Despite the report by Sabin (1967) that amantadine hydrochloride 
caused transitory side effects involving cerebration, in all the trials 
reported the compound was not found to possess any significant toxic 
side effects.
In conclusion it maybe said that amantadine hydrochloride 
undoubtedly exerts a limited but beneficial effect both in preventing 
and treating influenza A infections. However, its effectiveness appears 
to depend on the presence of pre-existing antibody, and thus it appears 
doubtful if the compound would be effective against an antigenically 
new strain of influenza virus (i.e. after antigenic shift).
Development of resistant strains
The problem of the development of resistant strains has proved of 
great importance in the treatment of bacterial disease, and is thus of 
interest in the treatment of virus infections. A number of papers on 
amantadine hydrochloride have been devoted to these studies, in cell 
culture (Cochran et al., 1985), in ovo (Goedmans and De Book* 1969), 
and in vivo (Oxford et al., 1970). All these authors found that 
resistant strains developed after 1 - 6 passages in the presence of 
amantadine hydrochloride. Oxford et al. (1970) demonstrated that at 
high concentrations of compound (150 mg/kg/day) A/Singapore/1/57(H2N2) 
became 100-fold more resistant and that this resistance extended to 
derivatives of amantadine hydrochloride.
Compounds structurally related to amantadine hydrochloride
Attempts have been made to improve on the antiviral activity of 
amantadine hydrochloride by synthesizing structurally related compounds 
(Whitney et al., 1970; Aldrich et at., 1971; Grunwald et al., 1972).
From this work a number of compounds were found which possessed activity 
against influenza virus both in vivo and in ovo, but none have been 
developed further. However, three analogues of amantadine hydrochloride 
have shown promise and limited trials in man have been conducted with 
these compounds. The structure of these compounds are illustrated 
in Fig. 1*2.
i. Rimantadine
The activity of rimantadine has been compared with amantadine 
hydrochloride in cell culture (calf kidney cells) and in vivo (Tsunoda 
et al., 1965). In this work it was found that rimantadine was marginally 
more active than amantadine hydrochloride in both systems, and displayed 
a similar mode of action and spectrum of activity. In man, rimantadine
was better tolerated than amantadine hydrochloride, although in cell 
culture and in mice the converse was found. In a double-blind clinical 
trial rimantadine given prophylactically at 300 - 400 mg/day was found 
to reduce morbidity significantly (Dawkins et ah, 1968). The compound 
was also found to be beneficial therapeutically (Wingfield et al., 1969).
ii. Cyclooctylamine
The activity of cyclooctylamine has not been compared directly with 
that of amantadine hydrochloride. However, in cell culture and in mice 
the antiviral properties of this compound are similar to those of 
amantadine hydrochloride (Flagg et al., 1969). In addition, 
cyclooctylamine was found to suppress the replication of several 
influenza A strains in ferrets (Pinto and Haff, 1969). A prophylactic 
trial involving challenge with A/Hong Kong/l/68(H3N2) and treatment with 
0.4% solution of cyclooctylamine administered intranasally every 2 hours 
(150 mg/day) revealed a marginal beneficial effect (Togo et al., 1972).
iii. N-Methyladamantane-2-spiro~3t-pyrrolidine (Du 34569)
A number of adamantane-spiro-3*-pyrrolidine analogues were 
synthesized by Lundahl et al. (1972). The most active of these 
analogues, Du 34569, was shown to be approximately three times more 
active than amantadine hydrochloride in reducing mortality in mice 
infected with A/Japan/305/57(H2N2) and A/Hong Kong/l/6S(H3N2)
(Peters et al., 1970). In this work Du 34569 was also found active 
against rhinovirus type 2 and coxsackie A21. In a double-blind challenge 
study with attenuated A/Hong Kong/l/68(H3N2) the compound was found to 
possess prophylactic activity at 70 mg/day (Beare et al., 1972).
However, the results of this trial and the trials with the other 
amantadine hydrochloride analogues have not been sufficiently encouraging 
to warrant their development for use against influenza in man.
1.2.3.6 The isoquinolines
Two isoquinoline derivatives, l-(jD-chlorophenoxymethyl) and
l-(£-methoxyphenoxymethyl)~3,4-dihydroisoquinoline hydrochloride (Fig. 1*1), 
UK 2054 and UK 2371 respectively, were developed after being found to 
possess anti-neuraminidase activity (Brammer et al., 1968). However, 
examination of the anti-influenzal activity of these compounds revealed 
that anti-neuraminidase activity was a secondary effect arising from 
inactivation of the virus (Coombes et al., 1970). In fact, the 
development of these compounds appears to have been completely fortuitous. 
Shinkai and Nishimura (1972) demonstrated that neither compound inhibited 
neuraminidase activity, but merely blocked the colour development of 
N-acetylneuraminic acid measured by Brammer et al. (1968).
Apart from directly inactivating influenza A, B and C viruses, both 
compounds were found to inactivate parainfluenza viruses 1, 2 and 3, 
fowl plague virus, Newcastle disease virus and rubella virus, and 
UK 2054 alone inactivated measles and herpes virus (Larin et al., 1968). 
These workers also found that both compounds inhibited the replicative 
cycle of certain echoviruses, reoviruses and rubella virus, and UK 2054, 
certain rhinoviruses and respiratory syncytial virus. Comparison of the 
inactivating ability of these two compounds (Williamson and Jackson, 1969) 
showed that both compounds were equally active against viruses of the 
A(H2N2) sub-type (20 pg/ml inactivated 10^*^ EID50 at 37°C for 2 hours), 
and both were more active against influenza B virus (20 pg/ml inactivated
3 . 5
10 * EID50.). In vivo (Coombes et al., 1970) both compounds were
inconsistent in their ability to prolong the mean survival time of mice 
when challenged intranasally with A/PR8/34(H0Nl).
Clinical trials
Despite the discouraging results obtained in vivo, a. number of 
clinical studies have been carried out (Beare et al., 1968; Williamson and
Jackson, 1969; Meenan and Hillary, 1969a, b; Reed nt al., 1970).
In all the above trials either UK 2054 or UK 2371 was administered 
orally (1 - 1.5 g/day) or intranasally (2 ~ 8 mg/day). Prophylactic 
trials involving challenge with either influenza A(H2N2) or (H3N2) sub- 
types or influenza B, gave variable results with different strains.
Reduction in clinical symptoms and antibody production, where present, 
were not highly significant. In two field studies involving prophylactic 
treatment against A/Hong Kong/1/68(H3N2) inconclusive results were obtained 
(Meenan and Hillary, 1969a, b; Williamson and Jackson, 1969). Challenge 
trials with parainfluenza 2 and rhinovirus 9 gave negative results (Reed 
et al., 1970). Although no toxic effects were observed in the above 
trials, the activity reported was insufficient to justify the further 
development of these compounds.
1.2.3.7 Ribavirin (Virazole)
In an effort to produce a broad spectrum antiviral agent 
Witkowski jet al. (1972) synthesized a large number of (3-D-ribofuranosyl 
derivatives of 1,2,4-triazole. This series of compounds was chosen for 
study because of earlier reports on the broad spectrum antiviral activity 
of some 5-membered heterocyclic (3-D-ribofuranosyl compounds (Fig. 1*3).
All these compounds including Ribavirin are related in structure to 
5’-phosphoribosyl-5-amino-4-imidazolecarboxamide (AICAR), an intermediary 
product of nucleic acid synthesis. As a result of this research
l-p~D~ribofuranosyl*-l,2,4~triazole-3~carboxamide (Ribavirin) was synthesized, 
and reported to be active against a large number of both DNA and RNA viruses 
in vitro, including both influenza A and B viruses (Sidwell et al*, 1972).
The possibility that interferon stimulation was responsible for this 
broad spectrum antiviral activity was eliminated in studies by
Ribavirin and related compounds
O
It
HOCH:
OH OH
Ribavirin
1~P-D-Ribofuranosyl-l,2,4-triazole-3- 
carboxamide
O
OH OH
AICAR
5~Araino~lrP*-B~ribofuranosylimidazole~4*
carboxamide
N-H
HO
O H  OH
Purazomycin
3-p -D-Ribofuranosy.i-4-hydroxypyrazole-5- 
carboxamide
HN- 
O^
-O
Showdomycin
3~P *-D-Ribof uranosy Imaleimide
HOCH, o.
Allen et al, (1973). Medium from cells collected 24 - 48 hours after 
incubation with Ribavirin, and serum collected from mice 2 - 24 hours 
after treatment with Ribavirin, gave negative results when assayed for 
interferon activity.
Activity against influenza virus in vitro was studied in chick 
embryo cells by reduction in virus yield titrated by haemagglutination 
(Huffman et al., 1973). The results obtained were not encouraging; 
for A/Aichi/2/68(H2N2) 50fo inhibition was observed at 32 jig/ml, and for 
B/Lee/40 at 3.2 jig/ml. The toxicity of the compound was also examined.
At all levels of Ribavirin tested (minimum 1 {ig/ral), cell growth rate 
was inhibited proportionally to the concentration of Ribavirin. However, 
only at 500 and 1000 |ig/ml was a reduction in the number of viable cells 
observed.
In vivo Ribavirin was tested for activity against three influenza 
strains, A/PR8/34(H0Nl), A/Japan/30o/57(H2N2) and B/Lee/40 (Khare et al., 
1973). Activity, measured as a reduction in percentage mortality and 
increase in length of survival time, was reported dot*n to a concentration 
of 18 mg/kg/day when administered orally or intraperitoneally.
Therapeutic tests revealed that the compound possessed inhibitory activity 
against A/Japan/305/57(H2N2) when treatment was commenced as late as 
24 hours after infection. These results appear more encouraging than 
those reported in vitro.
Studies on the mode of action of Ribavirin were first conducted with 
measles virus (Streeter et al., 1973). In this work the antiviral 
activity of Ribavirin and the reversal of this activity by nucleosides 
and nucleotides were tested by plaque formation in VER0 cells.
Substantial reversal of activity was reported for guanosine and xanthosine 
and to a slightly lesser extent for inosine, indicating that Ribavirin
possibly acts on some stage in the synthesis of guanosine-5*-monophosphate 
(GMP). Adenosine, deoxyadenosine, deoxyguanosine, cytidine, uridine, 
thymidine, orotidine, AICAR and AlCAR-5’-phosphate were all essentially 
inactive as reversal agents. Streeter et al. (1973) went on to study 
the inhibitory activity of Ribavirin on certain enzymes involved in the 
GMP pathway. Thus it was observed that the base of Ribavirin (1,2,4- 
triazole-3-carboxamide) inhibited the enzyme guanosine aminohydrolase, 
which converts guanosine to xanthine. Similarly Ribavirin-5*-phosphate, 
a derivative of Ribavirin synthesized in the rat liver, inhibited the 
action of inosine-5'-monophosphate dehydrogenase, which converts 
inosine-5*-monophosphate to guanosine-5*-monophosphate. All the above 
findings indicate that the antiviral activity of Ribavirin involves 
inhibition of nucleic acid synthesis.
Reversal experiments have also been carried out with A/FPV/Dutch/
27(HavlNeql) in chick embryo fibroblast cells (Oxford, 1975a). Again
activity was reversed by guanosine and xanthosine, but not by inosine or
adenosine. Direct evidence that Ribavirin inhibits the synthesis of
A/FPV/Dutch/27(HavlNeql) RNA was obtained by Scholtissek (1976) in
3experiments on the incorporation of H-uridine and subsequent hybridization 
of virus-specific RNA.
Ribavirin is the most recent compound showing significant activity 
against influenza. For this reason a clinical evaluation of Ribavirin 
has not yet been carried out. Before such studies can be initiated 
the compound must undergo detailed toxicity studies in animals.
1.3 INFLUENZA VACCINES, AND CONTROL OF INFLUENZA IN THE FUTURE
Apart from research into the chemotherapy of influenza, much work 
has also been done on the control of the disease by vaccination. The 
earliest vaccines were produced soon after the isolation of influenza A 
virus in 1933, but the major problem in the production of influenza vaccines, 
that is antigenic shift of the virus, was not realised until the late 1940’s 
when the A/(HlNl) antigenic sub-type first appeared (Mellanby et al., 1948). 
These earliest vaccines, and all marketed vaccines up to the present time, 
have contained inactivated virus, generally bivalent, containing the 
most recent A and B virus strains. However, in recent years many 
different lines of research have been explored in an attempt to develop 
an effective live or inactivated vaccines
With the inactivated vaccines one major problem has been the 
production of these vaccines in eggs. This has led to the presence of 
impurities in the final vaccines i/hich may cause adverse side reactions 
such as pyrogenic effects. However, in recent years the removal of a 
large amount of non-viral proteins by zonal ultracentrifugation has 
reduced such reactions considerably (Peck, 1968). The latest development 
with inactivated vaccines has been the production of split vaccines 
containing purified haemagglutinin with or vrithout neuraminidase, but 
these vaccines gave less protection than live or whole killed-adjuvant 
vaccines (Tyrrell et al., 1973).
One further problem is the time involved in the production of 
new vaccines, particularly with the presence of antigenic drift, which 
necessitates new vaccine production every 1 - 2 years. With newly 
isolated viruses growth in eggs requires a period of adaptation, with 
the result that new vaccines have taken 6 months to produce. However, 
Kilbourne (1969) demonstrated that recombination can take place between
influenza A/PR8/34(H0Nl) and new variants to give recombinants with 
external antigens of the new variant but with the growth properties of 
A/PR5/34(H0Nl). This process has been employed commercially in the last 
fei* years and has reduced production to less than 4 weeks.
One further development with both inactivated and live vaccines ha,s 
involved administration of vaccines via the nasal route instead of 
subcutaneously. This arose from work conducted by Smith et al. (1966) 
which established the importance of nasal antibodies to immunity. One 
important disadvantage of the inactivated vaccines is the high amounts 
of virus required to produce sufficient immunity, with the result that 
the cost of administering such a vaccine on a large scale has been 
prohibitive. For this reason, and because killed vaccines are no more 
than 70-8G/6 effective in producing immunity to influenza (Maugh, 1973), 
live vaccines have been considered for future use. The main problem 
with the latter is the development of attenuated strains. Not only is 
the time involved in the production of attenuation a problem, but also 
the demonstration of attenuation. One method of overcoming these 
problems has been the use of thermo-sensitive viruses produced by passage 
at low temperatures (Maassab et al., 1969) which have a built-in marker 
from the beginning. Such mutants are considered to be attenuated 
because growth should only occur at the low temperature of the upper 
respiratory tract and not in the lower respiratory tract, and thus induce 
mild infection.
Further problems with live influenza vaccines, particularly since 
the virus is so unstable, are the possibility of reversion to virulence 
and subsequent transmission to other individuals. However, despite 
these drawbacks, live vaccines appear at present to be the most promising 
method of conferring a high degree of protection on a susceptible 
community.
From the above it may be seen that the production of influenza 
vaccines is extremely problematic, and at present highly effective Vaccines 
are not available to the general public. However, it is generally believed 
that vaccination will be the main method for controlling influenza in the 
future. The search for anti-influenzal compounds has been carried out 
extensively over the years because of the lack of an effective vaccine 
to control influenza epidemics. The prophylactic use of an active 
compound over a prolonged period, to a large proportion of the public, 
does not appear feasible. However, limited use of such a compound may be 
of value particularly in the period when a new variant arises, before the 
production of the relevant vaccines. Another possible important application 
of any new anti-influenzal compound is in the therapy of cases of influenza. 
The efficacy of antiviral compounds in the therapy of acute viral disease 
has been questioned, but in the light of results obtained with amantadine 
hydrochloride, a compound without a very high degree of activity, this 
line of treatment appears more encouraging. Thus it may be concluded 
that chemotherapy may have an important role to play in the control of 
influenza, particularly in conjunction with influenza vaccines.
1.4 AIMS OF THE PRESENT WORK
In the previous review an attempt has been made to indicate the 
number and diversity of systems which have been employed in influenza 
chemotherapy. The initial aim of this study was to evaluate some of 
the ill vitro systems available, to attempt to find the most suitable 
methods for both detecting and quantitating activity. From this initial 
evaluation a few methods were selected for more detailed comparison, with 
particular emphasis on the sensitivity and reproducibility of each system. 
The systems employed included the allantois on shell system, and both 
primary chick embryo cells and primary calf kidney cells.
In addition, an in vivo system was selected for comparison with 
results obtained with the in vitro systems, to establish which in vitro 
method gave the best indication of activity in vivo. The mouse was 
selected for these in vivo studies because this animal has been used most 
widely and is relatively easy to work with. Although percentage mortality 
and survival time of mice have been employed extensively as criteria of 
response, these methods, as stated, have drawbacks because side reactions 
such as inhibition of lung consolidation may affect the results. For 
this reason the method selected for evaluation of activity in mice was 
direct titration of virus in the lungs. However, because survival time 
evaluations have been so widely employed, a comparison of results obtained 
by both methods was considered useful. For research with influenza in 
mice the strains of virus are usually adapted to mice before tests are 
carried out. However, frequently no passage history of the virus in mice 
is given. Thus it was considered useful to investigate whether there 
were any differences in results obtained with the same strain of virus 
at different passage levels. To evaluate all this comparative work 
one or more anti-influenza compounds were required as positive controls.
In the field of chemotherapy one fundamental requirement is the 
comparison of any n e w compound with a known standard compound. Such a 
standard should have been evaluated widely in different systems and 
preferably in man as well. In influenza chemotherapy such a compound 
was not available until the development of amantadine hydrochloride.
However, few detailed (dose-response) comparisons of n e w compounds with 
this compound have been conducted. One such compound which was of 
particular interest at the time of the study, and which had been reported 
to be more active than amantadine hydrochloride, was Ribavirin. The 
activity of this latter compound was examined and found to be sufficient to 
warrant a detailed comparison of Ribavirin and amantadine hydrochloride.
Thus the above two compounds were used as tools for comparing the 
sensitivity of the different systems available, and because a comparison 
of their inhibitory activity was of value to the field of chemotherapy.
For the majority of these studies four influenza A virus strains were 
selected, one from each of the four different subtypes, and a comparison 
of the relative sensitivity of these strains to the two compounds was 
carried out. No work was done with influenza B and C, because the 
former is insensitive to amantadine hydrochloride, and the latter is not 
considered to be of importance in respiratory disease.
In summary, the aim of this study was to evaluate methods available 
to determine the possible importance of the new compound Ribavirin by 
comparison with amantadine hydrochloride, and to determine in detail the 
relative sensitivity of a range of influenza strains to these two compounds. 
In addition, a large number of new compounds, including many nucleoside 
analogues, together with a few known anti-influenza compounds, were 
screened for activity in some of the above systems, in the hope that 
other compounds with sufficient activity in comparison with the above 
two compounds might be found.
MATERIALS AND METHODS
2.1 COMPOUNDS
2.1*. 1 Source of compounds
The two compounds, amantadine hydrochloride, obtained from Sigma 
Chemical Co., St. Louis, U.S.A., and Ribavirin, kindly supplied by 
Lederle Laboratories, Division of American Cyanamid Co., Pearle River,
New York, were employed throughout the study as reference standards with 
known anti-influenza activity. The nucleoside analogues, 1-raethylisatin 
3-thiosemicarbazone (methisazone), and 4,5,6~tFichloro~l-P-D-riboiuranosyl- 
benzimidazole, were supplied by Wellcome Laboratories; 6-azauridine and
2-deoxy-D~glucose were obtained from Koch-Light Laboratories Ltd.,
Colnbrook, Bucks, England; l-(p-chlorophenoxymeihyl)-3,4~dihydroiso- 
quinoline hydrochloride was supplied by Pfizer Group, Sandwich, Kent,
England; and bathophenanthroline disulphonic acid disodiuia salt was obtained 
from Aldrich Chemical Co., Milwaukee, Wisconsin, U.S.A. All these latter 
compounds were included for anti-influenza screening.
2.1.2 Preparation of solutions
In most cases the compounds were readily soluble in distilled water, 
but those which were insoluble were dissolved either in absolute ethanol 
or in diraethylforraaraide (British Drug House, Poole, Dorset, England).
All solutions of compounds in water were sterilized by placing in a hot air 
oven at 80°C for 30 minutes. Amantadine hydrochloride and Ribavirin were 
both soluble in water and fairly stable in solution, but fresh solutions 
were generally made up before each experiment and not kept longer than 
2 weeks. For in vivo work soluble compounds were prepared as above; 
insoluble compounds (e.g. methisazone) were ground in a pestle and mortar 
with Triton X-100 solution (Koch-Light Laboratories Ltd.) and a suspension 
was made in distilled water.
2.2 VIRUSES
2.2.1 History of viruses employed
A total of 8 viruses have been used, which together with all 
available historical information have been listed in Table 2.1.
2.2.2 Preparation of stocks of virus
The selected strains are listed in Table 2.1. Each virus 
(0.2 ml containing 0.04 haemagglutination unit/ml) was inoculated into 
the allantoic cavity of 10 or 11 day old enibryonated eggs (specific pathogen 
free; S.P.F. Farms Ltd., Winchester Road, Wickham, Hants) by the method 
of Horsfall and Taram (1965). After incubation for 48 hours at 35°C the 
eggs were chilled at 4°C for approximately 1 hour, and the allantoic fluid 
was harvested with a 10 ml plastic syringe. The pooled allantoic fluid 
was left at 4°C for approximately 18 hours to precipitate uric acid, and 
was then clarified by centrifugation (15 minutes at 2000 g). The haemagglutin 
titre was determined and the fluid was distributed in 1 ml and 10 ml 
volumes and stored at ~20°C ready for use. These stocks were used in 
all the in vitro systems employed, and for the preparation of mouse-adapted 
stocks, to be described in a later section.
2.2.3 Detection and titration of virus growth in ovo by the haemagglutination
technique
Titration of virus in the allantoic fluid was conducted by the 
haemagglutination technique devised by Salk (1944). All volumes used 
were adjusted to 0.25 ml. Chick red cells (suspended in Alsever solution 
1 : l) were thrice washed in 0.85% saline, centrifuged at 500 g for 
10 minutes and diluted in saline to give a 0.5% suspension; fresh cells 
were obtained each week. The technique was carried out in disposable
TABLE 2.1 SOURCE AND HISTORY OF VIRUSES EMPLOYED IN THE STUDY 
♦
Virus Sub-type Source History
A/NWS/33 HON 1 Dr. Bauer,
Wellcome Laboratories
Multiple passage in 
eggs and intra- 
cerebrally in mice
A/PRS/34 HON 1 Dr. Bauer,
WeiIcorne Laboratories
Multiple passage in 
eggs and mice
A/Sv/ed en/3/5 0 H1N1 Dr. Bauer,
Wellcome Laboratories
Multiple passage in 
eggs
A/FM1/47 H1N1 Dr. Schild, 
Mill Hill
Isolated in ferrets; 
multiple egg passes; 
7 passes in mice*
A/Okuda/57 'JI2N2 Dr. McCahon, 
Pirbright
ca. 208 passages in 
eggs
A/Singapore/l/57 H2N2 Dr. Schild, 
Mill Hill
Multiple passage in 
eggs
A/Hong Kong/1/68 H3N2 Dr. Oxford, 
Mill Hill
Multiple passage in 
eggs;
ca. 60 passes in 
mice*
A/England/42/72 II3N2 Dr. McCahon, 
Pirbright
6 passes in eggs
X
Lung passage
WHO plates (Linbro Chemical Co., New Haven Connecticut, U.S.A.) and
2-fold dilutions of virus in 0.85% saline were made with a 1 ml automatic
syringe (R.B. Turner and Co. Ltd., London). Finally, blood was added
to the wells and the plates were incubated at room temperature for 
- 2 hours. Plates were examined for the presence (uniform film 
of red blood cells) or absence of agglutination (button of red blood cells) 
and the haemagglutination titre was recorded as the highest dilution 
showing 50% haemagglutination. This technique has been employed in 
all the in vitro systems for detecting growth of viruses, and a modified
method has been used in some in vivo work.
2.3 IN VITRO CULTURE SYSTEMS '
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2.3.1 Allantois-on-shcll cultures (AOS)
2.3.1.1 Preparation of cultures
Preparation of AOS cultures was carried out by the method
described by Fazekas and White (1958). Ten or eleven day old embryonated
eggs were washed with 70?6 methylated spirit, and under sterile conditions
the top of the egg (air sac at the bottom) was cut open and the embryo
was removed, leaving the chorioallantoic membrane (CAM) still attached to
the shell. After washing with phosphate buffered saline solution A
(Wellcome Reagents) to remove blood, etc., the CAM plus shell was cut
2into pieces approximately 0.6 cm , which contained approximately 
10° cells/piece (Tamm et at., 1953b$ Finter and Armitage, 1957), and the 
pieces were placed in a petri dish (Pyrex, 9 cm in diameter) containing 
maintenance medium. The medium contained 10/6 medium 199 (Wellcome Reagents), 
5/6 tryptose phosphate broth.(Wellcome Reagents) with 600 pg/ml penicillin 
and 1000 |ig/ml streptomycin (Crystaraycin, Glaxo Ltd., Greenford, Middlesex) 
and sufficient tris buffer to adjust the pH to 7.2 - 7.4 (trishydroxyraethyl- 
aminomethane hydrochloride, 100 mM in distilled water, British Drug House, 
Poole, Dorset). The medium was dispensed into the wells of a WHO 
macrohaemagglutination tray (0.3 ml/well, Linbro, 96 SC), and one piece of 
shell with the CAM still fully attached was placed in each well (Fig. 2.1)., 
After infection the plates were closed with plastic covers (Linbro 58 PS) 
and incubated at 37° C on a horizontal shaker (Baird and Tatlock, Chadwell 
Heath, Essex, speed 100 strokes/minute, thrust 10 cm).
2.3.1.2 Infectivity titrations
Ten-fold dilutions of the virus were made in phosphate buffered 
saline (PBS) solution A, and eight replicates of each dilution were
4Fig. 2.1 Allantois-on~shelI system. Egg pieces in 
medium, after 24 hours incubation at 37°C.
inoculated (0.06 ml/well). After incubation for 48 hours on the shaker
the egg pieces were removed with forceps, and 0.25 ml of 0.5% chick red cell
suspension was added to each well. The presence or absence of 
haemagglutination was recorded after 1-| - 2 hours. The titre of virus 
present was calculated by means of the Karber equation (Karber, 1931).
2.3.2 Primary chick embryo cell cultures
'2.3•2•1 Preparation of ceil cultures
Chick embryos from 10 - 11 day old eggs (S.P.P. Farms, Wickham) 
were removed aseptically and were washed in a petri dish (9 cm diameter) 
containing wash medium, PBS (A, B and C) supplemented with 10% tryptose 
phosphate broth. The embryos were transferred to fresh medium 
and the head and viscera were removed. The remainder of the embryos were 
placed in a 10 ml plastic syringe in medium and were homogenized by being 
forced through the nozzle into a filtering flask containing medium. This 
medium was decanted and replaced by digesting medium which consisted of 
PBS (A, B and C) with 0.25% trypsin (Nutritional Biochemical Corporation, 
Cleveland, Ohio). The flask was placed on a magnetic stirrer (Gallenkamp 
and Co., London, E.C.2) at 37°C for 15 minutes, and afterwards left to 
stand.for 5 minutes before the digested suspension was drawn under 
pressure through a coarse in-line filter (Fig. 2.2) into a second flask 
placed in ice. The trypsinization was repeated twice and the final 
suspension was' filtered through a medium and fine filter consecutively.
The filtrate was centrifuged at 900 g for 10 minutes and the cells were 
resuspended in wash medium and washed 3 times. Finally the cells were 
resuspended in growth medium containing 10% 199 medium, 5% tryptose 
phosphate broth, 5% foetal calf serum (Flow Laboratories, Irvine, Scotland), 
75 pg/ml penicillin and 125 pg/ral streptomycin, with a pH 7.2 - 7.4 adjusted
Apparatus used for filtering cells in the 
preparation of primary.chick embryo ceils
with 100 mM tris buffer. The number of viable cells present was 
determined by staining with 0.5% non-vital trypan blue (B.D.H., Poole, 
England), and counting in a Neubauer counting chamber (Hawksley and Sons Ltd. 
Lancing, England). Tubes (151 x 15.5 mm, bacteriological grade, 
soda glass test tubes, Anderman and Co., London, S.E.l) were seeded
Q
with 10 cells in 1 ml of growth medium and incubated horizontally for
approximately 24 hours at 37° C to obtain confluent growth of cells for
infection. Tissue culture plates (60 x 15 ram, Falcon Plastics,
8Oxnard, U.S.A.) were seeded with either 3 x 10 cells in 5 ml of medium
Q
for confluent growth in 24 hours, or 2 x 10 cells for confluent growth 
in 48 hours (method l). Other plates (method 2) were seeded with cells 
in the medium recommended by Appleyard and Maber (1974). These plates 
were seeded with 5 x 10 cells in 5 ml of medium which contained 10% 199,
0.5% bovine serum albumin (Sigma Chemical Co.) and 0.04% bicarbonate 
solution with 75 pg/ml penicillin ana 125 p.g/ml streptomycin, and incubated 
for 24 hours. All the plates were incubated at 35°C in a humidified 
5% carbon dioxide atmosphere (MHotpack,r humidified CO^ incubator,
Hotpack, Y/aterloo, Ontario, Canada).
2.3.2.2 Infectivity titrations
a) Tube titrations
Before infection the growth medium was removed and the cells 
were washed with PBS (A) to remove serum. Tenfold dilutions of virus 
in PBS (A) were used to infect the tubes (0.1 ral/tube), with 5 tubes used 
for each dilution. The tubes were incubated horizontally for 1 hour 
at 35°C to allow adsorption of the virus to occur. After adsorption 
the cells were again washed with PBS (A) and 1 ml of maintenance medium 
(growth medium minus serum) was added to each tube. All tubes were 
incubated at 37°C on a roller drum (Matburn Ltd., London, W.C.l).
Haemagglutination determinations were carried out after 6 days incubation. 
The titre of virus was calculated using the Karber equation.
b) Plaque tests
Method 1. (Dr. D. McCahon, personal communication)
The growth medium was removed from confluent cultures and the cells 
\irere washed with PBS (A) to remove serum. Tenfold dilutions of virus 
in PBS (A) were prepared and 1 ml of each dilution was added to each 
plate, with each dilution set up in triplicate. The plates were shaken 
gently to distribute the virus, and incubated at 35°C for 1 hour to allow 
for adsorption of virus. After adsorption the plates were drained and 
the cells overlaid with 5 ml of medium. The overlay medium consisted 
of growth medium plus 0.005% neutral red (B.D.H.) and 1% Difco Noble 
Agar (Difco Laboratories, Detroit, Michigan, U.S.A.). The plates were 
incubated at 35°C in 5% carbon dioxide, and examined daily for the 
appearance of plaques.
Method 2. (Appleyard and Maber, 1974) The drained plates
inoculated as described in method 1, but without prior washing with PBS.
The overlay medium (5 ml/plate) consisted of 10% 199 medium with
100 pg/ml diethylaminoethyldextran (Sigma Chemical Co.) and 0.5% Difco
Noble Agar with or without 10 pg/ml crystalline trypsin (Armour
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Pharmaceutical Co. Ltd., Eastbourne, England) in 10 M hydrochloric 
acid. The plates were incubated at 35°C in air in a closed container 
for 4 days. A second overlay was added to each plate (2 ml/plate) 
xvhich contained 10% 199 medium, 0.5% Difco Noble Agar and 0.005% neutral 
red. Plates were examined for plaques after 18 hours incubation at 35°C. 
The virus titres were calculated on the assumption that one virus particle 
gave rise to one plaque.
2.3.3 Primary calf kidney cells
2.3.3.1 Preparation of cultures
Suspensions of calf kidney cells in growth medium were provided
by the tissue culture department of Y/ellcorae Laboratories. The number of
cells present was counted and diluted to the required concentration
in growth medium, which contained 10% 199 medium,.10% foetal calf serum,
0.1% bicarbonate, 75 {ig/ml penicillin and 125 pg/ml streptomycin.
5
Tubes (151 x 15.5 mm soda glass) were seeded with 2 x 10 cells in 2 ml 
of growth medium and incubated at an angle of 20° for 3 days at 37°C.
Fresh growth medium was added and the cells were incubated for a further
1 — 2 days at 37°C with rolling before infection. Plastic tissue culture 
plates (60 x 5 mm) were set up with 5 ral of growth medium containing a
Q
total of 5 x 10 cells. After 3 days incubation at 35°C in 5% CO^ 
atmosphere, the growth medium was renewed and the plates were incubated 
for a further 24 hours, until the cells were confluent. The growth 
medium was then replaced with maintenance medium (growth medium minus 
serum) and incubated for a further 24 hours before infection.
2.3.3.2 Infectivity titrations
a) Tube titrations
Titrations in tube cultures were carried out as described for 
chick embryo cells. The maintenance medium consisted of growth medium 
without serum. Haemagglutination titrations were made after 6 days 
incubation.
b) Plaque tests
The method described by Lehmann-Grube (1963) was adopted to 
obtain plaques in calf kidney cells. The cells were washed with PBS (A) 
and then infected as described for chick embryo cells. After adsorption,
5 ml of overlay medium containing 12.5% Eagle's Minimal Essential 
Medium (MEM)(Wellcome Reagents), 0.1% bicarbonate, both without phenol 
red indicator, 75 pg/ml penicillin, 125 [ig/ml streptomycin and 0.95%
Difco Noble Agar, was added to each plate. The plates were then 
incubated at 35°C in a humidified atmosphere containing 5% 00^. When 
virus plaques were just visible a second overlay medium was added 
(4 ml/plate) which contained either the above overlay medium plus 
0.006% neutral red, or alternatively 1% Difco Noble Agar plus 0.09%
2-(p~iodopheny1)~3-(p-nitropheny1)-51-phenyItetrazo1ium chloride 
(Koch-Light Laboratories). After approximately 18 hours incubation 
at 35°C the plates were examined for plaques. Y/ith the tetrazolium 
stain the cells were killed and fixed to the plastic and thus a 
permanent record of results was obtained. This was achieved by 
exposing plates at 37QC for 2 - 3  hours to allow partial dehydration of 
the agar, which was then carefully peeled off. A third method of 
staining was also used, where the plates were flooded with 10% formaldehyde 
solution in PBS for 1 hour to fix the cells, the agar was removed and 
the cells stained with methyl violet.
2*3.4 Chick embryo tracheal organ cultures
2.3.4.1 Preparation of cultures
Cultures were prepared by the method originated by Harnett and 
Hooper (1968). Chick embryos from 20 day old eggs (S.P.F. Farms, Wickham) 
were removed aseptically into sterile plastic petri dishes. The neck of 
the embryo was opened longitudinally above the trachea, and the trachea 
was freed of connective tissue and removed by cutting at the levels of 
the larynx and near to the division of the trachea into the two bronchi.
The trachea was placed on a second petri dish with a few drops of
maintenance medium which contained 10% 199 medium with 0.1% bicarbonate,
75 jig/ml penicillin and 125 pg/ml streptomycin. Transverse ring sections 
0.5 - 1 mm in width were cut with a sterile scalpel. Each ring was placed 
in a rubber stoppered soda glass test tube with 1 ml of medium and 
placed on a roller drum. After 24 hours incubation the cultures were 
examined microscopically (X 90) for ciliary activity. Any cell debris 
present in the lumen of the tracheal rings was removed by vigorous 
shaking of the tubes. All cultures with no ciliary activity or less than
25% of normal were discarded.
2.3.4.2 Infeetivity titrations
Five cultures were inoculated for each 10-fold dilution of virus 
in PBS (A). The medium was carefully removed and 0.1 ml of virus dilution 
with fresh medium were added to each tube. The tubes were observed daily 
over 4 days for any major reduction or cessation of ciliary activity.
Again the virus titres were calculated employing the Karber equation.
2.4 IN VIVO (MOUSE) SYSTEM
2.4.1 Source and type of mice employed
For all in vivo studies Swiss white mice, CD-I strain, received 
from Charles River, U.K. Ltd., Mansion Research Centre, Margate, Kent, 
England, were employed. The mice were used in experiments when 
approximately 26 days old, and within a weight range of 18 - 2 2  g.
2.4.2 Adaptation of virus to mice and preparation of virus stocks
f°r ill vivo work
Not all the viruses supplied for this research were adapted to 
mice (Table 2.1). Two unadapted viruses, namely A/Sweden/3/50 (HlNl) 
and A/0kuda/57 (H2N2), were adapted to mice for the in vivo work. The 
process of adaptation involved inoculating mice (5 per group) intranasally 
under light anaesthesia with 0.05 ml of virus suspension which initially 
consisted of undiluted allantoic stock. The anaesthetic consisted of 
2 parts ether, 2 parts chloroform and 1 part methanol. After allowing 
sufficient time for the virus to grow in the lungs, the mice were 
sacrificed by cerebral dislocation and the lungs were removed aseptically. 
The lungs were ground with sterile sand (B.D.H.) in a pestle and mortar, 
and a 10% suspension was made with a solution of PBS (A, B and C) plus 
2% bovine serum albumin and adjusted to pH 7.2 - 7.4 with sodium hydroxide 
This suspension was centrifuged at 1000 g, and the undiluted supernatant 
was used to infect further mice. For the first 10 passages the lungs 
were harvested after 48 hours incubation, but with further passages the 
lungs were harvested after 24 hours. This method was adopted because 
unadapted virus has been reported to take 48 hours to reach maximum titre 
in the mouse lung, whereas adapted virus reaches a peak within 24 hours 
(Vang, 1948).
Both A/Sweden/3/50 (HINl) and A/0kuda/57 (II2N2) were passed 30 times 
within the mouse lung, and virus stocks at passage numbers 20 and 30 were 
made up as desribed above and stored at —70°C for use. With previously 
adapted viruses stocks were prepared after two further passages in the 
mouse lung.
2*4.3 Haemagglutination, infectivity and mortality titrations of virus stocks
For haemagglutination titrations the virus suspensions were first 
incubated with an equal volume of receptor destroying enzyme (RDE, 
Philips-Bujhar, Amsterdam, Holland) for 18 hours at room temperature to 
remove unspecific inhibitors of haemagglutination present in serum. The 
haemagglutination titrations were carried out as described in section 2.2.3, 
with virus dilutions made in 2.5% trisodium citrate (B.D.H.); this compound 
was necessary in order to inhibit the action of RDS. All mouse-adapted 
stocks were also titrated for inf ectivity in the AOS system, as described 
earlier (section 2.3.2.l).
Mortality or LD50 (50% lethal dose) titrations were carried out in 
mice which were inoculated intranasally as described above with 10-fold 
dilutions of virus stocks diluted in PBS (A). Five mice were inoculated 
with each dilution and were observed daily. Deaths were recorded, and 
the LD50 titres were determined using the Karber equation.
RESULTS
3.! IN VITRO SYSTEMS
3.lol Infectivity titrations of virus in different culture systems
Four culture systems were tested: allantois on shell cultures (AOS), 
chick embryo and calf kidney cell monolayers (tube and plate cultures), 
and chick tracheal organ cultures. Allantoic stocks of 4 of the 
8 strains of virus (Table 2.1) were titrated in these culture systems,
A/NY/S, A/Sweden, A/Okuda and A/Hong Kong. The 4 remaining strains of 
virus were titrated in the AOS only.
In the plaque test in chick embryo cells the first method gave 
no plaques with any of the viruses tested. With the second method 
plaques were obtained with all strains provided trypsin was not used; 
the addition of trypsin at the recommended concentration proved toxic 
to the cells. However, under no conditions were good monolayers formed 
so the system was abandoned and chick cells were only used for tube 
culture tests. Plaques were obtained without difficulty in calf kidney 
cell monolayers, so these were used for titrations as well as the calf 
kidney cell tube cultures. The results of the titrations in all the 
systems are given in Table 3.1, which includes results of titrations of 
virus in the allantois of whole eggs (5 eggs/dilution). The titres 
given are the average results of two separate titrations.
Virus titres in ovo were very similar for all strains of virus 
and overall were higher than titres recorded in any of the other systems. 
With AOS titrations, again results were fairly similar for all 4 strains. 
From titrations in tube cultures of chick embryo and calf kidney cells 
the results for both A/Okuda and A/Hong Kong agreed well with those 
obtained in AOS cultures. Results for A/NWS showed good agreement
TABLE 3.1 INFECTIVITY OF DIFFERENT STRAINS OF VIRUS IN
DIFFERENT CULTURE SYSTEMS
Culture system A/NV/S
(HONl)
Strains
A/Svreden
(H1N1)
of virus*
A/Okuda
(H2N2)
A/Hong Kong 
(H3N2)
In ovo (allantois) 8.1** 8.3 8.2 8.5
AOS cultures 7.2 7.0 7.7 7.8
Chick embryo cells 
(tube cultures) 7.1 5.4 7.8 7.4
Calf kidney cells 
(tube cultures) 8.5 5.5 7.8 7.8
(plate cultures) 7.3 5.3 6.2 5.2
Chick tracheal 
organ cultures 4.1 NG 6.3 6.4
Key:
* The same allantoic stock of virus used for all titrations 
** infectivity/ml
NG No growth
for AOS cultures and chick embryo cells, but calf kidney cells appeared 
more sensitive, with a titre comparable to that obtained jn ovo. Both 
chick embryo and calf kidney cells were less sensitive to A/Sweden.
The plaque test in calf kidney cells was less sensitive than the tube 
test in these cells except for A/Sweden,' which gave low titres by both 
methods. When compared to titrations in ovo the efficiency of plaque 
production was highest for A/NWS and lowest for A/Hong Kong. For 
chick tracheal organ cultures the titres obtained were relatively low 
for all the virus strains, and with A/Sweden no growth was detected even 
with a high input of virus.
Since variations in sensitivity were observed with the different 
cell cultures and with different virus strains, in later antiviral tests 
the input of virus to be used in a cell culture system was calculated 
from results of inf ectivity titrations obtained with that system. Thus 
with the AOS cultures A0SID50 were used, with chick embryo cells CSCID50 
and with calf kidney cells CKCID50. In this way it was ensured that 
all cells or cell cultures were infected, depending on whether single or 
multiple cycle tests were used. Apart from the chick tracheal organ 
culture technique it was possible to estimate the number of cells in 
culture for each system. With the results from the above inf ectivity 
titrations the multiplicity of infection could be calculated fairly 
accurately for each system.
3.1.2 Virus growth curves obtained in the different systems
Growth curves were determined for the 4 strains of virus indicated 
in Section 3.1.1 in AOS cultures, and in tube cultures of chick embryo 
and calf kidney cells. For the 3 systems, cultures were set up and 
infected as described in Section 2.3. All cultures were infected with
a high multiplicity of virus, approximately 10 infectious particles per 
cell calculated from the results of infectivity titrations in the appropriate 
system. With A/Sweden titres were low in chick embryo and calf kidney cells, 
and it was therefore necessary to set up cultures with one-tenth of the 
number of cells and to double the volume of virus used, to obtain a 
multiplicity of approximately one. After allowing one hour for adsorption 
the cells were washed with PBS (A) to remove unadsorbed virus, fresh medium 
was added, and all cultures incubated at 37°C. Samples, in triplicate, 
were removed at 2-hourly intervals up to 24 hours after adsorption, and 
growth determined by measuring either infectivity or haemagglutination or 
both, as indicated below,
Y/ith AOS cultures, for 2 strains of virus, A/Sweden and A/!Iong Kong, 
infectivity titrations were carried out in AOS cultures on 2 replicates 
from each sample. The results (Fig. 3.1) showed that both strains 
reached peak titres within 16 hours. Haemagglutinin titrations were 
carried out on samples from all 4 strains of virus grown in AOS cultures.
The results were plotted as log haemagglutinin titre against time (Fig. 3.2). 
The strains reached peak titres within 16 hours, which was the same time 
as that found with infectivity titrations.
Samples from chick embryo and calf kidney cell cultures were 
titrated by haemagglutination only. In chick embryo cells (Fig. 3,3) 
the 4 strains multiplied at a similar rate and reached a maximum within 
16 hours, as in the AOS cultures. In the calf kidney cells (Fig. 3.4) 
the 4 strains all grew at a similar rate but more slowly than in chick 
embryo cells, with titres still rising at 24 hours, when the experiment 
was terminated. Overall titres were lowest in chick embryo cells and 
highest in calf kidney cells.
In the AOS system multiple cycle growth curves were also determined
^4
70
60
50
40
>o
30CD
O—1
20
10
Time (hrs)
Fig. 3.1 Growth curves for A/Sweden/3/50 ( ©) and A/Hong Kong/l/68 ( V ) 
in AOS cultures, under single cycle conditions
95
30
20
.2*«£oc
D
S'
E<DO_c
o
f_i
20
Fig. 3.2 Haemagglutination production by A/NWS/33 { ™  ); 
, A/Sweden/3/50 ( Q  ); A/0kuda/57 ( A ) ♦ and. 
A/Hong Kong/1/68 ( V ) j.n AOS cultures under 
single cycle conditions
Lo
gj
 
ha
em
ag
gl
ut
in
at
io
nt
it
re
Fig. 3
96
3-0
2-0
10
12
Time (hrs)
16 20 24
«3 Haemagglutination production by A/NWS/33 ('®), 
A/Sweden/3/50 ( © ), A/Oku da/57 ( *0 and 
A/Hong Kong/1/68 (V) in chick embryo cells/under 
single cycle conditions
yv
30
20
co
D
C
JD
O)D)D
E
CD
.8
o
U)
2420
Time (hrs)
Fig. 3.4 Haemagglutination production by A/lNWS/33 ( B )*
4 / n  J  /r* /f. S\ i V * <f/~\ 1 •» /r. r. / A \   j
n/oweueu/o/ou A/v/K.uaa/o/ v ***) and
A/Hong Kong/l/68 (V) in calf kidney cells* under
single cycle conditions
for the 4 virus strains. Here a low input of virus of approximately 
10 A0SID50 per inoculum was used. The growth rates were determined by 
taking samples in duplicate at 8-hourly intervals up to 48 hours after 
adsorption and titrating in the AOS system. The 3 strains A/Sweden, 
A/Okuda and A/Hong Kong reached maximum titres within approximately 
32 hours (Fig. 3.5), but A/NWS grew slightly slower, taking approximately 
40 hours to reach a maximum.
■3.1.3 Defection of anti-influenza activity
The compounds tested included 7 compounds previously reported to 
be active against influenza, and 53 nucleoside analogues not previously 
tested against influenza, prepared by the Wellcome Laboratories.
For this survey one strain, A/Hong Kong, was used because it belongs 
to the current II3N2 subtype and is a well-adapted laboratory strain.
Two culture systems were used to screen for anti-influenza activity, the 
AOS and plaque systems.
For tests in the AOS system egg pieces were prepared in 0.3 ml of 
medium which contained 50 pg/ml of test compound. All cultures were 
infected with a multiplicity of approximately 10 A0SID50/cell. After 
allowing 1 hour for adsorption of the virus at 37°C the egg pieces were 
washed in PBS (A) and transferred to fresh medium again containing the 
test compound. Control cultures without compound were also included.
On the basis of the results from growth curve studies cultures were 
incubated for 16 hours at 37°C, i.e. one complete growth cycle. Sixteen 
replicates were used for each compound and after incubation two pools of 
8 were prepared. Each pool was subjected to 3 successive cycles of 
freeze-thawing before haemagglutination titrations were.carried out.
For each compound tested the titres obtained were compared with those 
of the controls.
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With this system compounds were considered active if they caused
at least a 4-fold reduction in titre when compared with the controls.
Any compound which gave only a 2-fold reduction in titre was retested 
at a concentration of 100 pg/ral. Compounds found active were tested 
to see if they could inhibit the haemagglutination reaction and thus 
give a false positive result. This was done by adding an equal volume 
of a 50 [ig/ral solution of compound to a virus stock and diluting 
(2-fold range) the virus stock and virus stock plus compound in saline, 
as described for the haemagglutination test (Section 2.2.3). With this 
system once a compound was found active it was also necessary to establish 
whether the inhibition of growth was a true antiviral effect or whether 
it was caused by toxicity of the compound. Two methods of testing for 
toxicity were used. With the first, after incubating egg pieces in the
presence of an active compound for 24 hours the vital stain, neutral red, 
was added (l drop of 0.0001% solution/well), and the trays were incubated 
for a further 18 hours. The membranes were removed from the egg shells 
and placed on slides, and the intensity of the stain taken up was compared 
with that of control membranes treated in the same way. With the second 
method, egg pieces were incubated with medium containing test compound 
for 24 hours at 37°C, and then washed and left in medium without compound 
for 3 hours at 4°C to allow any remaining compound to diffuse from the 
cells. The cultures were then infected and incubated for 16 hours at 
37°C, Haeraagglutination titres were again compared with controls.
For plaque inhibition tests in calf kidney cells, plates were 
set up as described in Section 2.3.3, using a dilution of virus which 
would give approximately 200 - 250 plaques per plate. After the overlay 
had solidified paper discs (6 mm diameter, Whatman No. 3MM paper) saturated 
with stock solutions of the test compounds were placed on the centre of
the overlay, so that the test compounds could diffuse through the overlay 
to the cells. By using stock solution of 5 mg/ml it was calculated that 
the discs took up approximately 50 |ig of compound. After 3 days 
incubation at 35°C the plates were overlaid with a second overlay 
containing either neutral red or tetrazolium salt, and the results were 
read 18 hours later. When these two staining methods were compared 
neutral red, although not a permanent stain, proved superior to the 
tetrazolium salt in that plaques were much easier to see. Thus after 
the initial comparison of the two staining methods neutral red alone 
was adopted.
With this system compounds were considered active if a zone of 
plaque inhibition or a reduction in plaque size was present around the 
disc. Any compound showing questionable activity was retested using a 
10 mg/ml (100 pg/disc) stock solution. Toxicity appeared as an area of 
unstained dead cells around the disc. However, with this method problems 
sometimes arose because of the difficulty of distinguishing between toxicity 
and activity. When a toxic compound did not cause 100% death of cells a 
slight reduction in intensity of the stain occurred, with a definite area 
without plaques. In such cases it was impossible to determine whether 
the compound was active or toxic. The tests were therefore repeated, 
and after fixing with 10% formalin solution the plates were stained with 
crystal violet. With this method dead or damaged cells were washed away, 
and thus toxic areas with no or few cells became apparent.
A list of compounds found active by one or both methods employed, 
together with results for the 7 compounds previously reported active, 
was compiled (Table 3.2). A total of 60 compounds was tested by these 
methods, out of which 9 showed some activity. Of the 7 known 
compounds tested only amantadine hydrochloride and Ribavirin showed
TABLE 3.2 ANTIVIRAL ACTIVITY OF DIFFERENT COMPOUNDS IN AOS AND 
PLAQUE TESTS
Compound Antiviral activity 
AOS test Plaque test
Amantadine hydrochloride ++
Bathocuproin sulphate
2-Deoxy-D-glucose - . + -■ + (toxic)
1~(p-Chlorophenoxyraethyl)-3,4- 
dihydroisoquinoline hydrochloride 
(UK 2054)
1-Meihylisatin 3~thioseiaicarbazone 
(methisazone) -
Ribavirin ++ ++
4,5,6-Trichloro-l-p-D-ribofuranosyl- 
benzimidazole 
(TRB) , + +'(toxic)
V/ellcome compound A
Wellcome compound B •f
V/ellcome compound C +
Wellcome compound D + .
Key: ++ '. 8-fold or greater reduction in haemagglutination
titre. 25 mm or greater sons of plaque inhibition.
+ 4-fold reduction in haemagglutination titre.
10 - 25 ram zone of plaque inhibition.
+ 2-fold reduction in haemagglutination titre.
10 mm or less zone of plaque inhibition or 
reduction in plaque size only.
- no activity
marked activity in both systems. The isoquinoline compound UK 2054 was
inactive in the AOS system, and showed only a small zone (10 mm) of
plaque inhibition. The two chelating agents, bathocuproin sulphate 
and 1-methylisatin 3-thiosemicarbazone, were found to be inactive in 
both systems. Both 2-deoxy-D-glucose and TRB were found active in the 
AOS system, but in calf kidney cells both were very toxic, with only a
narrow zone of activity outside the central area of toxicity. None of
these known compounds proved toxic in the AOS system, and none inhibited 
the haemagglutination reaction.
Out of the 53 compounds with unknown activity tested, only 4 were 
active. Two of these compounds were slightly active in both systems 
and two were active in the AOS system only. Compounds found to be very 
toxic were not included in the table. However, Wellcome compound A was 
found to be slightly toxic in the second toxicity test carried out in 
AOS cultures. In this test the haemagglutination titre was reduced
3-fold, and thus activity may have resulted from the toxicity of the 
compound. None of the compounds were found to inhibit the haemagglutination 
reaction. Of the 4 Wellcome compounds found active and the 7 known compounds 
only amantadine hydrochloride and Ribavirin showed a fairly high degree 
of activity. Thus these two compounds were selected for further comparisons 
to be made of their sensitivity in the different systems.
3.1.4 Spectrum of activity of amantadine hydrochloride and Ribavirin
Three cell culture systems were used to test for activity, the 
AOS system and calf kidney cells (plaque inhibition) as described above, 
and chick tracheal organ cultures.
3.1.4.1 AOS system
For this work the 8 strains listed in Table 2.1 were used.
The tv/o compounds were employed at a concentration of 50 pg/ml, and the 
tests were set up as described in Section 3.1.3. The results obtained 
have been assembled into Table 3.3.
All of the 8 strains tested were very sensitive to Ribavirin, 
since each shoived an 8-fold or greater reduction in titre. With 
amantadine hydrochloride some variation in sensitivity of the 8 strains 
was observed, A/PR8 was completely insensitive, A/NWS and A/FMI were 
only slightly sensitive, with a consistent 2~fold reduction in titre 
at the concentration used. Both of the more recent strains, A/Hong Kong 
and A/England, were very sensitive to amantadine hydrochloride.
3.1.4.2 Plaque inhibition in calf kidney cells
With this method the A/NWS, A/Sweden, A/Okuda and A/Hong Kong 
strains l^ ere used. The plaques produced were found to vary in size 
when incubated for the same length of time (Fig. 3.6). After 5 days 
incubation both A/NWS and A/Sweden produced large plaques, on average 
6 mm and 5 ram in diameter respectively. The other 2 strains, A/Okuda 
and A/Hong Kong, produced smaller plaques, on average 3 ram in diameter.
For comparisons to be made of the sensitivity of different strains 
to the same compound, it was considered necessary to obtain plaques of 
similar size for all strains. This was of particular importance for 
quantitating activity because with large plaques a reduction in plaque 
size without reduction in plaque number could occur, which would be 
difficult to quantitate, whereas when the plaques are small complete 
inhibition of plaque formation could occur at the same concentration of 
compound, and thus similar strains would appear to differ in sensitivity. 
Plaques of similar size were obtained by incubating the two strains 
producing large plaques for 48 hours, and the two producing small plaques 
for 72 hours. By this method plaques of approximately 2 mm diameter were
TABLE 3.3 INHIBITION OF STRAINS OF VIRUS IN AOS BY
AMANTADINE HYDROCHLORIDE AND RIBAVIRIN
Virus strain Sub-type Amantadinehydrochloride’5'
Ribavirin*
A/NV/S/33 HON 1 + + +
A/PR8/34 , H0N1
A/FMl/47 H1N1 i ++
A/Sweden/3/50 HINT. + + 4-
A/Singapore/1/57 H2N2 ' + +  ' + +
A/0kuda/57 H2N2 -h ++
A/Hong Kong/l/68 H3N2 '++ ; ++
A/England/42/72 H3N2 ++ : + 4-
Key:
* 50 [xg/ml
- no activity
+ 2-fold reduction in haemagglutination titre
+ 4-fold reduction in haemagglutination titre
++ 8-fold or greater reduction in haemagglutination
titre
a) A/NWS/33{HONl)
b) A/Sweden/3/50 (II IN 1.)
Fig* 3.6 Plaque morphology in calf kidney cells of the
four influenza A strains used, stained with 0.005% neutral red. 
Small plaques appear less distinct on photographic plates.
c) A/Oku da/57 ( JI2N2)
d} A/Hong Ko ng/1/68{
Fig. 3.6 (continued)
obtained. Tests were set up as described in Section 3.1.3, with
50 pg of each compound per disc.
In this test all strains were sensitive to both compounds 
(Table 3.4). However, A/NWS was only slightly sensitive, with a 
reduction in plaque size only. All the remaining strains with both 
compounds, and A/NWS with Ribavirin, gave zones of plaque inhibition 
greater than 25 mm diameter.
3.1.4.3 Chick tracheal organ cultures
When infectivity titrations were carried out in this system 
as described in Section 2.3.4, the cultures were observed twice daily 
to determine if any relation existed between the time required for 
reduction in ciliary action to occur and the concentration of virus used. 
It was found that at the lowest dilution used (10 ) an effect \vus
apparent after only 24 hours, but with higher dilutions the cultures 
were all inhibited after 48 - 72 hours. Thus there was no definite 
virus dose-related effect. This system was therefore not suitable for 
tests involving delay in reduction of ciliary activity.
Instead, for antiviral tests the virus strains were titrated as 
described, in the presence and absence of compound (50 pg/ral), with 
3 control and 3 test cultures per compound set up for each virus dilution. 
Reduction in virus titre in the presence of test compound when compared 
with control was taken to be an indication of antiviral effect. The 
three strains A/NWS, A/Okuda and A/Hong Kong were used, and the results 
obtained for these strains have been plotted in Table 3.5. All three 
strains were inhibited by both compounds, with reductions in titre from 
2 - 4  log units.
TABLE 3.4 INHIBITION OF STRAINS OF VIRUS IN CALF KIDNEY CELLS
(PLAQUE INHIBITION) BY AMANTADINE HYDROCHLORIDE AND
RIBAVIRIN
Virus strain Sub-type Amantadinehydrochloride* Ribavirin*
A/NV/S/33 H0N1 + 4*4-
A/Sweden/3/50 H1N1 4-4- 4-4- V
A/0kuda/57 H2N2 4-4- 4+ v
A/Hong Kong/1/68 II3N2 - ;++ 4-4-
* 50 pg/disc
+ 10 mm or less zone ox plaque inhibition or
reduction in plaque size only
4-4- 25 mm or greater zone of plaque inhibition
TABLE 3.5 INHIBITION OF STRAINS OF VIRUS IN CHICK TRACHEAL ORGAN
CULTURES BY AMANTADINE HYDROCHLORIDE AND RIBAVIRIN
Virus strain Sub-type
Reduction in virus 
Amantadine hydrochloride*
titre
Ribavirin*
A/NtfS/33 IION1 2.0 2.4
A/0kuda/57 H2N2 3 . 3 4.0
A/Hong Kong/l/6S H3N2 4.3 3.1
Key:
3.1.5 Quantitation of the activity of amantadine hydrochloride and Ribavirin 
From the results of the previous section it was seen that all 8 strains 
of influenza virus tested were sensitive to Ribavirin, and 7 out of 8 strains 
showed some degree of sensitivity to amantadine hydrochloride. To compare 
the sensitivity of these different strains to the 2 compounds, quantitative 
studies were carried out in the different cell cultures. With all methods 
the concentration of amantadine hydrochloride used never exceeded 400 pM 
and of Ribavirin 200 pM, at which levels no toxic effects on the cells 
were observed with either compound. To obtain some measure of 
reproducibility of each method, tests with A/Sweden and A/Hong Kong were 
repeated on three separate occasions and the results were pooled to obtain 
dose-response lines.
3.1.5.1 AOS cultures
a) Single cycle experiments
For this work stock solutions of test compounds were diluted 
in medium to give a 2-fold range of concentrations. With amantadine 
hydrochloride the concentrations ranged from 400 pM down to 3.125 pM 
and with Ribavirin from 200 pM down to 3.125 pM. Egg pieces were 
prepared as described earlier (Section 2.3.1) and placed in wells 
containing medium plus test compound. For each dose level 24 egg pieces 
were used. To minimize variation, each dose level was tested on an 
equal number of pieces from each egg and at least 4 eggs were used for 
a test. Control cultures without any compound were also included.
The egg pieces \*ere infected with a high multiplicity of virus (approximately 
10 A0SID50/cell) and the virus was allowed to adsorb for 1 hour at 37aC.
After incubation the unadsorbed virus was removed by careful washing 
with PBS (A), and the egg pieces were placed in fresh medium again
containing test compound. All cultures were incubated for 16 hours 
at 37°C on a horizontal shaker. After incubation the cultures were 
freeze-thawed 3 times, and the egg pieces from each dose level were 
pooled in groups of 8 to give results in triplicate. Haemagglutination 
titrations were carried out on all cultures and infectiviiy titrations 
on control cultures to determine the proportion if any of incomplete 
virus present.
All 8 strains of virus used in this study were employed in the 
above tests. The results obtained with both infectivity and 
haemagglutination titrations for these strains have been assembled in 
Table 3*6. The majority of strains produced high proportions of 
incomplete virus, only A/Sweden producing virtually all complete virus.
With A/Sweden and A/England further infectivity titrations were carried 
out on 2 samples from each dose level for both amantadine hydrochloride 
and Ribavirin. The results expressed as the percentage of the 
control virus titre against compound concentration are illustrated in 
Figs. 3.7 and 3.8.
In all cases the dose-response lines obtained by both methods 
of titration appeared similar. The greatest deviation occurred with 
amantadine hydrochloride against A/England. From these results it 
appeared that haemagglutination titrations gave a true indication of 
what was happening to infectious virus even in the presence of incomplete 
virus. Thus with further tests haemagglutination titration alone was 
adopted as the method of titrating virus.
The dose-response lines obtained by the above method were plotted 
as the percentage of the control virus titre against compound concentration 
so that the sensitivities of the different strains to the 2 compounds 
could be compared (Fig. 3.9). The strains were found to vary in their
TABLE 3.6 HAEMAGGLUTININ/INFECTIVITY RATIOS AND PERCENTAGE
INCOMPLETE VIRUS PRODUCED IN AOS CULTURES UNDER 
SINGLE CYCLE CONDITIONS FOR 8 STRAINS OF VIRUS
Virus strain
Haemagglutinin/infactivity 
ratio
% incomplete 
virus'*
A/NWS/33 1 : 2208 97.8
A/PR8/34 1 : 7812 92.2
A/Sweden/5/50 1 : 69632 30.4
A/FM1/47 1 : 591 99.4
A/0kuda/57 : 1 : 8786 91.2
A/Singapore/1/57 1 : 27597 : V 72*4 ,
A/Hong Kong/l/68 1 : 6234 93.7
A/England/42/72 1 : 881 99.1
* assuming that 1 HA-unit = 10^ A0SID50/ral
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Figs. 3.7 and 3.8
Dose-response lines for amantadine hydrochloride { - - - - )
and Ribavirin (----- ) against A/Sweden/3/50 (© O  ) and
A/England/42/72, ( v v )  titrated by infectivity (closed symbols) 
and haemagglutination (open symbols)
sensitivity to amantadine hydrochloride. A/NWS was the least sensitive, 
and A/Singapore by far the most sensitive. The lines obtained for the 
remaining strains frequently crossed one another and this made comparisons 
difficult. However, of these A/Sweden and A/FMI appeared less sensitive 
than A/Okuda, which in turn was less sensitive than A/Hong Kong and 
A/England, which were similar in sensitivity. The strains may be listed 
in order of sensitivity as NWS < Sweden < FMI < Okuda “C Hong Kong =
England < Singapore. With some of the more sensitive strains, namely 
A/Singapore and A/Hong Kong, the activity of amantadine hydrochloride 
appeared to tail off at higher concentrations, and thus there was no 
complete inhibition of growth under single cycle conditions by amantadine 
hydrochloride.
Fig* 3.10 illustrates dose-response lines for Ribavirin against 
the 8 different strains. The similarity in sensitivity of all strains 
tested to Ribavirin was apparent. The lines obtained were so close 
that it was impossible to list the strains in any order of sensitivity.
As with amantadine hydrochloride, tailing off in activity v/as recorded 
at higher concentrations for the majority of strains.
A comparison of the sensitivity of amantadine hydrochloride and 
Ribavirin against the 4 strains A/NWS, A/Sweden, A/Okuda and A/Hong Kong 
is shown in Fig. 3.11. Fig. 3.12 gives the results for the remaining 
4 strains. Ribavirin was more active than amantadine hydrochloride 
against the strains tested except for A/Singapore, which was much more 
sensitive to amantadine hydrochloride, particularly at lower 
concentrations.
In addition, because of results obtained later in vivo it was 
necessary to carry out tests as described above with amantadine hydrochloride 
and Ribavirin against an A/Okuda mouse lung adapted (M20) stock, to compare
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Fig, 3.9 Dose-response lines for amantadine hydrochloride against
7 strains of virus in AOS cultures under single cycle conditions
Key: B  A/FWS/33; © A/Sweden/3/50; O  A/FMl/47;
AA/0kuda/57; A A/Singapore/1/57;
V A/Hong Kong/1/68; V A/England/42/72
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Fig. 3.10 Dose-response lines for Ribavirin against 8 strains of 
virus in AOS cultures under single cycle conditions.
Key: E3 A/NWS/33; □ A/PR8/34: ©A/Sweden/3/50;
O  A/FM1/47; A A/0kudo/57; A A/Singapore/l/57; 
V A/liong Kong/l/68; V A/England/42/72
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Fig. 3.11 Comparison of dose-response lines for amantadine hydrochloride
(- ~ - -) and Ribavirin (--- -) against A/NWS/33 ( 0 );
A/Swcden/3/50 ( © ); A/Oku da/57 ( &  ) • and A/Hong Kong/1/68 ( V ) 
in AOS cultures
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A/FMl/47 ( O  ); A/S.ingapore/l/57 ( ^ ); and 
A/England/42/72 ( V ) in AOS cultures
the results with those obtained with the unadapted virus. Similar 
results (Fig. 3.13) were obtained with both stocks of virus.
b) Multiple cycle experiments
The activity of amantadine hydrochloride and Ribavirin was also 
quantitated under multiple cycle conditions. For these tests egg pieces 
were set up in medium without compound and infected with approximately 
10 A0SID50 of virus per well. The virus was allowed to adsorb for 
1 hour, after which the egg pieces were washed in PBS (A) and placed in 
fresh medium containing the compound in a range of concentrations from 
400 pM down to 6.25 pM for amantadine hydrochloride and 100 pM down to
6.25 pM for Ribavirin. Control cultures without compound were also 
set up. Egg pieces were distributed as described for single cycle tests 
and 8 egg pieces were pooled for one replicate test. All dose levels 
and controls were set up in duplicate. Cultures were incubated at 37°G 
for 48 hours, a time in which all strains tested had been found to reach 
peak titres (Fig. 3.5). After incubation the cultures were freeze-thawed 
3 times, and infectivity titrations in the AOS system were carried out on 
each replicate.
Dose-response lines were obtained with the 4 strains tested (Fig. 3. 
The log reduction in virus titre was plotted against compound concentration 
and this allowed a comparison of the sensitivities of the different strains 
to be made. Again the 4 strains were found to vary in sensitivity to 
amantadine hydrochloride, but were all of similar sensitivity to Ribavirin. 
The order of sensitivity of the 4 strains to amantadine hydrochloride was 
NWS 4 Sweden 4 Okuda 4 Hong Kong, which was in agreement with results 
obtained under single cycle conditions. However, when the sensitivity 
of the 4 strains to the 2 compounds was compared the results were found
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Fig. 3.13 Dose-response lines for amantadine hydrochloride ( - - - - )
and Ribavirin (----) against A/0kuda/57, allantoic stock (M0, A )
and mouse-adapted stock (M20, A ) in AOS cultures
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Fig. 3.14 Dose-responsd lines for amantadine hydrochloride ( - - - - )
and Ribavirin (--- ) against A/NtfS/33 ( B ): A/Sweden/3/50 ( ©  ):
A/0kuda/57 ( ^ ) •, and A/Hong ICong/1/68 ( V ) in AOS cultures 
under multiple cycle conditions
J. Af o
to differ slightly from those obtained with single cycle experiments.
Both A/NWS and A/Sweden were definitely less sensitive to amantadine 
hydrochloride, bat there was little difference in sensitivity of the 
2 strains A/Okuda and A/Hong Kong to the 2 compounds. Thus it appeared 
that with more sensitive strains the activity of amantadine hydrochloride 
was greater under multiple cycle conditions.
3.1.5.2 Chick embryo cells
All determinations made with these cells were carried out 
under single cycle conditions in tube cultures. The 4 strains A/NhS, 
A/Sweden, A/Okuda and A/Hong Kong were used. All cultures were set up 
overnight as described in Section 2.3.2; The cells were washed with 
PBS (A) to remove serum, and 0.6 ml of maintenance medium with or without 
test compound was added to each tube, followed by 0.1 ml of virus to give 
an approximate multiplicity of 10 CECIDoO/cell. With A/Sweden an 
approximate multiplicity of 1 CECXD50/cell was used. The ratio of 
medium to virus inoculum was calculated to agree with that used in the 
AOS system, for comparison to be made of the 2 systems* The compounds 
were diluted in maintenance medium in a 4-fold dilution range from 
400 pM down to 3.125 pM for amantadine hydrochloride and 200 pM down to
6.25 pM for Ribavirin. Each dose level and controls were set up in 
triplicate. After allowing 1 hour for adsorption the cell layers were 
again washed with PBS (A) to remove excess virus, and 1 ml of fresh medium 
again with or without compound was added. After incubation at 37°C on a 
roller machine the cultures were freeze-thawed 3 times and haemagglutination 
titrations were carried out on each individual tube. Infectivity titrations 
in the AOS system \^ ere carried out on control cultures to check if 
incomplete virus was produced.
The dose-response lines obtained for amantadine hydrochloride 
against the 4 strains are illustrated in Fig. 3.15. Again, the order 
of sensitivity of the 4 strains to amantadine hydrochloride was 
NWS < Sweden < Okuda < Hong Kong. The two strains A/Okuda and A/Sweden, 
however, were very similar in sensitivity. From the dose-response lines 
obtained with Ribavirin (Fig. 3.16) the sensitivity range for the 4 strains 
tested was Okuda 4 Hong Kong < Sitfcden X NWS,.-which was the complete reverse 
of the results obtained with amantadine hydrochloride. However, there was 
little difference in the sensitivity of the last 3 strains. When the 
sensitivities of the 4 strains to both compounds was compared (Fig. 3.17), 
it was seen that A/NWS and A/Sweden were more sensitive to Ribavirin, but 
that with A/Okuda and A/Hong Kong the reverse applied. With these latter 
2 strains the differences in sensitivity to each compound were not clear cut, 
since the dose-response lines crossed. This resulted from the tailing off 
in activity of amantadine hydrochloride at higher concentrations.
A comparison of results with infectivity and haemagglutination 
titrations revealed that all 4 strains produced large quantities of 
incomplete virus (Table 3.7).
3.1.5.3 Calf kidney cells
a) Single cycle experiments
Dose-response experiments with amantadine hydrochloride and 
Ribavirin were carried out under conditions identical with those described 
for chick embryo cells in the previous Section. Again the same 4 strains, 
A/NWS, A/Sweden, A/Okuda and A/Hong Kong, were used. The 2 compounds 
were diluted in 4-fold dilution ranges from 400 pM down to 0.3 pM for 
amantadine hydrochloride and 200 pM down to 1.5 pM for Ribavirin.
Although all the strains were found to take at least 24 hours to complete
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Fig. 3.15 Dose-response lines for amantadine hydrochloride
against' A/NV/S/33 ( E ); A/Sweden/3/50 ( © ); A/0kuda/57 ( A ); 
and A/Hong Kong/1/68 ( V ) in chick embryo cell cultures
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Fig. 3.16 Dose-response lines for Ribavirin against A/NWS/33 { H );
A/Sweden/3/50 ( G  ); A/0kuda/57 ( A ); A/fiong Kong/1/68 ( ^ ) 
in chick embryo cell cultures
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Fig. 3.17 Comparison of aose-response lines for amantadine hydrochloride
(*--*--) and Ribavirin (----) against A/NV/S/33 ( E3 );
A/Sweden/3/50 ( © ); A/0kuda/57 ( ^ ) and A/Hong Kong/1/68 ( V )in 
chick embryo cell cultures
TABLE 3.7 HAEMAGGLUTININ/INFECTIVITY RATIOS AND PERCENTAGE
INCOMPLETE VIRUS PRODUCED IN CHICK EMBRYO AND CALF KIDNEY 
CELLS UNDER SINGLE CYCLE CONDITIONS FOR 4 STRAINS OF VIRUS
Cell culture Virus strain HA/.tnfectivityratio
/o incomplete 
virus*
A/NWS/33 1 : 198 99.81
Chick embryo
A/Sw eden/3/50 
A/0kuda/57
1 : 39
1 : 4930
99.96
95.1
A/Hong Kong/l/68 1 : 1573 98.4
A/NWS/33 1 : 1100 98.9
Calf kidney
A/Sweden/3/50
A/Gkuda/57
1 : 220 
1 : 843
99.8
99.2
A/Hong Kong/l/68 1 : 494 99.5
5
assuming that 1 HA unit = 10 A0SID50/ml.
a single cycle of growth (Section 3.1.2), cultures were incubated for 
16 hours only so that conditions were comparable in respect of time to 
those used with AOS and chick embryo cell cultures. After incubation 
the cultures were freeze-thawed 3 times and haemagglutinati’on titrations 
were carried out on all cultures. Infectivity titrations were done on 
control cultures only.
The results ifere plotted as the percentage of the control virus 
titre against compound concentration (Fig. 3.18). A/NWS was considerably 
less sensitive to amantadine hydrochloride in this system than the other 
3 strains. These 3 strains appeared very similar in sensitivity since 
all the dose-response lines converged at higher concentrations. An 
attemptwas made to arrange the strains in order of sensitivity, which 
was NWS < Hong Kong < Sweden < Okuda. In this system all strains showed 
some tail-off in activity with higher concentrations of amantadine 
hydrochloride*
With Ribavirin none of the dose-response lines crossed, and thus 
there was no problem in arranging the strains in order of sensitivity.
The range of sensitivities was Okuda < Hong Kong < Sweden < NWS. The 
dose-response lines obtained with the first 3 strains were fairly close, 
so that there was little difference in sensitivity between strains.
When the 2 compounds were compared, only A/NWS appeared less 
sensitive to amantadine hydrochloride than Ribavirin. With the 3 
remaining strains amantadine hydrochloride was much more active than 
Ribavirin. Again all 4 strains were found to have produced large 
quantities of incomplete virus (Table 3.7).
b) Plaque reduction experiments
All 4 strains used throughout this study were found to produce 
plaques in calf kidney cells. However, as stated in Section 3.1.3.5,
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there was considerable variation in the size of the plaques produced 
by the different strains, and thus for all tests with A/NWS and A/Sweden 
plates were incubated for 48 hours, and with A/Okuda and A/Hong Kong 
for 72 hours.
From the results obtained with the infeciivity titrations the 
dilution factor necessary to give between 100 - 150 plaques per plate 
was determined and used in tests. For all experiments the plates were 
infected as described in Section 2.3.5.2. After allowing 1 hour for 
adsorption the excess virus was removed and the plates were overlaid 
with medium containing the test compounds. Serial 2~fold dilutions 
were made up in double strength medium to which was added an equal 
volume of melted agar (42°C) to give a final range of concentrations 
from 3.125 pM to 0.05 pM for amantadine hydrochloride and 6.25 pM down 
to 0.7 pM for Ribavirin. All dose levels were set up in triplicate 
together with 3 controls without test compounds. All plates were 
incubated at 35°C for the times indicated.
Dose-response lines were obtained with both compounds against 
all 4 strains (Fig. 3.19). Again it appeared that A/NWS liras considerably 
less sensitive to amantadine hydrochloride than the other 3 strains, all 
of which appeared very similar in sensitivity. The strains increased in 
sensitivity in the'order .NWS < Hong Kong < Sweden < Okuda, which agreed 
\*ell with the observations made in single cycle tests with the same cells. 
With Ribavirin all 4 strains appeared similar in sensitivity. From these 
results A/NWS appeared the least sensitive, which was the complete opposite 
of the results obtained under single cycle conditions. With the remaining 
3 strains it was impossible to give any order of sensitivity because the 
dose-response lines crossed.
Comparison of the results obtained with both compounds revealed
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Fig. 3.19 Dose-response lines for amantadine hydrochloride ( - - - - )
and Ribavirin (--- ■) against A/NWS/33 ( F3 ) ; A/Sweden/3/50 ( © ) ;
A/0kuda/57 ( A ) and A/I long Kong/l/68 ( V ) determined by 
plaque reduction in calf kidney cells
that apart from A/MWS all strains were marginally more sensitive to 
amantadine hydrochloride than to Ribavirin. With these plaque reduction 
tests there appeared to be little or no tailing off of activity with 
amantadine hydrochloride of the kind seen in the single cycle tests.
This phenomenon therefore appeared to be associated with single cycle 
conditions.
3.1.6 Comparison of results obtained in different cell cultures
From the results of the previous section certain trends were 
noted. In all systems used the 4 strains of virus were found to be 
similar in sensitivity to Ribavirin, whereas with amantadine hydrochloride 
considerable variation between strains was observed. In addition, some 
variations were observed in the sensitivity of the strains to the two 
compounds depending on the cell culture used. To compare the results 
obtained with different cell cultures graphs were drawn (Figs. 3.20 ~
3.27) of the results obtained with each compound against one virus 
for the single cycle cell culture tests. The results obtained were 
fitted to curves by using one of the two equations given in Fig. 3.28. .
From these 8 graphs it may be seen that with amantadine hydrochloride 
for any one strain of virus there was a high degree of variation in 
sensitivity with the different cell cultures used. For all 4 strains 
tested a similar pattern of sensitivity was seen, with AOS cultures the 
least sensitive, calf kidney cells the most, and chick embryo cells in 
an intermediate position. With Ribavirin there was much closer 
agreement between the results obtained with the different cell cultures 
for all strains of virus. However, a pattern in sensitivity again 
emerged; for 3 out of 4 strains the AOS system was the most sensitive 
and chick embryo cells the least sensitive. With A/NWS calf kidney cells
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•igs. 3.20 and 3.21 Comparison of dose-response lines for amantadine hydrochloride
( - - - - )  and Ribavirin (----) against A/NWS/33, in
AOS cultures ( ^ ), chick embryo cell cultures ( @ ) and 
calf kidney cell cultures ( &  )
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3.23 Comparison of dose-response lines for amantadine hydrochloride
(~ - - -) and Ribavirin (----) against A/Sweden/3/50, in
AOS cultures ( E3 )1 chick embryo cell cultures ( © ) and 
calf kidney cell cultures ( ^ )
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Comparison of dose-response lines for amantadine hydrochloride
(_ - „ _) aao Ribavirin (-- —) against A/Okuda/57, in
AOS cultures { £3 ), chick embryo cell cultures ( ® ) and 
calf kidney cell cultures ( A )
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Comparison of dose-response lines for amantadine hydrochloride
(~ - - -) and Ribavirin (--- -) against A/Hong Kong/l/68 .i in
AOS cultures ( El ), cl;ick embryo cell cultures ( ®  ) and 
calf kidney cell cultures ( A )
were the most sensitive, with AOS cultures intermediate in sensitivity.
To obtain a more quantitative interpretation and to evaluate 
the significance of the results, ED50 values (the dose estimated to 
achieve a 5G$> reduction of control titre) were calculated from each 
dose-response line. Before such values could be obtained, it was 
necessary to find the 'best fit' for each line. From previous graphs 
(Figs. 3.9 - 3.19) it was frequently observed that the dose-response 
effects were not linear, and because of this significant deviation 
from linearity the results were fitted to curves by using either 
equation 1, which fits lines to a hyperbolic curve, or *
equation 2, which fits results to a sigmoid curve (Fig.,3.28). All 
results were evaluated to minimise the sum of squares of the deviation 
between the log expected titres and the log observed titre for each 
dose-level (method of least squares). Computer programmes were used 
to calculate the expected results, the constants for the two equations 
and EDoO values. Calculations were made by using either an arithmetic 
error or a Poisson error. The ED50 values were selected from whichever 
method gave the least deviation from the observed results. The ED50 
values thus obtained have been assembled in Table 3.8 and represented 
graphically in Fig. 3.29. This graph will be referred to later when 
considering the significance of the results.
To determine the significance it was possible with the ED50 values 
obtained to apply X2 tests for significant heterogeneity between groups or 
pairs of values. Before such tests could be carried out it was necessary 
to determine the overall replicate error associated with the methods used, 
so that ED50 values could be weighted appropriately depending on the 
variance of the method. An analysis of variance to establish the error 
involved was carried out with the triplicate ED50 values determined from
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[Young, P., 1977, in preparation] 
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all tests involving A/Sweden and A/Hong Kong. Separate analyses of 
variance were also carried out on the results from single and multiple 
cycle experiments alone and the results compared to see if the errors 
associated with these methods were significantly different. Pooled 
replicate errors were also obtained for the 2 strains of virus and 
for each individual compound. Variance ratio (F) tables for p = 0.05 
were used to determine whether the differences in replicate error values 
recorded were significant. The replicate errors obtained, together 
with their significance, have been tabulated (Table 3.9), from which 
it may be seen that there was no significant difference between any of 
the factors compared. Therefore for heterogeneity tests the overall
error value was used throughout. With these tests X2 tables were
used to determine whether the results were significantly heterogeneous.
Tests were first carried out to determine whether there was any 
significant variation in sensitivity of the 4 strains of virus to each 
compound, in each individual system. It was found that with amantadine 
hydrochloride in every cell culture used the variations observed between 
strains were highly significant. However, with both calf kidney cell 
culture methods and with the AOS multiple cycle tests A/NWS was 
considerably less sensitive to amantadine hydrochloride than the other 
3 strains of virus (Fig. 3.29). Therefore further X2 tests were
carried out with these systems omitting the results obtained with A/NWS. 
From this further analysis it was found that results with the AOS method
were still heterogeneous. However, in calf kidney cells the 3 strains,
A/Sweden, A/Okuda and A/Hong Kong, were similar in sensitivity to 
amantadine hydrochloride whichever method was used.
With Ribavirin in both AOS (single cycle) and chick embryo cell 
cultures the results were not significant, thus indicating that there
TABLE 3.9 COMPARISON OF REPLICATE ERROR (Ve) VALUES
Factors compared Ve value Significantdifference
Single cycle 
Multiple cycle
0.0377
0.0487
A/Sweden/3/50 
A/Hong Kong/l/68
0.0449
0.0415
-
Amantadine hydrochloride 
Ribavirin
0.04S6
0.0389
Total 0.0432
was no difference in sensitivity between the 4 strains. With 
calf kidney cells (single cycle) the results were significant for 
the 4 strains but not for A/Sweden, A/Okuda and A/Hong Kong alone.
These latter 3 strains were therefore of similar sensitivity to 
Ribavirin. With multiple cycle tests the results were not significant 
for either cell culture used, and thus gave further evidence to indicate 
that there was no difference in sensitivity of the 4 strains to Ribavirin.
The sensitivity of the strains of virus in the different cell 
cultures was next compared to see if there was any significant variability 
with the cell cultures used. With amantadine hydrochloride each individual 
strain was tested separately because of the significant variation between 
strains. Comparisons were made initially with the 3 single cycle systems. 
The variations found between cell cultures for all 4 virus strains were 
highly significant with amantadine hydrochloride. With Ribavirin tests 
were carried out on the pooled results for the 4 strains of virus. Again 
significant variation between cell cultures was found. However, with 
Ribavirin there was much closer agreement between results obtained for 
calf kidney and chick embryo cells than with AOS cultures (Fig. 3.29).
The results obtained with the 3 strains, A/Sweden, A/Okuda and A/Hong Kong, 
were in fact homogeneous in the above 2 cell cultures.
From the results with Ribavirin it appeared that there were 
some variations associated tdith the cell culture used. Overall,
AOS cultures were marginally more sensitive, which was the complete 
reverse of observations made with amantadine hydrochloride. However, 
as stated earlier, the variation found with amantadine hydrochloride 
was much greater than that shown by Ribavirin.
When the AOS single and multiple cycle methods were compared 
it was found that the results were significantly heterogeneous for both
compounds. However, all strains were more sensitive to Ribavirin in 
the multiple cycle tests, and apart from A/NWS, the same applied with 
amantadine hydrochloride (Fig. 3.29). With A/NWS the results for 
amantadine hydrochloride were homogeneous with the two methods. In 
calf kidney cells with Ribavirin plaquing was more sensitive for all 
strains except A/NWS, which was similar in sensitivity in both tests.
Y/ith amantadine hydrochloride A/NWS. was more sensitive in the single 
cycle than in the multiple cycle test, and with A/Sweden the reverse 
applied. With A/Okuda and A/Hong Kong there was no significant difference 
in results obtained under either conditions.
The results obtained in the two multiple cycle systems were 
compared as described for single cycle methods. With amantadine 
hydrochloride only A/NWS gave comparable results in the two cell cultures, 
with the 3 remaining strains the differences were highly significant.
With Ribavirin when tests were carried out on the combined results for 
all 4 strains of virus the differences between the methods were not 
quite significant (X = 12.1393, p=.05), thus indicating some agreement 
between the two methods. However, with the results for Ribavirin there 
was considerable overlap in ED50 values for the two systems (Fig. 3.29)• 
Thus again the variation between systems was greater for amantadine 
hydrochloride than for Ribavirin, and again with amantadine hydrochloride 
calf kidney cells were found to be the most sensitive cells tested.
3.1.7 Comparison of the sensitivity of the strains to the turo compounds
The variability in results associated with the different cell lines 
made interpretation difficult, particularly since the variations were not 
consistent for the two compounds. Thus \dien comparing sensitivity in the 
different cell cultures considerable variation was apparent.
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To obtain a quantitative comparison of the activity of the compounds 
the ratios of the ED50 value for each compound against each strain in > 
each system were calculated, taking amantadine hydrochloride as the 
reference compound with a relative potency of 1 (Table 3.10). Thus 
where negative values were recorded, Ribavirin was the most active 
compound.
Heterogeneity tests were carried out on all pairs of results.
In the majority of comparisons the results were significantly different. 
Only the one strain, A/NWS, was consistently more sensitive to Ribavirin. 
However, in both multiple cycle tests the differences between the two 
compounds were greater, on account of the lower sensitivity of the virus 
to amantadine hydrochloride under the conditions of the test. With 
both A/Sweden and A/Okuda much variation was observed, which paralleled 
the variations of amantadine hydrochloride in the different cell cultures. 
Thus in single cycle tests amantadine hydrochloride was less active than 
Ribavirin in AOS cultures, the two compounds had equivalent activity in 
chick cells, and amantadine hydrochloride was more active in calf kidney 
cells. With A/Hong Kong amantadine hydrochloride was significantly more 
active in all tests except with A.0S single cycle experiments. With' 
multiple cycle AOS tests there was no significant difference in the 
activity of the compounds against either A/Okuda or A/Hong Kong. This has 
arisen from the greater increase in activity of amantadine hydrochloride 
than of Ribavirin under multiple cycle conditions. With plaque reduction 
tests amantadine hydrochloride was more active than Ribavirin against 
all strains except A/NWS. However, although with A/Okuda there was 
nearly a 4-fold difference between results, this was not quite significant 
(X^ = 3.792, p = .05).
TABLE 3.10 RATIO OF ED50 VALUES FOR AMANTADINE HYDROCHLORIDE
AND RIBAVIRIN IN DIFFERENT CELL CULTURES
Cell culture
A/NtfS
Virus strain 
A/Sweden A/Okuda A/Hong Kong
AOS (single cycle) -36.2 -25.3 -11.1 -4.0
Chick embryo cells -5.6 -2.1 (NS) +2.0 (NS) +3.0
Calf kidney cells 
(single cycle) -11.2 +4.2 +39.1 +17.9
AOS (multiple cycle) -94.5 -5.7 -1.9 (NS) +1.9 (NS)
Calf kidney plaques -155.0 +4.3 +3.7 (NS) +2.8
Key: NS not significant at p = 0.05
3.2 IN VIVO SYSTEM
For Jjn vivo work 5 strains of virus were used, A/NWS, A/PR8,
A/Hong Kong, A/Sweden and A/Okuda. The first three of these had already 
been passed numerous times in the mouse lung when received, and in fact 
with the two former viruses no stocks were available which had not been 
adapted to mice. In order to make satisfactory comparisons of the 
sensitivity of the 5 strains to amantadine hydrochloride and Ribavirin 
the two unadapted strains, A/Sweden and A/Okuda, were also adapted to 
mice. In addition, to determine whether variations in passage history 
of virus stocks could affect the results, a number of different stocks 
of A/Okuda and A/Sweden were prepared. These were, with A/Okuda, 
unadapted virus stock (allantoic fluid, MO), mouse lung stocks passed 
20 (M2Q) and 30 (M30) times, and also an allantoic fluid preparation of 
the latter (i.e. M30E1) stock. With A/Sweden an unadapted allantoic 
stock (MO) and mouse lung stocks passed 20 (M2Q) and 30 (M30) times 
were used. Details of the passage history of the different stocks of 
virus were recorded in Table 3.11.
3.2.1 Comparison of mortality, haemagglutination and infectivity
titrations of virus stock
All virus stocks used with the in vivo system were titrated by 
three different methods: mortality (LD50) titrations in mice, infectrvity
titrations in the AOS system, and titrations of haemagglutination 
(Table 3.11). The differences between LD50 and infectivity titrations, 
and haemagglutination and infactivity titrations, were calculated, and 
from these calculations it was found that with adapted strains the 
LD50 titres were on average 1.7 log unit lower than the AOS ID50 titres, 
and it was concluded that approximately 50 AOS ID50 was equivalent to 1 LD5Q.
TABLE 3.11 COMPARISON OF MORTALITY,'HAEMAGGLUTINATION AND INFECTIVXTY 
TITRATIONS OF VIRUS STOCKS USED FOR IN VIVO WORK
Virus stocl Passage LD50 . .. Infectivity* Difference Difference'history titre titre titre A0SID50-LD50 ID50-HA
A/PR8/34
A/NWS/33
A/Sweden/
3/50
A/0kuda/57
A/Hong Kong/ 
1/68
>M30 105.8 512 io7-9 2.1 0.2
>M30 105*6 32 io7-° 1.4 0.5
MO 0 256 107*° 7.0 -0.4
M20 105,2 128 107-2 2.0 0.1
M30 106' 8 64 107-? o 4 Cl 0.5
MO ,0” *° 512 107*7 ■ ■ 4.7 0
M20 104-8 16 106"8 2.0 0.6
M30 105-4 32 lO7' 8 2.4 1.3
M30E1 1q5*2 128 107*3 2.1 0.2
M62 105-2 2
©o 1.8 1.7
Key:
/ 1 HA. unit' = 105 A0SID50
* infectivity titration in AOS cultures
Therefore since 1 AOS ID50 was equivalent to 10 EID50 (Section 3.1*1), 
approximately 500 infectious virus particles were necessary in the 
initial inoculum for death to occur. With the unadapted virus stocks 
A/Sweden produced no deaths, and A/Okuda caused the death of only a 
few mice at high virus inputs, which was considered to be due to some 
toxic property of the virus.
To calculate the difference between haemagglutination titre and
infectivity titre it was assumed that 1 haemagglutination unit was
. " ■ ' 5equivalent to 10 AOS ID50, since previous workers have shown 1 HA unit
■ - 6
to be equivalent to 10 EID50 (Fasekas and Cairns, 1952). The results 
of these calculations indicated that there was close agreement between 
the two methods for both unadapted stocks and for mouse lung stocks of 
A/PR8 and A/Sweden. However, with A/NWS and particularly with A/Okuda 
and A/Hong Kong, the haemagglutination titres were much lower, which 
indicated that although RD£ was used some inhibitors must have been present. 
For this reason it was considered that titrations by haemagglutination 
were not sufficiently reliable to be used extensively with this system.
From the results obtained with LD50 titrations the virus inocula 
to be used in later experiments were calculated. For all experiments
either a 10 or 100 LD50 virus dose was employed. Infectivity titrations
in the AOS system were used in later experiments to titrate the growth of 
the virus in the mouse lung.
3.2.2 Virus growth curves in the mouse lung
To determine the rate of growth of the different strains and of 
different stocks of the same strain, mice were infected with 10 or 100 ED50 
of virus, as described earlier (Section 2.4.2). At 8 hourly intervals 
up to 48 hours after infection, groups of 5 mice were killed and
lung suspensions were made in 2% bovine serum albumin and titrated in 
duplicate in the AOS system.
3.2.2.1 Comparison of growth of stocks of A/Okuda
With the unadapted stock the input inoculum used ’was calculated 
by comparing infectivity titres of this stock with the M30 adapted stock, 
so that an inoculum equivalent to 10 LD50 of virus was used. When 
compared with the M20 stock this was equivalent to a dose of 30 LD50.
From the growth curve obtained with the unadapted stock it was found 
that the virus reached a peak titre within 24 hours (Fig. 3o30). With 
the M20 stock in a dose of 10 LD50 growth did not reach a peak until 
48 hours, although with 100 LD50 a peak was reached within 24 hours.
The titres obtained \fith both unadapted and M20 stocks were similar,
and thus the adaptation of the M20 stock involved an increase in virulence
of the virus with no increase in growth rate.
With the M30 stock the virus was again at a maximum within 24 hours,
but the titres obtained were approximately 2 log units higher than with 
the other stocks. Thus further adaptation involved an increase in growth 
with little or no increase in virulence. With the M30E1 stock the titres 
obtained were lower than with the M30 mouse lung stock, so from these 
results the M3Q stock appeared the most suitable for comparing the
sensitivity of the different strains of virus to a compound.
3.2.2»2 Comparison of growth of stocks of A/Sweden
The growth curves for the M20 and M30 stocks v/ere obtained by 
using a 10 LD50 inoculum of virus (Fig. 3.3l). Although attempts were 
made to grox* the unadapted virus in mice only very loi* titres, on average 
1.5 log unit, we re obtained, and therefore this work was not pursued further.
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Fig. 3.30 Growth curves in the mouse lung for A/0kuda/57 virus
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Fig. 3.31 Growth curves in the mouse lung for A/Sv/eden/3/50 virus 
stocks: M20 ( O  ) and M30 ( @ )
The results obtained with A/Sweden stocks differed from those 
obtained with A/Okuda M20 and M30 stocks* The A/Sweden strain appeared 
well adapted to mice, since it grew to high titre at the M20 passage 
level. When passed 30 times the virus appeared to have increased in 
virulence and thus gave a very high LD50 titre, but with no apparent 
increase in growth. Thus at a 10 LD50 virus dose the M20 stock grew 
to higher titre than the M30 stock.
3.2.2.3 Comparison of growth of strains of the 5 mouse-adapted viruses 
Growth curves were determined urith a dose of 10 LD50 for the
remaining 3 strains, A/NWS, A/PR8 and A/Hong Kong, and with the M30 stocks 
of A/Sweden and A/Okuda. All strains grew to a peak within 24 hours and 
all reached similar titres. From these results the 5 strains appeared
similarly adapted to mice. (Fig. 3.32)
3.2.3 Dose-response effect of virus
-1 ~5
Virus stocks were diluted in a 10-fold range from 10 up to 10 
and 10 mice were inoculated per dilution. Five mice from each dilution 
step were killed 24 hours after infection, the lungs were harvested and 
the virus content was titrated in the AOS system. The remaining 5 mice 
from each dilution step were observed daily and deaths were recorded 
up to 15 days after infection. From the results the mean reciprocals 
of survival times were calculated. Reciprocals were used so that any 
mice surviving at the end of the experiment, i.e. a notional survival 
time of infinity, would have a reciprocal of survival time of 0, and 
thus could be included in the calculations to give a more accurate 
result. The results obtained were fitted to straight lines by the
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Fig. 3.32 Grouch curves in the mouse lung of the 5 mouse-adapted 
virus strains: A/PH8/34 ( □ ), A/NWS/33 ( B ),
A/Sweden/3/50 ( 0 ), A/0kuda/57 ( A ), A/Hong Kong/1/68 ( V
method of least squares using the equation :-
2xy - 2x 2y/n 
2x2 - ( Sx2)/n
b = slope 
x = log virus dose
y = response (mean reciprocal of survival or virus titre) 
n = number of animals
3.2.3.1 Dose-response effect for stocks of A/Okuda virus
-1
For the unadapted stocks deaths were recorded at the 10 and
*-210 dilutions (Fig. 3.33). However, when repeated there was 
found to be considerable variation in the number of deaths recorded.
Apart from the unadapted stocks, all the remaining stocks gave reproducible 
linear responses for mean reciprocal survival time against virus concentration. 
With both the M20 and M30 stocks survival times were very similar, and with 
the M30E1 stock survival times were only marginally longer. Again with 
infectivity titrations the M20 and M3Q stocks gave definite linear responses, 
but the two allantoic stocks MO and M30E1 gave extremely shallow dose- 
response lines with slopes of -0.64 and -0.54 respectively (Fig. 3.34).
3.2.3.2 Dose-response effect for stocks of A/Sweden virus
The dose-response lines for A/Sweden are shown in Figs. 3.35 
and 3.36. Again both stocks gave a linear response by both methods of 
evaluation. The 2 stocks gave very similar results, apart from the 
much shorter survival times recorded for the M30 stock.
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Fig. 3.33 Dose-response lines determined by mean, reciprocal of
survival time for A/0kuda/57 virus stocks, MO (1),
M20 (2), M30E1 (3) and M30 (4)
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Fig* 3*34 Dose-response lines determined by 24 hour titrations of
vix'us content of the lungs for A/Giuida/57 virus stocks,
M0 (1), M20 (2), M30E1 (3) and M30 (4)
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Fir. 3,35 Dose-response lines determined by mean reciprocal of
survival time for A/Sweden/3/50 virus stocks,
M20 (1) and M30 (2)
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Fig* 3.38 Dosc-rcsponsc lines determined by 24 hour titrations of
virus content of the lungs for A/Sweden/3/50 virus stocks* 
M20 (1) and M30 (2)
3.2.3.3 Dose-response effect of the stocks of the 5 mouse-adapted viruses
With survival time determinations (Fig. 3.37) the 4 strains 
A/NWS, A/PR8, A/Okuda and A/Hong Kong gave similar results, but with 
A/Sweden very much shorter survival times were recorded, indicating that 
this strain was much more virulent than the other 4 strains. The results 
with the infectivity titrations (Fig. 3.38) indicate that the 5 strains 
were all growing to similar titres in the mouse lung.
3.2.4 Detection of anti-influenza activity
In section 3.1.3 the results of tests carried out iri vitro with
60 compounds against A/Hong Kong were reported. From the results given
in Table 3.2 it may be seen that only two compounds tested had significant
activity in both the systems used. These two compounds were amantadine
hydrochloride and Ribavirin, which were considered sufficiently active
to be tested in animals. In addition the two compounds methisazone and
TRB were also tested in vivo because the former compound and a compound
(DRB) related to the latter have been reported to be active in mice 
\ f
(Smejkal et al., 1971; Tamm et al., 1954).
Tests were carried out by inoculating mice intranasally with 
10 LD50 of virus. Treatment was begun before infection to maximize the 
sensitivity of the test, with each compound given subcutaneously in 
0.1 ml volumes 4 hours before and 4 and 20 hours after infection.
Both methisazone and TRB were given at 100 mg/kg/dose, which is equivalent 
to double the dosage used in vitro, and amantadine hydrochloride and 
Ribavirin were given at 37.5 mg/kg/dose, which is the reported optimum 
dosage for Ribavirin (Khare et al., 1973). Untreated mice were used 
as controls. The mice were killed 24 hours after infection, lung extracts 
were made and titrations were carried out in the AOS system.
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Fig. 3.37 Dose-response lines determined by mean reciprocal of
survival time for the 5 mouse-adapted strains, A/PR8/34 (l), 
A/NV/S/33 (2), A/Sweden/3/50 (3)* A/0kuda/57 (4) and
A/Hong Kong/1/68 (5)
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Fig. 3.38 Dose-response lines determined by 24 hour titrations 
of virus content of the lungs for the 5 mouse-adapted 
strains, A/PK8/34 (l), A/N'wTS/33 (2), A/Sweueii/3/50 (o) ,
A/0kuda/57 (4) and A/IIong Kong/l/68 (5)
Comparisons of titres obtained in treated and untreated mice 
were made (Table 3.12). Both amantadine hydrochloride and Ribavirin 
reduced the virus titres reached in the mouse lung by approximately 
2.0 log units. Neither methisazone nor TRB caused any reduction in 
viru3 titre. With amantadine hydrochloride, methisazone and Ribavirin 
the results obtained agree with those obtained in vitro. With TRB 
it would appear that the activity observed jLn vitro was not sufficiently 
great for the compound to be active in vivo.
3.2.5 Spectrum of activity of amantadine hydrochloride and Ribavirin 
in relation to the passage history of the viruses
Antiviral tests to detect activity fn vivo against the 5 virus
strains and different stocks listed in Table 3.11 were carried out.
Mice were infected intranasally with 10 LD50 or equivalent (MO, A/Okuda 
stock) of virus. They were killed and the virus content of the lungs 
was titrated xtfhen the growth had just reached a maximum, as indicated 
by growth curve determinations (Figs. 3.30 - 3.32). Thus titrations 
were carried out at 48 hours after infection for the A/Okuda >120 stock 
and at 24 hours for all other stocks. In addition, with A/Okuda M30
stock tit rations were carried out at both 24 and 48 hours after infection
for comparison. All titrations were carried out in the AOS system.
Both compounds were given subcutaneously in 0.1 ml volumes in a daily 
dose of 75 rag/kg. Two treatment regimes were adopted. In the first
the compounds were administered at 4 hours before and 4 hours after 
infection and then twice daily until the end of the experiment. In the 
second, treatment ’was begun 4 hours after infection and continued twice 
daily. Thus mice were dosed a total of 2 - 3 times for tests completed 
in 24 hours and 4 - 5  times for tests completed in 48 hours.
TABLE 3.12 IN VIVO ACTIVITY OF COMPOUNDS TESTED AGAINST
INFLUENZA A/HONG K0NG/l/68(H3N2) *
Compound Dose r Titre X Reduction in titre
Control - 5.6
5.2
-
1-Methylisatin 3- 
thiosemicarbazone 
(methisazone)
100 6.0
5.1
4,5,6-Trichloro-l-p-D-
ribofuranosylbenzimidazole
(TRB)
100 5.2
5.8
-
Amantadine hydrochloride 37.5 3.6
3.4
+
Ribavirin 37.5 3.0
3.6
+
Key:
* mouse lung stock 
/ mg/kg/dose 
x titrated in AOS cultures
All the results obtained with the different virus stocks have 
been recorded in Tables 3.13 and 3.14 for amantadine hydrochloride and 
Ribavirin respectively. With all sensitive strains reductions in 
virus growth v/ere greater when the compounds were given before rather 
than after infection. When treatment was begun before infection all 
strains tested were sensitive to Ribavirin but only 3 out of 5 strains 
were sensitive to amantadine hydrochloride. Both A/NWS and A/PR8 were 
insensitive to amantadine hydrochloride. Thus the spectrum of activity 
obtained in vivo compared fairly well with that obtained in vitro.
Only the results obtained for amantadine hydrochloride against A/NWS 
did not agree. However, the sensitivity of this strain jun vitro to 
amantadine hydrochloride was much lower than for the other strains, 
and therefore does not appear to have been great enough for activity 
to have been manifest in vivo.
When the effect of mouse passage history on the results was 
examined the picture became slightly more complex. With all virus 
stocks passed 30 or more times in mice, no or only marginal activity 
was recorded for both compounds when given after infection. This 
applied to A/Okuda (M30 stocks) whether a mouse lung or allantoic stock 
was used. However, with A/Okuda and A/Sweden M20 stocks considerable 
activity was recorded whether the compounds were given before or after 
infection. Thus there appears to have been a reduction in sensitivity 
of strains with an increase in passage history in the mouse. Contrary 
to this, the imadapted A/Okuda stock appeared of similar sensitivity to 
the two compounds as the M30 stock and thus less sensitive than the 
M20 stock.
Finally the activity of the two compounds against A/Okuda M30 stock 
was compared after 24 and 48 hours. In Tables 3.13 and 3.14 it may be
TABLE 3.13 INHIBITORY ACTIVITY OF AMANTADINE HYDROCHLORIDE AGAINST
DIFFERENT STRAINS OF INFLUENZA A VIRUS IN MICE
Virus strain Sub-type
Passage No. 
in mice
Log reduction of control titre 
A B
A/NtfS/33 HON 1 >30 0 0.1
A/PR8/34 H0N1 >30 0.2 0
A/Sweden/3/50 H1N1 20 0.8 ' 2.4 '
30 0.2 1.1
A/Okuda/57 II2N2 0 o 1.0
20 1.2*
30 0.1 1.3
0* 0.6’
30(E1) ' ' 0 1.0
A/Hong Kong/1/68 H3N2 62 0.4 1.1
treatment commencing 4 hours after infection
treatment commencing 4 hours before infection
titrations carried out 48 hours after infection 
in AOS cultures
Key:
A = 
B =
TABLE 3.14 INHIBITORY ACTIVITY OF RIBAVIRIN AGAINST DIFFERENT
STRAINS OF INFLUENZA A VIRUS IN MICE
Virus strain Sub-type Passage No. in mice
Log reduction of control titre 
A B
A/NWS/33 HON 1 >30 0.2 1.2
A/PR8/34 H0N1 >30 0.6 1.3
A/Sweden/3/50 H1N1 20 1.9 2.7
30 0.6 1.6
A/0kuda/57 H2N2 ■ ■ 0 , 0.3 0.8
20 2.2* 2.9*
30 0.2 0.8
0* 0.4*
30(E1) 0.3 0.9
A/Hong Kong/1/68 H3N2 62 0 0.7
Key: ■ '
A = treatment commencing 4 hours after infection 
B = treatment commencing 4 hours before infection 
* . = titrations carried out 48 hours after infection
seen that when the compounds were given after infection there was no 
significant reduction in virus titre. When the compounds were given 
before infection both compounds caused a slightly greater reduction in 
virus titre at 24 than at 48 hours. From these results it appeared 
that 24 hours was the most suitable time for titrating the virus content 
of the lungs, and this was therefore adopted for further quantitative 
studies. In addition, because of the increased sensitivity of the 
test where treatment was begun before infection, this treatment regime 
was used in the majority of the quantitative studies.
3.2.6 Quantitation of the activity of amantadine hydrochloride and Ribavirin
Further studies to compare the sensitivity of the different strains 
to amantadine hydrochloride and Ribavirin were carried out by titrating 
the virus content of infected lungs (infectivity tests). For such tests 
the dosage of Ribavirin used never exceeded 75 mg/kg, at which level 
no overt signs of toxicity were observed. With amantadine hydrochloride 
the highest dose used was 150 rag/kg. However, at this level of compound, 
mice were observed to show serious respiratory distress shortly after 
dosing which proved fatal in one case. Therefore in further tests 
75 mg/kg was the maximum dosage used, at which level all mice appeared 
healthy.
Tests with A/Sweden M30 stock and A/Hong Kong M62 stock were 
repeated on 3 separate occasions, to determine the reproducibility of 
the method. However, before beginning this work a comparison was made 
of results obtained with infectivity tests and the more widely used 
mortality tests.
3.2.6.1 Comparison of infectivity and mortality tests for quantitating
activity
The M20 and M30 stocks of A/Okuda were used for this work. For 
mortality determinations, experiments were carried out to find the most 
suitable length of time to continue dosing mice to obtain a maximum effect 
without using unnecessarily large quantities of compounds. The strains 
adapted to mice had been found to reach peak titres \tfithin 48 hours, 
although the mice took several days after this to die. Two dosage regimes 
were therefore adopted, one involving 3 days treatment, and thus covering 
the period of peak virus growth, and the second involving treatment for 
5 days. :
To compare these two dosage regimes mice were infected intranasally 
with a 10 LD50 dose of the M20 virus stock, and split up into 5 groups of 
10 mice each. One group was left untreated as controls, and the remaining 
groups were treated subcutaneously with either amantadine hydrochloride or 
Ribavirin in a dose of 37.5 rag/kg for either 3 or 5 days. Treatment was
begun 4 hours after infection and continued twice daily for the duration
of the dosing regime. Thus mice treated for 3 days received a total of 
5 doses, and for 5 days, 9 doses. Mice were observed daily and deaths 
were recorded to the nearest half day. Cumulative mortalities were 
plotted in Figs. 3.41 and 3.40 for amantadine hydrochloride and Ribavirin 
respectively. With both compounds a greater beneficial effect was observed 
when treatment was continued for 5 days. From these results the 5 day 
treatment regime was selected for further mortality studies.
For quantitation of activity mice were divided up into groups of 
10 for mortality tests and groups of 5 for infectivity tests. With the 
M20 stock mice were infected with either 10 or 100 JLD50 of virus, and
treatment was begun 4 hours after infection. With the M30 stock mice
were infected with 10 LD50 of virus and treatment was begun 4 hours before
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infection* All groups of mice except controls were injected twice daily 
as described earlier. Individual groups of mice were treated with either 
amantadine hydrochloride, in doubling dosages within the range 4*56 mg/kg 
up to 150 mg/kg, or with Ribavirin within the range 4*56 mg/kg up to 
75 mg/kg. For mortality tests mice were observed daily and survival 
times were recorded over an observation period of 15 days. For infectivity 
tests all mice were killed after 24 or 48 hours and the virus content ox 
the lungsHras titrated as described earlier.
In the mortality tests the survival time, of each individual mouse 
was recorded (Tables 3.15 - 3.17). The values obtained were converted to 
reciprocals and the mean reciprocal of each treatment group plotted against 
dose level gave the dose-response lines shown in Figs. 3.41 and 3.43.
In the infectivity tests the log reductions in virus titres were 
plotted against dose level (Figs. 3.42 and 3.44). Infectivity results 
for the M20 stock at 10 LD50 input of virus will be presented later.
Variable results were obtained with survival time determinations 
for the M20 stock at 10 LD50 input of virus (Table 3.15). With both 
compounds no dose-response relationship was recorded and thus these results 
were not represented graphically. The lack of a dose-related response 
was considered to have occurred because with both compounds some survivors 
were present, so that the results obtained would depend more on individual 
variations between mice than when all mice were dying. Possibly if 
greater numbers of mice had been used this variation would have been 
overcome. Instead, tests were carried out using a higher virus dose 
(100 LD50). At this level of infection all mice died even with treatment, 
and dose-related effects were obtained with both compounds (Fig. 3.41).
The results of infectivity titrations at the same level of infection also 
gave linear responses for both compounds (Fig. 3.42). When these results
TABLE 3.15 SURVIVAL TIMES OF MICE TREATED WITH AMANTADINE HYDROCHLORIDE
AND RIBAVIRIN COMPARED WITH UNTREATED CONTROLS FOR
A/OKUDA M20 (10 LB50) STOCK
/• Compound dose Survival tisne* Mean reciprocal survival time
Amantadine hydrochloride
9.375 7, 7, 7, 8, 8, 8, 8, 8, 9, S 0.1164
18.75 5, 7, 7, 7, 9,-10, S, S, S, S 0.0821
37.5 7, 7, 8, 8, 9, 9, 10, 11, 14 0.1020
Ribavirin
9.375 7, 8, s, s, S, S, S, S, S, S' 0.0267
18.75 6, 7, 8» 9, S, S, S, S, S, S 0.0545
37.5 3, s, s, s, S, S, S, S, S, S 0 ■
Control 6* 7, 7 * 7, 7, 7, 7, 8, 9, 9 0.1371
Key;
/ mg/kg 
* days 
S survivor
TABLE 3.16 SURVIVAL TIMES OF MICE TREATED WITH AMANTADINE HYDROCHLORIDE
AND RIBAVIRIN COMPARED WITH UNTREATED CONTROLS FOR
A/OKUDA M20 (100 LD50) STOCK
• /Compound dose Survival time❖ Mean reciprocal survival time
Amantadine hydrochloride
18.75 6, 3, 6V 6, 6, 6, 6, 6»' 7, 8 0.1601
37.5 6, 6, 3, 6, 6, 7, 7, 7, 7, 7 0.1548
75.0 7, .7 > 7, 7, 7, 7/7, 7, 8, 8 0.1393
Ribavirin
4.68 6, 3, ■6, 6, •7, 7, 7, 7, 8* 9 0.1507
9.375 '5, 5,' 7, 7, 7 , 7, 7, 7 v ■8, 8 0.1474
18.75 7, 7, 7, 7, 7, 7, 8, 8, 8, S 0.1232
Control 3, 6, 6, ■7, 7, 7, 7, 7» 7/ 8 0.1649
Key:
/ mg/kg 
♦ days 
S survivor
TABLE 3.17 SURVIVAL TIMES OF MICE TREATED WITH AMANTADINE HYDROCHLORIDE
AND RIBAVIRIN COMPARED WITH UNTREATED CONTROLS FOR
A/OSUDA M30 STOCK
Compound dose^ Survival time* Mean reciprocal 
survival time
Amantadine hydrochloride
4.68 8, 8, 8, 8, 9, 9, 9, 15 0.1124
9.375 '8, 8.5, 8.5, 9, 9, 9, 9, 9, 10, 11 0.1106
18.75 8, 8, 9, 9, 9, 10, S, S, S, S 0.0683
37.5 9, 9, 9, 9, 11, 13, S, S 0.0765
Ribavirin
18.75 8, 8, 9, 9, 9, 10, 11, 13, 13, 13 0.1004
37.5 11 , 12, S, S, S, S, S, S, S, S 0.0174
75.0 s. S, S, S, S, S, S, S, S, S o '
Control 6, 6,7, 7, 7, 7, 7, 8.5, 10, 10 0.1365
Ke£:
/ rag/kg 
* days 
S survivors
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were compared there appeared to be good agreement between the two methods.
Thus under the conditions of this test Ribavirin was considerably more 
active than amantadine hydrochloride.
The results obtained in mortality tests with the M30 stock (Fig. 3.43) 
showed none of the variation observed with the M20 stock (10 LD50), although 
some survivors were recorded. Thus further tests with a virus dose of 
100 LD50 were not considered necessary. Comparison of the results 
obtained by mortality and infectivity tests showed good agreement, with 
a straight dose-response line for Ribavirin and a dose-response curve 
for amantadine hydrochloride which tailed off at higher concentrations.
From these results it was impossible to say which compound was more 
active overall, since at lower concentrations amantadine hydrochloride 
was more active, but at higher concentrations Ribavirin had the greater 
activity.
Further calculations were carried out to obtain a more quantitative 
comparison of the results obtained by both methods. However ED50 values 
were not determined because comparison on the basis of ED50 values would 
be meaningless for results such as those obtained for the M30 virus stock, 
on account of the differences in the slopes of the curves, and also 
xdien some ED50 values were determined using the two equations of Fig. 3.28 
there was found to be poor agreement between observed and expected results* 
With the M20 virus stock the lines obtained by the method of least squares 
were linear and virtually parallel for the two compounds. The results 
were therefore combined to give a mean slope from which parallel dose-response 
lines were constructed (Figs. 3.45 and 3.46). The horizontal distance 
between the lines was then calculated to give the relative potency of 
the compounds using the equation
J. I
where xs
mean dose of standard compound
xI mean dose of test compound
y, mean response of standard compound
mean response of test compound
b mean slope of the regression lines
Taking amantadine hydrochloride as the standard compound,
Ribavirin was 0,83 log unit (6.8-fold) and 0.57 log unit (3.7-fold) 
more active than amantadine hydrochloride in the mortality and 
infectivity tests respectively. Thus both methods gave comparable 
results.
With the M30 virus stock a comparison of results obtained by the 
two methods was made by converting all results to a notional reduction in 
virus input by reading results off from the virus dose-response lines 
obtained for the M30 stock (Figs. 3.33 and 3.34). The reductions in 
virus input for both methods have been tabulated (Table 3.18)» With 
amantadine hydrochloride the results for all dosage levels agreed very 
closely, with a maximum variation between methods of only 0.4 log unit. 
With Ribavirin the results at 18.75 mg/kg were similar for both methods; 
at 37.5 mg/kg and 75 mg/kg the reductions in titre recorded with 
infectivity titrations were considerably lower than those recorded by 
mortality titrations. This appeared to have arisen because of the 
presence of survivors with these latter two dose levels. However, 
the results agreed better than appeared from Table 3.18, since the 
reduction in virus input recorded for infectivity titrations was high 
enough to indicate that survivors would be present.
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TABLE 3.18 COMPARISON OF INFECTIVITY AND MORTALITY TESTS 
FOR A/OKUDA M30 STOCK, AFTER CONVERSION TO 
REDUCTION IN INPUT OF VIRUS
Compound Compound dose (mg/kg)
Reduction in
Infectivity
titration*
input of virus
Mortality
titration
4.6 0.3 0.6
9.37 1.0 0.6
Amantadine hydrochloride
18.75 1.3 1.7
37.5 1.4 1.5
18.75 0.4 0.9
Ribavirin 37.5 1.9 3.0
75.0 2.3 >5.0
Key:
in AOS cultures
3.2.6.2 Reproducibility of infectivity tests
As stated earlier, because of the nature of the dose-response 
lines obtained in vivo it was of no value to determine the ED50, and 
it was therefore not possible to establish whether the differences 
between results were significant. To try to obtain an estimate of 
the variability of the method, the dose-response lines determined on 
three separate occasions for A/Sweden M30 stock and A/Hong Kong M62 stock 
were plotted individually (Figs. 3.47 - 3.50). V/ith Ribavirin the 
reproducibility for both strains of virus was good, since nowhere was 
there greater than a 2-fold variation in results. With amantadine 
hydrochloride greater variability was noted, particularly with A/Hong Kong. 
With both strains of virus there xms good agreement between results of 
two experiments, but not so good for the third*
3.2.6.3 Dose-response effect of amantadine hydrochloride and Ribavirin
against different stocks of A/Okuda
Tests were carried out as described earlier with the 4 different 
stocks of virus (M20 and M30 mouse lung stocks; MO and M30E1 allantoic 
stocks). For all tests a virus dose of 10 LD50 was used. With the 
M20 stock tests were carried out with treatment begun before and after 
infection, and all mice were killed after 48 hours. With the remaining 
stocks treatment was begun before infection and the mice were killed 
after 24 hours. All samples were titrated in AOS cultures.
The results obtained for all 4 stocks with treatment commencing 
before infection were first compared for each compound (Figs. 3.51, 3.52).
It may be seen that there were quite definite differences in sensitivity 
of the different stocks which followed a similar pattern for both compounds. 
With Ribavirin the M20 stock was considerably more sensitive, with a
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sensitivity at least 4 times greater than those of the MO and M30 stocks.
For the M20 and M30 mouse lung stocks fairly steep dose-response lines 
were obtained. However* with the two allantoic stocks (MO and M30E1) 
the dose-response lines were very shallow. With amantadine hydrochloride 
the lines obtained with all stocks showed a definite tailing off in activity 
with the M30 stock the plateau effect extended from 18.75 mg/kg up to 
150 mg/kg, where the compound showed some toxic effects on the mice.
The MO and M30E1 stocks appeared the least sensitive, with the M20 stock 
marginally more sensitive than the M30 stock. With both compounds, 
there appeared to be no difference in the sensitivity of the MO and 
M30E1 stocks. Again, results for both compounds showed an increase in 
sensitivity of the virus with passage in the mouse lung, which with further 
passage and increased growth reverted back to that observed before 
adaptation.
Secondly, a comparison of the relative sensitivity of the different 
stocks to the ti^ o compounds \ia.s made. In Fig. 3.53 results have been 
plotted for the M20 stock with treatment begun either before or after 
infection for both compounds. In both cases the virus appeared more 
sensitive to treatment begun before infection. However, with amantadine 
hydrochloride the difference was much greater for the two treatment 
regimes than with Ribavirin. With amantadine hydrochloride there was 
approximately a 4-fold difference bet\*een results, but with Ribavirin 
the difference was less than 2-fold, and therefore within the variability 
of the method. When the compounds were compared, as stated earlier 
if treatment was begun after infection Ribavirin was considerably more 
active than amantadine hydrochloride. With tests where treatment was 
begun before infection the compounds were very similar in sensitivity; 
only at higher concentrations where the activity of amantadine hydrochloride
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began to tail off was Ribavirin possibly more active. Similarly, 
with the MO and M30E1 virus stocks (Figs. 3.54 and 3.55) there was no 
difference in the activity of the compounds when treatment was begun 
before infection. With the M30 stock (Fig. 3.44), as stated earlier, 
the nature of the dose-response lines made comparison difficult; 
however, the range of activity was again similar for the two compounds.
3.2.6.4 Dose-response effect of amantadine hydrochloride and Ribavirin
against different stocks of A/Sweden
With the two A/Sweden stocks tests were carried out as 
described for A/Okuda. With the M20 stock treatment was begun either 
before or after infection, and with the M30 stock tests were carried out 
with treatment begun before infection only. A dose of 10 LD50 was 
used in all tests, and the mice were killed after 24 hours. With both 
compounds doubling dosage levels were used which ranged from 9.375 m g / k g  
up to 75 mg/kg. The results obtained with A/Sweden wereplotted (Fig. 3. 
and there appeared to be no difference in sensitivity of the virus to the 
two compounds under the different conditions of the three tests. Also, 
with the two different stocks there appeared to be no difference in 
results obtained with treatment begun before infection. In tests where 
treatment was begun after infection with the M20 stock both compounds 
appeared marginally less active.
3.2.6.5 Dose-response effect of amantadine hydrochloride and Ribavirin
against the stocks of the 5 mouse-adapted viruses
The methods used were identical to those described earlier.
The compounds were administered in doses ranging from 4.56 rag/kg up to 
75 mg/kg in individual groups.
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Vfith amantadine hydrochloride dose-response lines were obtained 
for the 3 sensitive strains (Fig. 3.57). The lines obtained for all 
3 strains were curved, with a tail off in activity for all strains 
above 75 rag/kg. With A/Okuda the tail off in activity was particularly 
pronounced. A/Hong Kong appeared to be the most sensitive; however, 
the variability of the method recorded (Fig. 3.49) and the nature of the 
lines made it difficult to compare results.
Vfith Ribavirin (Fig. 3.58) fairly straight dose-response lines 
were obtained for all 5 strains of virus. As with the in vitro methods, 
there appeared to be no difference in the sensitivity of the 5 strains, 
with variability within that recorded for A/Hong Kong and A/Sweden.
The results obtained with amantadine hydrochloride and Ribavirin 
were compared (Fig. 3.59). For simplicity the results obtained for 
Ribavirin against the 5 strains of virus were pooled to give one line. 
Results obtained with A/Okuda and A/Sweden have already been discussed. 
With A/Hong Kong amantadine hydrochloride was more active than Ribavirin 
with an approximate 2-fold difference over most of the dose-response 
lines.
Lo
g1
0re
du
ct
io
n 
vir
us 
tit
re 
Lo
g1
Qr
ed
uc
ti
on
 
vir
us 
tit
re
1 'J 3
2*0
3*0
3753 18-7
Dose(mg\kg)
4*6
2-0
X X.
18 79*3 37*5 754-6
Dose(mg\kg)
Figs. 3.57 and 3.58
Dose-response lines for amantadine hydrochloride ( - - - - )
and Ribavirin (-----) agaInst the different mouse-adapted stocks
Key: A/NWS/33 ( .h .) , A/Sweden/3/50 ( © ),
A/Okuda/57 ( ^ ) and A/Hong Kong/l/68 ( T  )
Lo
g1
Qr
ed
uc
ti
on
 
vir
us 
ti
tr
e
IJM
30
1504-6 3 187
Dose(mg\kg)
3752-3
Fig. 3.59 Dose-response lines for amantadine hydrochloride ( - - - - )
and Ribavirin (-----) against the mouse-adapted virus stocks
(results for all 5 adapted strains pooled with Ribavirin)
Key: A/Sweden/3/50 ( © ), A/0kuda/57 ( A ) and 
A/Hong Kong/1/68 ( V )
DISCUSSION
4,1 IN VITRO SYSTEMS
4*1.1 Reasons for adopting the chosen methods
When this study was undertaken the'aim was to try to establish 
suitable methods for detecting and quantitating anti-influenza activity, 
which could be used to evaluate the activity of different anti-influenza 
compounds. In the introduction an indication was given of the number 
of cell lines, both primary and continuous, and the variety of. methods 
involving hen’s eggs, which have been used for such work.
The number and diversity of the methods which have been used were 
such that not all systems could be examined, and therefore attempts were 
made to select the most promising. On this basis continuous cell lines 
were examined first, because the homogeneity of the cells should result 
in a high degree of reproducibility, which is of particular importance 
when comparing the activity of different compounds quantitatively.
In addition, continuous cell lines have an advantage over primary cell 
lines and egg systems in the relatively short time required for their 
preparation. Two lines were chosen for this work, baby hamster kidney 
cells (BHK) and Madin Darby canine kidney cells (MDCK), but neither 
proved altogether satisfactory because some of the strains of virus 
would not grow in them. Primary cell cultures were therefore used, 
despite the fact that the cell population in these was heterogeneous 
and thus possibly not all the cell types were equally sensitive to virus. 
Furthermore, the preparation of such cultures is relatively time- 
consuming.
The selected cultures were respectively primary chick embryo cells 
and primary calf kidney cells. The former were selected because they
have been extensively used in influenza research, and the latter because 
they have been reported to be suitable for plaque assay of a wide range 
of strains of influenza virus.
In addition AOS cultures were also selected after recommendations 
made by Dr. D. McCahon, because these cultures had the advantage that, 
all the egg-adapted influenza strains should grow well in them, as well as 
providing a relatively simple method of titrating virus infectivity.
Finally, for some tests chick tracheal organ cultures were used 
because such cultures might be expected to respond to virus in a manner 
similar to the intact animal. Furthermore with such cultures the 
concentration of compound and duration of contact can be controlled 
better than in animals, although many of the physiological functions 
which may influence drug activity would presumably be absent.
Besides selecting the most suitable culture system for this 
research, it was also necessary to find the most suitable methods for 
assay of virus growth and thus activity. The plaque assay provides 
the most direct assay on the assumption that each plaque reflects the 
activity of one infectious virus particle, whereas the quantal method 
for determining 50% endpoints is indirect and is based on a statistical 
estimate of infectious units. However, plaque formation by some strains 
of influenza virus has proved unreliable, and in this study great 
difficulties were experienced in trying to obtain plaques in the selected 
cell lines. Thus alternative methods for titrating virus were sought*
The most extensively used was haemagglutination titration, which was 
simple and rapid to set up, and easy to read. In addition, for some 
in vitro work and all the in vivo work, the quantal or 50% endpoint method 
was employed for titrating infectivity. In this study hen’s eggs were 
found to be the most sensitive method of titrating infectivity, but
were not much used because they were rather cumbersome, and the AOS system 
was used preferentially. This system, although not as sensitive as the 
whole hen’s egg, was more economical and less dependent on individual 
variation between eggs, since pieces from several eggs could be 
randomised and included in any one titration.
For detection and quantitation of antiviral activity plaque 
inhibition and plaque reduction tests were considered among the most 
suitable methods. In addition, it was considered important for 
quantitation of activity to carry out tests under single cycle conditions 
and to determine the reduction in virus yield under these conditions*
With such tests conditions are less complex than with multiple cycle 
tests, and thus the results should be more meaningful and more suitable 
for comparative work. However, there were disadvantages with these 
tests, which depend for their success on a high input, because under 
such conditions influenza virus can produce large quantities of incomplete 
virus. This was found, to occur in many tests carried out in this study, 
and made the validity of such tests questionable. Many studies have been 
made of the nature and structure of incomplete virus, and under the 
electron microscope such virus particles were found to be more flattened 
and pleomorphic than complete virus (Paucker et al., 1959). In a later 
study Duesburg (1968) revealed that the main difference between complete 
and incomplete virus was that viral RNA of relatively high molecular 
weight was either missing or present in reduced amounts in the particles, 
ivhile the amount of low molecular weight RNA was increased. Kilbourne 
(1975) suggested that this effect may have arisen from high molecular 
weight RNA being unstable and breaking down into low molecular Weight 
components in incomplete virus and hence nonfunctional.
From these findings it would appear that all components of the 
influenza virus are formed even when incomplete virus is present, and 
thus it could be concluded that replication of incomplete virus ifould be 
vulnerable to antiviral compounds. On the basis of these conclusions 
it was considered that results of single cycle tests would be meaningful. 
However, because of the presence of incomplete virus it was thought 
desirable to compare the results of haemagglutination and infectivity 
titrations. It was found that both methods of titration gave comparable 
results whether incomplete virus was present or not (Figs. 3.7 and 3.8), 
which justified the use of haemagglutination titration alone.
Single cycle tests \«rere used not only to compare the activity 
of different compounds, but also to compare the sensitivity of different 
strains to one compound. Since any variation in growth rate of the 
different strains could affect the sensitivity of a strain to a compound 
great care was taken to obtain growth curves for at least one strain from 
each virus sub-type. All strains were found to grow at a similar rate 
and thus this situation was ideal for comparative work.
In addition it was considered important to compare the activity 
of the two compounds in more than one system under similar conditions. 
Single cycle tests seemed most suitable for this work, and again it was 
necessary to establish whether any variations in growth in the different 
cultures could affect results. Growth curves in AOS cultures and 
chick embryo cells were identical, but in calf kidney cells growth was 
sloi^ er and it was therefore necessary to consider this when interpreting 
results.
Considerable care was also taken to titrate the virus stocks in 
all the different cultures used, because variations in infectivity titres 
have been observed in different culture systems (Lehmann-Grube, 1963).
By using the infectivity results obtained for each different system, 
single cycle conditions should have been obtained with all cultures.
The lower infectivity titres generally obtained with the culture systems 
used, compared with in ovo titrations, indicated that in many instances 
large amounts of virus particles were present which were apparently 
incapable of causing infection* What effect these virus particles 
could have had on the activity of the compounds tested is not known. 
Probably the inability of the virus to infect cells was associated with 
the receptor sites on the cells being unsuitable for virus adsorption.
Thus, when cells were washed after allowing 1 hour for adsorption this 
excess virus should have been removed and would probably not have 
interfered with the action of the compounds.
Finally, multiple cycle tests were also carried out in AOS cultures. 
These tests were considered necessary because of the problems associated 
xtfith single cycle conditions, particularly the production of incomplete 
virus. With multiple cycle tests incomplete virus should not have been
formed. However, because of the lower infectivity titres obtained in
AOS cultures, again a proportion of virus particles 'were present which 
ykere incapable of infecting these cells. One further reason for including
such tests'was the frequency with which they have been used to detect
anti-influenza activity in the past. Thus, it was considered of interest 
to compare the results with single cycle tests and with plaque reduction 
tests.
For all this work a number of strains of influenza A virus were
used. To obtain a comprehensive picture of the sensitivity of the
influenza viruses to the two compounds examined, 2 strains from each 
of the 4 sub-types were employed.
4.1.2 Assessment of methods used
An outline has been given above of the reasons why the different 
methods used were adopted. When these methods were used to detect and 
quantitate antiviral activity the merits and shortcomings of each method 
became apparent. For detection of activity two methods were used 
fairly extensively. These were AOS single cycle tests and plaque inhibition 
tests in calf kidney cells. The AOS system proved to be a good alternative 
method to plaque inhibition in that it was a reliable system which was 
fairly easy to set up, so that several replicates could be used for each 
test compound which maximised the accuracy of the results. Similar 
numbers of tests in tubes of either chick embryo cells or calf kidney cells 
would have proved extremely cumbersome. However, the AOS system did have 
some disadvantages. One of these was the necessity for toxicity tests 
to be carried out independently of the antiviral tests, although the 
amount of work involved was reduced by only carrying out such tests on 
apparently active compounds. Another problem with this method was that 
only compounds which caused at least a 50% inhibition of growth could be 
detected, and thus compounds i/ith slight activity could have been missed. 
Other problems already mentioned which could have affected results were 
the presence of large amounts of unadsorbed virus and the production of 
incomplete virus.
The plaque inhibition technique was very suitable for detecting 
activity in that both activity and toxicity can be observed in the same 
test. However, in this particular screen some problems arose because 
of the difficulty in distinguishing between activity and toxicity. This 
was overcome by staining cells with methyl violet, which obliterated plaques 
but revealed areas of thin cells due to toxicity. One inherent jjroblem 
of the plaque inhibition test is that all compounds must diffuse from the
disc through the agarose to the cells, and thus the rate of diffusion of 
the compound could affect the assessment of activity* This means that 
the method does not given an accurate measure of the activity of a compound, 
and it is possible that a compound of low solubility may appear inactive*
With AOS cultures these problems do not arise, and the results obtained 
are indicative of the degree of activity of a compound*
Chick tracheal cultures were found to be unsuitable for large scale 
screening of compounds, since considerable time was required in setting up 
and reading results. Similarly, because no virus dose-related effect was 
observed, these cultures were also unsuitable for quantitative work*
However, it was of value to determine if active compounds could inhibit 
viral effects in these cultures, and to check that the compounds themselves 
did not affect ciliary activity.
Of the three cell cultures used to quantitate antiviral activity 
AOS cultures were the simplest and least time consuming to prepare. However, 
AOS cultures had the disadvantage that it was only possible to estimate the 
number of cells present, and not to count them directly as with chick embryo 
and calf kidney cells, and thus some accuracy in determining multiplicity 
of infection must have been lost. Some of the problems associated with 
single cycle tests have already been mentioned; when the tests were used 
more widely, further problems became apparent. One important disadvantage 
with haemagglutination titration was the low sensitivity of the method 
which resulted from using a 2-fold dilution range for the virus. Thus, 
where high titres of virus were present (e.g. titres from 256 - 1024) the 
variability on an arithmetic scale was very high, which made statistical 
analysis difficult. Greater sensitivity and accuracy could have been 
attained if a lower dilution factor had been used, such as a 1.25 range, 
but this \*ould have involved considerably more 'work. Y/ith multiple cycle
tests titres were often too low for haemagglutination titrations, 
which need at least 10 logs of virus, to be used, and thus much time 
was required for infectivity titrations. One other disadvantage of 
multiple cycle tests was that sometimes the virus failed to grow up, 
presumably because very low quantities of virus were used to infect the 
cultures. This could have arisen either because of a slight drop in 
titre of the virus, or possibly because of a slight variation in 
susceptibility of different batches of eggs used.
Plaque reduction tests were also not without problems. On some 
occasions no plaques were obtained and thus the tests had to be repeated. 
There was also some variation in the time the plaques took to develop, 
and thus although attempts were made to obtain plaques of approximately 
2 ram diameter, they were sometimes larger or smaller. Y/ith Ribavirin 
the order of sensitivity of the 4 strains, although close, agrees with 
the variation in plaque size observed, thus A/NWS and A/Sweden produced 
the largest plaques and were the least sensitive. It therefore appears 
that although allowance was made for the variation in plaque size, it 
may have had a slight effect on the results obtained.
Finally, as indicated in section 3, with all quantitative tests 
carried out a measure of the reproducibility of each system was obtained 
by repeating tests with 2 strains of virus on 3 separate occasions.
From these results an overall replicate error was obtained which was 
used to estimate the significance of results. By the same method it 
was possible to obtain replicate errors or a measure of reproducibility 
for each different cell culture system used (Table 4.1). However, the 
replicate errors were obtained from only 12 experiments for each system 
and thus can only give an indication of the reproducibility of the tests. 
Three methods, AOS single cycle tests, calf kidney single cycle tests and
TABLE 4.1 REPLICATE ERRORS (Ve) OBTAINED FOR DIFFERENT TEST SYSTEMS
Cell culture Test Ve value
AOS
Chick embryo 
Calf kidney
Single cycle 
Multiple cycle 
Single cycle 
Single cycle 
Plaque reduction
0.0198
0.0778
0.0589
0.0226
0.0196
plaque reduction tests, gave very reproducible results with just under a 
2-fold variation in log BD50 values. The results with chick embryo 
single cycle tests appeared more variable. However, one very low result 
was obtained with amantadine hydrochloride against A/Sweden, and when 
■this result was removed from calculations the variation liras comparable to 
that of the above-mentioned systems. Only the AOS multiple cycle tests 
gave a high degree of variability, which presumably arose because the 
number of cycles of replication magnified the variations obtained with 
single cycle tests. These results therefore indicated that multiple 
cycle tests, other than plaque reduction tests, are not really suitable 
for accurate quantitation of activity.
4.1.3 Consideration of results obtained
With antiviral screening tests it was found that not all of the 
7 compounds previously reported to be active were active in the two test 
methods used in this study. Various reasons may be put forward for the 
differences in results. With the isoquinoline compound UK 2054 no activity 
was observed in the AOS system, and only slight activity in the plaque test. 
The lack of activity of this compound in the AOS system probably arose from 
the design of the experiment. The compound UK 2054 has been reported to 
cause direct inactivation of influenza virus, and therefore a period of 
time in contact with the virus before infection of the cells would be 
necessary for an effect to be detected. In the AOS system the compound 
was added at the time of infection and thus there was, presumably, 
insufficient time for the compound to act. The fact that the AOS system 
used would not detect compounds causing direct inactivation of the virus 
was not a serious drawback since, as stated in the introduction, an agent 
acting directly on the virus is unlikely to be a feasible proposition for
the treatment of viral disease. Both bathocuproin sulphate and 
methisazone were inactive in both systems. The former compound had not 
previously been tested for inhibition of growth of any strain of influenza 
virus, but was reported to inhibit influenza virus RNA polymerase (Oxford 
and Perrin, 1974). This result showed that compounds active against 
RNA polymerase will not necessarily be active in intact cells, and therefore 
such enzyme assays are not really suitable for initial screening for 
potentially active compounds. Methisazone had previously been reported 
active against strains of influenza A both in vitro (Bauer et al., 1970) 
and in vivo (Smejkal et al., 1971). The reason for the failure to 
corroborate these results is not known, but in previous tests in vitro 
a different strain of virus was used. None of the Y/ellcome compounds 
proved to be very active, and thus quantitative comparisons of activity 
were carried out with amantadine hydrochloride and Ribavirin alone.
From the quantitative studies carried out a number of interesting 
points arose. Firstly, comparisons were made of the sensitivity of 
different strains to the two compounds, because the frequent antigenic 
changes of the virus make it important that.a compound should be active 
against a wide range of strains of virus. Y/ith amantadine hydrochloride 
strains have been compared by earlier researchers, so that this study was 
merely an extension of previous work, with comparisons made in a greater 
number of cell cultures, and with different methods of quantitating activity. 
With Ribavirin few comparative studies have been carried out, and with 
only a few strains, and thus this work was of value in recording the 
relative sensitivity of a number of strains of virus from the 4 different 
sub-types.
The results obtained in this study with amantadine hydrochloride 
showed considerable variation in sensitivity of the different strains.
Throughout the study A/NWS (HONl) proved the least sensitive of the 
4 strains tested; A/Sweden (HINl) was generally less sensitive, depending 
on the cell culture used, than A/Okuda (H2N2), which again was generally 
less sensitive than A/Hong Kong (H3N2). Y/hen further strains were tested 
in the AOS system a similar relationship in the sensitivity between 
sub-types was observed, except for A/Singapore (H2N2). This strain 
was considerably more sensitive than either A/Okuda, A/Hong Kong or 
A/England.
These findings agreed fairly well with those of previous reports 
where comparisons have been made. Schild and Sutton (1965), using 
chick embryo cells, reported A/PR8/34 (HONl) to be insensitive,
AA t^ S/33 (HONl) and A/FMl/47 (HINl) of similar sensitivity, and a number 
of strains of the H2N2 sub-type to be most sensitive to amantadine 
hydrochloride. However, a considerable variation in sensitivity of 
the II2N2 strains was recorded. A similar variation in sensitivity of 
H2N2 strains was noted by Neumayer et al. (1965). In the latter work 
dose-response lines were plotted for two HONl strains and two H2N2 strains. 
However, comparisons were not easy to make because results were plotted 
as the negative log of the haemagglutination titre, which did not allow 
for any difference in growth rate of the different strains. In these 
tests A/Japan/305/57 (H2N2) was considerably more sensitive than the 
A/Ann Arbor/2/60 (H2N2) strain, which was similar in sensitivity to 
A/PR8/34 (HONl) and A/WSN/33 (HONl). These latter two strains appeared 
fairly sensitive, with activity down to 1 pM. These results do not 
agree with the findings of this thesis or with the results of Schild 
and Sutton (1965), and since the tests appear to have been carried out 
in chick embryo cells these differences are impossible to explain.
In a more recent paper the sensitivity of A/Mill Hill/l/72 (H3N2), 
a strain closely related to the A/England strain used in this study, was 
found to be similar to that of A/Hong Kong, and the result thus agrees 
ifith the observations made here.
With Ribavirin, in every cell culture used there was no difference 
in sensitivity of the 4 strains tested. With calf kidney cells some 
variation was noted in single cycle tests with A/NWS, but in plaque 
tests all strains were similar in sensitivity. Results of tests in 
AOS cultures for 8 strains of virus showed again that all strains were 
similar in sensitivity. Whether this would apply to all influenza A 
strains is not known, but the fact that 8 strains from the 4 different 
sub-types were so similar in sensitivity strongly suggests that this 
could be so. In an earlier comparison (Togo, 1973) three H2N2 strains 
and one influenza B strain were found to be of similar sensitivity to 
Ribavirin, with minimum inhibitory concentrations from 0.5 to 1 p>i in 
monkey kidney cells. Oxford (1975b), using the AOS system to titrate 
virus stocks in the presence and absence of compound (40 pM), found a 
similar reduction in titre for two H2N2 strains and one influenza B strain, 
although a much greater reduction in growth was recorded with 
A/FPV/Butch/27 (HavlNeql).
One further paper (Suganuma and Ishida, 1973) compared the 
sensitivity of two influenza A strains to Ribavirin in two different 
cell cultures, HeLa S'and chick embryo cells. The two strains used 
were A/PR8/34 (HONl) and A/Kumamoto/67 (H2N2). For both of these strains 
again the ED50 values were the same; however, the concentrations required 
to inhibit virus were 10 times higher in chick embryo cells than in HeLa 
cells. These results therefore agree with those presented here except 
for the concentrations used. With HeLa cells approximately 100 pM of
compound gave 50% inhibition, but v/ith chick embryo cells 1000 pM was 
required. This latter concentration is extremely high, considerably 
higher than the highest concentration used in this study, and one which, 
judging from reports of the toxicity of Ribavirin (Huffman et' al.,' 1973), 
would be extremely toxic. With the two previous papers the concentrations 
used were much lower and within the ranges used in this study.
One of the main aims achieved in this work'was'the comparison of 
the activity of the two compounds against a number of strains of virus 
taking one of the compounds, amantadine hydrochloride, as the reference 
compound. Little such comparative work has been carried out in the past, 
and no detailed comparisons appear to have been made of the activity of 
amantadine hydrochloride and Ribavirin. The only report where a comparison 
appears to have been made is with A/Aichi/2/68 (H2N2) and the therapeutic 
ratio was the same for both compounds in chick embryo cells (Huffman, 1973).
In the present study, however, a comparison of the two compounds 
v/as not found to be a simple matter, since a number of problems arose 
which made comparison difficult. One of these problems was the variation 
in results obtained with different cell cultures for amantadine hydrochloride. 
With Ribavirin there v/as little difference in the activity of the compound 
in the three cell cultures used, although AOS cultures were marginally 
more sensitive; With amantadine hydrochloride, on the other hand, there 
were considerable differences between the cultures, with. AOS cultures the 
least sensitive and calf kidney cells distinctly the most sensitive.
Such variations have not been observed previously v/ith amantadine 
hydrochloride, although differences have been observed with Ribavirin 
as indicated earlier (Suganuma and Ishida, 1973).
In tv/o previous papers (Davies et jal., 1964; Neumayer et al., 1955) . 
it v/as reported that amantadine hydrochloride was active in a number of
cell lines including chick embryo cells, monkey kidney cells, canine 
kidney cells, human amnion cells and hamster kidney cells, but it v/as 
not stated whether the degree of activity of the compound was affected 
by the cell culture used. However, Schild and Sutton (1965) reported 
no difference in results obtained with chick embryo cells and monkey 
kidney cells.
The variation in sensitivity with cell lines observed with 
amantadine hydrochloride is not a unique phenomenon. Similar variations 
have been observed with 5-iodo~2’-deoxyuridine against herpes types 1 and 
2 (Stubbs et al., 1971), and with isatin 3-thiosemicarbazone against 
rabbitpox virus (Appleyard et al.', 1965). Thus it is a problem of 
antiviral chemotherapy that three variables can affect the end result, 
that is* the virus, the compound and the cell. Viral inhibition is not 
just a case of a compound acting on a virus but also on the cell in which 
the virus is replicating. The reason for these variations observed in 
the activity of amantadine hydrochloride in different cell cultures is not 
known, but since amantadine hydrochloride has been shown-to act on 
penetration of the virus into the cell (Hoffmann et al., 1965), differences 
in cell receptors and uptake of the compound into the cell may be responsible 
for the variation. Another possibility is that the compound may have been 
broken down at different rates in different cells, with consequent 
alteration in functional activity. However, the results do indicate 
the importance of using more than one cell line for detecting activity, and 
particularly when comparing the activity of different compounds quantitatively.
One further problem which became apparent when trying to compare 
the activity of the two compounds was the difference in the type of 
dose-response lines obtained. The lines for Ribavirin were generally 
very much steeper than those obtained for amantadine hydrochloride.
These differences were reflected in the asymptote values, and the potency 
factors obtained for the two compounds calculated from equation 1 (Table 4.2). 
Generally the asymptote values were much higher for Ribavirin and the 
potency factors were lower. These differences may have arisen from 
differences in the mode of action of the two compounds. As stated 
earlier, amantadine hydrochloride acts very early in the replicative 
cycle on penetration and uncoating of the virus, whereas Ribavirin acts 
slightly later in the replicative cycle, on RNA synthesis (Scholtissek,
1976). On occasions the dose-response lines of the two compounds crossed 
(e.g. A/Okuda in chick embryo cells) which made it impossible to establish 
which compound was the most active. Unless lines or curves are parallel 
or nearly parallel it is impossible to give a useful quantitative estimate 
of the relative activity (distance between the lines) of two compounds.
In this study ED50 values were used to compare compounds because they 
afforded a quantitative way of comparing compounds with curved dose-response 
lines. However, it v/as appreciated that such estimates are subject to the 
errors indicated above. In particular, ED50 estimates were ideal for 
comparing the activity of the two compounds in different cell cultures, 
although again where lines have very different slopes the same error 
applies. Thus with these estimates differences between cell cultures 
became apparent, and it was possible to determine whether such differences 
were significant.
Y/ith single cycle tests it was noted that with both compounds 
some tail off in activity was present at higher concentrations. This 
was particularly pronounced with amantadine hydrochloride. For example, 
with A/Singapore in AOS cultures, although a 6.25 pM concentration caused 
87.5% reduction in virus growth, at a 400 pM concentration growth was 
still present v/ith 98% reduction in virus growth. Thus, as stated by
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Davies et al. (1964) there was no complete inhibition of growth under 
single cycle conditions by amantadine hydrochloride. The reason for 
this tail off in activity v/as probably associated with the timing of the 
experiments. In all single cycle experiments the compounds were added 
at the same time as the virus, and since both compounds act fairly early 
in the replicative cycle this method may not have given the compounds 
sufficient time to inhibit completely the high concentrations of virus 
present. Since amantadine hydrochloride acts earlier in the replicative 
cycle than Ribavirin its effect would be expected to be greater, as was 
the case. Some other limiting factors may have been involved with the 
tailing off effect, such as the amount of compound which could enter the 
cells. Possibly with amantadine hydrochloride, which becomes localized 
at the plasma membranes of the cell (Greenhalgh and Gaush, 1970), the 
cell surface area was saturated at higher concentrations.
Despite these problems, comparisons were made of the activity of 
the two compounds. In all culture systems A/NWS was more sensitive to 
Ribavirin than to amantadine hydrochloride. However, with the remaining 
strains results were variable with the different cultures used, particularly 
with the two strains A/Sweden and A/Okuda. With A/Hong'Kong amantadine 
hydrochloride v/as significantly more active than Ribavirin in all systems 
except AOS cultures.
4-2 IN VIVO SYSTEMS
4.2.1 Reasons for adopting methods
For all jjn vivo studies mice were selected as the most suitable 
animal, although as stated in the introduction ferrets have been used 
increasingly over the past few years. However, mice were used in this
study because they are less expensive and easier to handle, and thus
more suitable for quantitative work where relatively large numbers of 
animals are required. For similar reasons the mouse is also more 
suitable for routine screening of potentially active compounds, with 
the ferret only really needed when a promising compound has been found. 
Ferrets may then be used to establish whether a compound is active in a
disease model which closely resembles human influenza.
To detect and quantitate activity tests were carried out by 
titrating the virus content of infected lungs. This method was preferred 
because it indicates directly what is happening to infectious virus, 
unlike mortality tests. Although mortality tests are simple to carry 
out they are not ideal, because death of mice results from the 
immunological reactions of the body and is thus not typical of influenza 
which is generally a self-limiting disease. Furthermore the mice must be 
held up to 15 days because of the time required for mice to die. With 
infectivity tests results may be obtained within 5 days using the AOS 
system. In the past infectivity tests have only rarely been carried out, 
presumably because there has been no convenient method for titrating 
infectivity apart from eggs, which are rather cumbersome. Thus, because 
mortality tests have been used so extensively by previous investigators, 
it was considered of interest to compare the two methods of quantitating 
activity.
V/ith in vivo tests as with jln vitro tests it v/as considered important 
to work with strains from each of the 4 influenza A sub-types. However,
only one strain from each sub-type was used, except for the HONl sub-type, 
because of the time involved in adapting different strains to mice. As 
stated earlier, some strains were already adapted to mice, and to make 
valid comparisons of the sensitivity of strains, the unadapted strains 
were also adapted to mice. To check that all strains were behaving 
similarly in mice, and were thus suitable for comparative work, growth 
curves and virus, dose-response lines ’were determined for both infectivity 
and mortality tests. From these determinations it appeared that the 
M20 stock of A/Okuda was not as well adapted as other strains of virus, 
in that although mice were dying the virus was talcing longer to reach 
peak titres, which were from 1.5 - 3.0 log units lower than those obtained 
with other previously adapted strains. The A/SweGen M20 stock appeared 
to be well adapted to mice, and this shows that different strains of virus 
vary in their rate of adaptation to mice. When these variations became 
apparent it was considered of interest to compare the sensitivity of 
these two strains to amantadine hydrochloride and Ribavirin at different 
stages of adaptation, including unadapted virus.
4.2.2 Assessment of methods used
As indicated above, one important disadvantage of mortality tests 
as opposed to infectivity tests was the possible effect compounds could 
have on inflammatory and immunological response to infection, which could 
give rise to false positive results. Since both compounds used in this 
study have been reported to possess immunosuppressive properties 
(Suganunui and Ishida, 1973; Rawls et at., 1967; Potter et al., 1976) 
the comparison of the two methods was of particular interest. This 
immunosuppressive effect of the two compounds may be one explanation of 
the results obtained with cumulative mortality tests to determine the
J i v/to
most suitable length of time to dose the mice. In these tests it was 
found that 5 days treatment gave a greater beneficial effect than 3 days 
treatment, although virus growth had been shown to reach a peak within 
48 hours. The other possibility is that the virus produced a second 
burst of growth when the compound was removed early.
However, when the two methods of quantitating activity were 
compared the results obtained agreed very closely, and thus indicated 
that if the compounds were immunosuppressive this effect had not altered 
the outcome of the disease.
Apart from this, mortality tests had the disadvantage of requiring 
large amounts of compound, since 5 days treatment was required to give a 
maximum effect. In addition, large numbers of mice were required, which 
again increased the amount of compound needed. Mortality tests were also 
found to be subject to some variations. In tests with A/Okuda M20 stock, 
using a 10 LD50 dose of virus, dose-related responses were not obtained 
v/ith either amantadine hydrochloride or Ribavirin.
No such variations were observed with infectivity tests. However, 
with infectivity tests, because of the time involved with titrating virus, 
groups of 5 mouse lungs were pooled for titration, and thus individual 
values for each mouse were not obtained, in contrast to mortality tests. 
With infectivity tests attempts were made to try and assess the variability 
of the method. However, it was not possible to quantitate this variance 
because log ED50 values were not determined and thus statistical analysis 
was not carried out. Comparison of three replicate experiments with 
A/Sweden and A/Hong Kong revealed that reproducibility was fairly good, 
particularly with Ribavirin. With in vivo work the lack of statistical 
analysis was an important drawback since it meant that interpretation of 
results vfas more difficulty.
4.2.3 Consideration of results obtained
One very important problem which \/as encountered v/ith the studies 
carried out in mice v/as the variation observed between strains on 
adaptation to the mouse lung. It v/as not possible to explain these 
variations satisfactorily; however, the process of adaptation v/as not 
the primary consideration of this thesis and v/as therefore not examined 
in great detail. Earlier investigators (Davenport, 1954; Wen and Wang, 
1959) examined the process of adaptation with different strains of virus 
more thoroughly, and concluded that the process involved selection of 
variants with slightly increased rate and capacity for growth in the 
mouse lung. It was suggested that selection of mutants which occurred 
during mouse passage v/as probably also involved. However, the process 
involved is not simple since some unadapted strains are capable of growing 
in the mouse lung to titres comparable to those obtained after adaptation, 
without always causing death of the mice (Hirst, 1947; Ledinko and 
Perry, 1955).
In this study the A/Okuda unadapted stock was found to grow up to 
titres comparable to those of the M30E1 stock, and to cause some deaths.
By the M20 passage level the virus appeared to have adapted to mice in 
that it always caused death of the mice; however, the growth of the virus 
was much reduced. By the M30 passage level growth of the virus had again 
increased, with a slight increase in virulence. Similar variations have 
been observed with A/Taiwan/22/57 (H2N2) and B/Rob/53, two viruses which 
were also sufficiently toxic to cause some deaths on the first mouse 
passage (Ledinko and Perry, 1954; Wen and Wang, 1959). The reason for 
these variations is not known, but possibly stimulation of interferon 
or some other viral inhibitor may have played some part. During 
adaptation, with the selection of more toxic virus, possibly higher levels
of interferon were stimulated, which limited virus growth but not 
sufficiently to prevent death. With further passage the virus may 
have become more resistant to interferon, and thus able to grow to higher 
titres. Hoizever, with the M20 stock deaths occurred, although according 
to infectivity results the virus had not grown' to a particularly high 
titre. These results indicate that possibly the AOS system was not 
recording all the virus present. This effect is again difficult to 
explain, but could possibly have.resulted from the presence of some 
incomplete virus in the mouse lung which caused death of the mice.
One further problem which arose was the flatness of infectivity 
dose-response lines compared with mortality dose-response lines obtained 
v/ith allantoic virus stock, i.e. MO and M30E1 stocks. These results again 
indicate that at low dilution of virus the AOS system was not determining 
all the virus present. Again this could have resulted from the presence 
of incomplete virus. Possibly the large amounts of egg material which 
were inoculated at low dilutions of virus produced some effect in the 
mouse. Similar results have been observed previously when allantoic 
stocks were used (Davenport and Francis, 1951). These findings indicate, 
therefore, that allantoic virus stocks are not suitable for in vivo work, 
particularly when infectivity titrations are used.
With the A/Sweden virus stocks the above problems did not arise.
The unadapted virus was found to grow very poorly in the mouse lung. 
However, by the M20 passage the virus was well adapted, growing to high 
titre and causing death; further passage resulted in an increase in 
virulence.
Experiments to detect antiviral activity demonstrated that both 
amantadine hydrochloride and Ribavirin were active iri vivo. Methisazone 
was also included in tests in vivo because it had previously been reported
to be active against A/Hong. ICong/l/68 (H3N2) iri vivo (Smejkal et aJL_* y 1971), 
However, this observation was not confirmed. This disagreement in results 
could have arisen because the activity of methisazone reported in the above 
paper was only marginal, and may have been due to biological variation.
The compound TRB was found to be active in vitro but inactive in vivo.
This difference probably arose because the compound was not sufficiently 
active for activity to be manifest in vivo, that is, sufficiently high 
concentrations could not be achieved in the tissues because of transport, 
metabolism and excretion. Vfhen the spectrum of activity of amantadine 
hydrochloride and Ribavirin v/as determined, it was found that with both 
compounds all strains of virus found to be sensitive in vitro were also 
sensitive tn vivo, except for A/WV/S which was resistant to amantadine 
hydrochloride in vivo. However, this strain was only marginally sensitive 
to the compound in vitro and thus again there was probably insufficient 
activity to be demonstrated in vivo.
For detection of activity it was initially intended that treatment 
should commence after infection. However, it was found that the
A/Hong Kong virus v/as resistant to treatment given after infection at
the levels of compound administered, but sensitive when the compounds 
were given before infection. It was also found that all strains which 
t/ere well adapted to the mouse lung and the unadapted A/Okuda stock 
behaved similarly. The A/Okuda and A/Sweden M20 stocks, however, were 
sensitive to treatment given either before or after infection. Later 
quantitative studies further substantiated the differences between the 
A/Okuda virus stocks, but with the A/Sweden stocks the differences were
not as great as indicated by the initial experiments for detecting activity
Further tests \/ere carried out in vitro with A/Okuda to establish whether 
the virus had changed and thus become more sensitive to the two compounds.
However, the results in vitro revealed no difference in sensitivity of 
the unadapted and M20 adapted stocks. These differences therefore 
probably arose because of the poorer growth of the M20 stock in the 
mouse lung, which could result in the virus being more sensitive to 
antiviral compounds. . With A/Sweden the M20 stock was growing up as well 
as the M30 stock and therefore this explanation cannot apply. The slight 
variation in sensitivity observed with the two A/Sweden, stocks may have 
arisen because of minor differences in adaptation of these stocks.
The main aim of quantitative studies carried out in mice was to 
compare the sensitivity of different strains to the two compounds, and to 
compare the activity of the two compounds against each strain. Few 
in vivo comparisons of the sensitivity of different strains to either 
compound have been made previously, and no comparisons of the activity 
of the two compounds. In this study the variations observed with the 
adaptation of different strains to mice indicated the complexity of the 
system, which means that great care should be taken when comparing the 
sensitivity of different strains to a compound. From this work it 
appeared that highly adapted (>M30) mouse lung stocks should be used for 
these comparisons. When the sensitivity of the highly adapted strains to 
amantadine hydrochloride was examined it was found that the three sensitive 
strains were very similar in sensitivity, with A/Sweden marginally less 
sensitive than A/Okuda, which was slightly less sensitive than A/Hong Kong. 
However, all three strains showed a marked tail off in activity at higher 
concentrations, as observed in vitro. This effect has been observed before 
with amantadine hydrochloride (Grunert et al*, 1965), and is probably 
associated with a limit on the amount of compound which can be absorbed 
into the tissue.
The order of sensitivity observed jin vivo agrees with that observed 
in vitro with AOS and chick embryo cell cultures, although the differences
were greater in vitro. V/ith calf kidney cells the order of sensitivity 
differs, but in this system as with in vivo tests the three strains were 
very similar in sensitivity. With Ribavirin all five highly adapted 
strains showed very similar sensitivity to the compound, as found with 
in vitro tests. In an earlier comparison with four strains of virus 
B/Hong Kong, A/England/42/72 (H3N2), A/Hong Kong/1/68 (H3N2) and A/Japan/305/57 
(H2N2), Durr et al. (1975) found variations in susceptibility to Ribavirin. 
However, no information was given on the passage history of these strains 
in mice and therefore variations in adaptation to mice may have affected 
the results.
If all strains of influenza A virus are similar in sensitivity to 
Ribavirin as indicated in this study, then this compound could be used as 
a means of checking that strains are behaving similarly in the mouse system.
The results obtained in this thesis may also help to explain the anomalies 
reported by Wood (1965), who found that A/Swine was resistant to treatment 
with amantadine hydrochloride begun after infection, whereas A/Ann Arbor/
2/60 (H2N2) and other strains were sensitive. Since no information on 
passage history was given, it can only be suggested that differences in 
passage level may have accounted for these findings.
Comparison of the activity of the two compounds in vivo was difficult 
because of the tail off in activity observed with amantadine hydrochloride. 
Overall there was little difference in the activity of the two compounds, 
with dose-response lines crossing at higher concentrations. At low 
concentrations amantadine hydrochloride was more active, while Ribavirin 
was more active at high concentrations. Only with A/Hong Kong was 
amantadine hydrochloride more active over the greater part of the dose- 
response lines. These results compare most closely with those obtained 
in chick embryo cells. V/hen the two compounds \/ere compared against the
A/Okuda M20 stock Ribavirin was considerably more active than amantadine 
.hydrochloride when given after infection* This indicates that in man 
Ribavirin may be more active than amantadine hydrochloride for treating 
but not for preventing influenza infections. The reason for these 
differences probably stems from the mode of action of the two compounds, 
in that amantadine hydrochloride acts earlier in the growth cycle than 
Ribavirin.
4.3 CONCLUSIONS
The reasons for carrying out this study have been outlined above.
The two main aims were to find the most suitable systems for detecting and 
quantitating activity in vitro and in vivo, and to find the most active 
compound available at present against influenza A infections. However, 
in the majority of cases the results did not give a clear cut answer, 
although some interesting points arose.
V/ith in vitro systems plaquing was considered and found to be a good 
method both for detecting and quantitating activity, although the considerable 
difficulty in obtaining plaques was a serious drawback. For comparison of 
results in different cell cultures single cycle tests proved to be useful, 
since growth curves were very similar in different systems. In this case 
plaquing was unsuitable because good plaques were not obtained in more than 
one cell culture. If plaques had been obtained in more than one system 
it is possible that variation in size and time of development of plaques 
would have made comparisons more difficult. For this same reason 
single cycle tests were also considered more suitable than plaque tests 
for comparing the sensitivity of different strains. However, production 
of incomplete virus under such conditions was an important problem in 
either the detection or quantitation of activity.
In the absence of a plaque test for detecting activity single cycle 
tests were considered more suitable than multiple cycle tests. However, 
possibly if low inputs of virus had been used to give rise to a double 
cycle of growth with titrations at 24 - 30 hours, the problem of incomplete 
virus could have been overcome without a drop in reproducibility. For 
both detection and quantitation of activity under single cycle conditions 
the AOS system was considered the most suitable of the three systems 
examined, in that cultures were quicker and easier to set up, although
all three methods gave fairly good reproducible results. However, chick 
embryo cells gave the closest agreement with the results obtained in vivo.
For more detailed studies, such as mode of action studies, chick embryo or 
calf kidney cells should be more suitable than AOS cultures because it is 
possible to count the number of cells present directly with these cell lines.
With in vivo tests the situation was a little less complex. The 
mouse proved to be a suitable animal for use in both detecting and 
quantitating activity, although the necessity for adapting the virus to 
the mouse v/as an important problem. The method of choice for mouse tests, 
that is infectivity titration of the virus content of the lungs, proved to 
be satisfactory for both detection and quantitation of activity. From 
the studies with different virus stocks it appeared that mouse lung stocks 
were superior to allantoic stocks, and that highly adapted stocks - greater 
than 30 passes in mice - were most suitable for the comparison of different 
strains.
A total of 60 compounds were screened for activity in AOS cultures 
and by plaque inhibition tests in calf kidney cells. However, out of all 
these only two compounds, amantadine hydrochloride and Ribavirin, showed 
sufficient activity to be considered for further comparative work. To 
obtain a comprehensive picture of the relative activity of the two compounds 
quantitative tests were carried out in a number of in vitro systems and 
in vivo with 4 strains of virus from the 4 different sub-types. From 
these results it was not possible to say which compound was the most 
active overall because variation occurred with the different strain's of 
virus and cell cultures used. However, these variations indicated 
the importance of using more than one cell line when detecting and 
quantitatively comparing the activity of different compounds. Only 
two strains of virus were consistently more sensitive to Ribavirin than
to amantadine hydrochloride, and they were A/NWS and A/PR8, both of which 
are known- to be relatively insensitive to amantadine hydrochloride.
In all in vitro systems except AOS cultures, and in vivo, A/Hong Kong was 
more sensitive to amantadine hydrochloride than to Ribavirin, but the 
differences were only marginal in chick embryo cells and in vivo.
One further strain, A/Singapore, was also more sensitive to amantadine 
hydrochloride than to Ribavirin, even in AOS cultures which showed least 
activity for amantadine hydrochloride.
This variation in sensitivity of strains to amantadine hydrochloride, 
particularly strains of the same sub-type, is an important disadvantage of 
amantadine hydrochloride when considering treatment in man. This problem 
does not apply to Ribavirin since all strains were similar in sensitivity, 
although the activity of Ribavirin does not appear to be sufficiently great 
for it to be of any advantage over amantadine hydrochloride in the prevention 
of influenza in man. However, the results of tests carried out in mice 
with treatment begun after infection showed that Ribavirin was superior, 
and thus possibly this compound would be of greater value than amantadine 
hydrochloride in the treatment of influenza infections in man. The 
results of clinical trials being carried out at the present time should 
establish whether this is correct. In conclusion it may be said that 
from the results of this study there still does not appear to be a compound 
with sufficient activity to be of real value in controlling influenza 
in man.
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